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Abstract
Interactions of small organic molecules and proteins have been studied extensively
in the search of therapeutic drugs. Historically, the interaction partners have been
attributed to separate scientific disciplines: small organic molecules to the domain of
chemistry, proteins to the domain of biology. Likewise, chemical and biological data
have been stored and maintained separately. The aim of my thesis was to integrate the
ChEMBL database, a public repository of small molecule bioactivity measurements, with
resources of protein evolutionary relationships, and exploit these new links to further our
understanding of small molecule bioactivity.
In order to link biological assays via the evolutionary relationships of their protein
targets, I established a mapping of small molecule binding to specific structural protein
domains - the fundamental building blocks of protein architecture and evolution. By
mapping small molecule binding to protein domains, I was able to examine links between
the properties of small molecules and the evolutionary units that mediate their binding. I
used domain definitions from Pfam, a database of protein domains derived from conserved
sequence blocks. The mapping is now an integral part of the ChEMBL database and can
be used to limit sequence-based queries to sequence partitions that are relevant to small
molecule binding.
Further, I integrated information from the homology resource EnsemblCompara
Genetrees with bioactivity data from ChEMBL to examine the conservation of small
molecule potency between homologous proteins within and across species. Potency
diﬀerences between related proteins are a useful indicator of small molecule specificity.
Specificity is an early milestone for most drug discovery projects as it allows for the
manipulation of a desired process in a targeted manner, with side eﬀects reduced to a
minimum. I examined pairs of closely related human proteins and found that potency
diﬀerences were overall greater than the estimated background noise. Using the outlined
integration approach in a cross-species comparison, I also observed that potency diﬀerences
between pairs of related proteins in human and rat were overall no greater than the
background noise. This is relevant to the use of model organisms for drug discovery,
which relies on extrapolation from a measured response in one species to a therapeutic
eﬀect in humans.
Taken together I have integrated small molecule bioactivity and protein evolutionary
data from two resources, Pfam and EnsemblCompara Genetrees. This has provided a
framework for studying small molecule binding in the context of protein evolution.
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Chapter 1
Introduction
In 1900, Paul Ehrlich introduced a theory of ‘receptors’ to explain the process of
recognition between cells and toxins (Ehrlich and Morgenroth, 1900, reviewed in Maehle
et al., 2002). Over the course of decades, this theory of receptors developed into a central
concept for the scientific discipline of pharmacology. The idea that drug action relies on
the interaction with highly specific receptors was first proposed by the pharmacologist
Alfred Joseph Clark (Clark, 1933) and forms the basis of modern receptor theory. Today
we understand that most drug receptors are proteins, and the majority of them belong
to one of four functional categories, membrane receptors, ion channels, enzymes or
transcription factors (Drews, 2000).
This knowledge is a valuable foundation for the development of new medicines, but it
also means that drugs can be used to understand physiological processes by interfering
with defined cellular components. The discipline of chemical biology can maybe be best
described as making available the small molecule tools for such studies and providing
insights into how the modulation of drug receptors is coupled to the physiological and
pathological function of cells and whole organisms. In many cases, these tools are not
suitable as therapeutic agents, but are nevertheless useful in the drug discovery process
as standards of comparison, and increasingly as tools for target validation.
Besides molecular tools or drugs, both chemical biology and drug discovery generate
large amounts of data that are related to the biological activity of small molecules. These
data are obtained from assays of various formats, and encompass a large number of
diﬀerent read-outs. Growth of publicly available small molecule bioactivity data is driven
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mainly by automatic and semi-automatic aggregation of published measurements.
In my thesis, I describe approaches of integrating these data with resources of protein
evolutionary relationships. The promise of data integration is that new insights can be
gained from previously isolated measurements. This is not only a promise, but also a
great challenge: How can we compare measurements obtained in diﬀerent experiments
and what confidence can we place in these comparisons? What kind of questions can
be answered using published bioactivity measurements, which are vast in number, but
sparse or at best widely clustered in terms of their coverage of ligand and target space?
During my time at the European Bioinformatics Institute, I have examined and probed
these questions. Small molecule bioactivity measurements from the ChEMBL database
and protein domain assignments from the Pfam database have been combined to produce
a map of the target and ligand space covered by biochemical assays in the ChEMBL
database. Further, integration of homology information from the EnsemblCompara
Genetrees resource helped me pursue a phylogenetic analysis of small molecule activity
against related protein targets.
1.1 The quest for small molecules as therapeutics
and research tools
Small organic molecules form the prominent class of therapeutic drugs. In this context,
small molecules are understood to be organic compounds of typically 550 Daltons
molecular weight, with lower and upper limits on weight at around 200 Daltons and 1,000
Daltons. Small molecules also occur naturally, for example as hormones, metabolites,
and vitamins. However, most of the therapeutic small molecules are of artificial synthetic
origin, even though many of them are derived from naturally occurring molecules. Small
molecules have a number of advantageous properties that make them desirable candidates
for drug discovery. First among these is that many small molecule drugs can reach tissues
and organs after oral ingestion. The degree of oral availability varies between small
molecules and depends on a number of factors, including their capability to cross the
luminal membrane of the gut as well as avoiding enzymatic degradation in the gut and
liver. A famous, but rough, approximation of oral availability is compliance with the
Lipinski rule-of-five, a set of rules concerning four simple molecular properties (Lipinski
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et al., 2001). Many small molecules can also cross cellular membranes through integral
carrier proteins and thus interfere with processes taking place inside the cell (Kell et al.,
2011; Kell et al., 2012). Furthermore, small molecules are generally outside the functional
remit of the immune system and do not typically provoke immune responses.1 Crucially,
small molecules can engage in highly specific and energetically favourable interactions
with proteins, and through these interactions influence physiological and pathological
functions on a molecular level. Linus Pauling said about the process underlying these
interactions that “the secret of life is molecular recognition; the ability of one molecule
to ‘recognize’ another through weak bonding interactions” (Dunn, 2010). The general
principles of ligand-receptor interactions have been studied extensively and four main
types of interactions that mediate small molecule binding have been identified.2 These
include electrostatic interactions between opposite charges on a ligand and receptor
(Perutz, 1978; Hol et al., 1978), van der Waals attractive forces (Hamaker, 1937) and
the formation of hydrogen bonds (Moore and Winmill, 1912; Latimer and Rodebush,
1920). A fourth and sometimes dominant contribution comes from the displacement
of water molecules from the interface of the ligand and receptor binding site. This
displacement of water molecules is believed to be entropy-driven and is often referred to
as the hydrophobic eﬀect (Searle et al., 1992; Dunitz, 1995; Chandler, 2005). All of the
aforementioned types of interactions rely on shape complementarity between the ligand
and receptor. A common analogy used to convey the high specificity of such interactions
is that of a lock (the receptor) and key (the small molecule).3 Figure 1.1 illustrates an
exemplary small molecule-protein interaction of biotin (Vitamin B7) and streptavidin.
Taken together, the properties of small molecules have proven highly valuable in the
development of new drugs and to date, the vast majority of approved drugs are small
molecules. In the following, I give an overview of historical and current approaches to
identify small molecules that can be used as therapeutic agents or research tools.
1Immune reactions are nevertheless a frequent side eﬀect of the administration of small molecule
drugs, see e.g. Pichler, 2003.
2For a review of interactions in published crystal structures of drug-receptor complexes, see Babine
and Bender, 1997.
3This analogy is helpful, but it omits the conformational flexibility of both the receptor and small
molecule as well as the crucial role of water molecules and metal ions in some of these interactions.
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Figure 1.1: Illustration of a small molecule-protein interaction: biotin and streptavidin. Panel
A and B show the streptavidin protein in surface and cartoon representation, while biotin (green)
and the interacting residues in B are shown in stick representation. Panel A highlights the
complimentary shapes of biotin and it’s receptor streptavidine. Panel B shows the positioning
of the binding site in the barrel formed by two antiparallel β-sheets. Panel C illustrates some
of the interactions that contribute to the binding of biotin to streptavidin. Three tryptophan
residues (Trp79, Trp92, Trp108, yellow, unlabelled) are engaged in hydrophobic interactions
with the uncharged parts of the biotin molecule. Hydrogen bonds are observed between Asn23,
Ser27, Tyr43, and the ureido ring oxygen of biotin. The ring nitrogens form one hydrogen bond
each with Ser45 and Asp128. The carboxylate oxygens of biotin form two hydrogen bonds, one
with the main chain N-H of Asn49 and the other with Ser88. Under physiological conditions,
the biotin-streptavidin complex forms homo-tetramers and each biotin molecule undergoes an
additional hydrophobic interaction with a tryptophan residue from an adjacent monomer (not
shown). The figure was adapted from Livnah et al., 1993, the pdb accession of the associated
crystal structure is 1stp.
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1.1.1 Small molecules as therapeutics
The discovery of therapeutic small molecules has been driven by a number of diverse
strategies and innovations that are reviewed in this chapter. The outlined strategies
are supplemented with examples of drugs that were discovered using a given approach.
Literature references for individual examples were in many cases obtained from Sneader,
2005.
Written accounts of the use and preparation of therapeutic drugs reach back as far
as to the ancient civilisations of Egypt, Mesopotamia and Greece (Powell, 1993). The
basis on which drugs were used and developed was a set of mainly irrational beliefs,
until in the early 19th century the technology of solvent extraction from plant materials
provided pure, pharmacologically active compounds (Sneader, 2005). This kindled the
recognition that plant drugs exert their eﬀect through isolated components that were
referred to as ‘active principles’. Solvent extraction paved the way for the development
of drugs from alkaloids, basic substances that are extracted from plants and form crystal
salts with acids. Two of the most famous among the alkaloid drugs are the analgesic
morphine, isolated in 1804 by Friedrich Willhelm Sertu¨rner (Schmitz, 1985) and quinine,
an antipyretic and analgesic drug that was isolated in 1820 by Pierre Joseph Pelletier
and Joseph Bienaime´ Caventou (Pelletier and Caventou, 1820). The successes of alkaloid
drugs inspired pharmacists and chemists to seek synthetic derivatives of alkaloids with
therapeutic value. For example, in an attempt to obtain an analog of quinine, Emil
Fischer and his student Ludwig Knorr developed phenazone in 1884, an antipyretic
drug that did not exhibit the severe side eﬀects of quinine. Other synthetic derivatives
of alkaloids include the morphine derivative heroine, first synthesised in 1897 by Felix
Hoﬀmann (Sneader, 1998) and the tranquilliser haloperidol, which is a derivative of
atropine and was discovered in 1958 by Paul Jannsen (Jannsen et al., 1959).
Over the course of the 19th century, the extraction of active compounds from plants
and the synthesis of chemical derivatives of these compounds followed by animal testing
had emerged as a viable strategy in drug discovery. This strategy is sometimes described
as the extractive heuristic (Nightingale, 2000; Hopkins et al., 2007). Soon, it was extended
to extract active compounds from various human tissues and other organisms. Extraction
of drugs from the hormone system prove particularly fruitful and yielded compounds
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such as adrenaline4 and histamine (Dale, 1950). The synthesis of hormone analogues
allowed pharmacologists to obtain compounds that interact with hormone receptors, but
elicit a response that diﬀers from that of the endogenous hormone. This approach was
pioneered by the pharmacologist James Whyte Black, who developed propanolol, an
analog of adrenalin that binds the β-adrenergic receptor without activating it (Black and
Stephenson, 1962; Prichard and Gillam, 1964). Propanolol reached the market in 1964
and was widely used as an antihypertensive drug. A similar strategy was used by Black
and Charon Robin Ganellin in the development of the histamine H2 receptor antagonist
cimetidine, which is an analog of histamine and became a “block-buster” drug for the
treatment of stomach ulcers in 1976 (Brimblecombe et al., 2010).
Apart from the hormone system, the extractive heuristic was also applied to mimic
metabolites and naturally occurring antibiotic compounds. A derivative of the vitamin
folic acid (vitamin B9), methotrexate, was developed in 1947 for the treatment of acute
leukemia (Seeger et al., 1949). Other antimetabolites include modified nucleosides that
inhibit the growth of tumours or DNA or to control viral infections. Among the extracted
antibiotic compounds are for example chloramphenicol, which was isolated by John
Ehrlich and Quentin Bartz from a bacterial culture of streptomyces venezuelae (Ehrlich
et al., 1947) and erythromycin, isolated by Robert Bunch and James McGuire from a
bacterial culture of streptomyces erythreus (Bunch and McGuire, 1953).
An entirely diﬀerent strategy emerged early in the 20th century, the synthetic organic
chemistry heuristic (Nightingale, 2000; Hopkins et al., 2007). The advent of synthetic
organic chemistry had made available large collections of diverse artificial compounds that
could be screened for activity in pharmacological screens. A pioneer of this approach was
Paul Ehrlich, who, in 1910, together with Sacachiro Hata, discovered arsenophenylglycine
(Salvarsan) from a screening of organic dyes (Ehrlich and Hata, 1910). Salvarsan was
prescribed as a potent drug to treat patients with syphilis. Continuing Ehrlich’s work
on dyes, Gerhard Domagk screened a large number of azo-dyes for their potential to
treat bacterial infections. Eventually, the red sulfonamide dye sulfamidochrysoidine was
discovered as a potent antibiotic (Domagk, 1935).
Advances in molecular biology in the 1970s and 1980s provided techniques for the
cloning and functional characterisation of proteins and thus for the investigation of indi-
vidual proteins as potential drug targets. Technological innovations such as automation,
4The discovery, isolation and synthesis of adrenalin is reviewed by Aldrich, 1905.
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miniaturisation (Silverman et al., 1998) and combinatorial chemistry (Merrifield, 1963;
Brenner and Lerner, 1992; Gallop et al., 1994; Fodor et al., 1991) made it possible to
screen ever larger numbers of compounds in assays targeting specific proteins. By the
early 1990s, systems for high throughput screening (HTS) emerged to turn over libraries
in the order of one hundred thousand and more compounds in a matter of days (Pereira
and Williams, 2007). Considered a breakthrough in cancer therapy, the lead structure for
Imatinib, a drug for the treatment of chronic myeloid leukemia, was discovered by HTS
in the mid 1990s (Buchdunger et al., 1996; Deininger and Druker, 2003). More recently,
a number of limitations of HTS have been discussed in the literature, including limited
diversity of combinatorial libraries (Feher and Schmidt, 2003), high false positive rates
(Malo et al., 2010) and vulnerability to reporting artifactual interactions (Rishton, 1997;
McGovern et al., 2002; Walters and Namchuk, 2003). A general criticism of target-based
approaches is that biochemical inhibition does not reliably translate into therapeutic ef-
fects and that phenotypic screens, which assess small molecule response on an organismal
or functional systems level, may be more suitable to identify eﬀective small molecules
(Swinney and Anthony, 2011).
Underlying the diverse approaches discussed above is a process that encompasses the
identification of a candidate or lead structure followed by iterative cycles of modification
and retesting, or lead optimisation. While traditional approaches of lead optimisation
were guided by medicinal chemistry rules derived from the properties of functional groups,
the increasing availability of protein crystal structures by the 1980s had given way to a
methodology called structure-based design. Structure-based design relies on structural
information from an observed or predicted binding site to instruct the synthesis of
a suitable ligand (Greer et al., 1994; Whittle and Blundell, 1994). This methodology
most commonly requires computer graphics (Goodsell et al., 1989) and methods for the
calculation of electrostatic potentials (Gilson et al., 1988). The discovery of the carbonic
anhydrase inhibitor, dorzolamide, a topical treatment for glaucoma, in 1995, was based
largely on structure-based methods (Ponticello et al., 1998; Davis et al., 2003).
Over the course of two centuries, small molecule drugs have been established as
essential components of modern medicine, provided cures for previously incurable diseases
and supported the advance of evidence-based medicine. While valuable as therapeutics,
small molecules also play a significant role as research tools. The next section reviews
the development of such tools.
7
Chapter 1. Introduction
1.1.2 Small molecules as research tools
The use of small molecules to induce specific conditions in a biological system under
study has a long history and early examples include the use of atropine and acetylcholine
to investigate chemical transmission of nerve signals (Barger and Dale, 1910). However,
it was Linus Pauling’s theory of molecular recognition (Pauling and Delbru¨ck, 1940;
Pauling, 1974) combined with progress of biochemical methods for protein purification
and quantitation (Cuatrecasas et al., 1968; Lowry et al., 1951) that promoted the use of
small molecules to interfere with the function of specific proteins and to thus dissect and
study biological processes. For example, colchicine was used to elucidate the role played
by α- and β-tubulins in the homeostasis of the cytoskeleton (Weisenberg et al., 1968) and
the puﬀerfish toxin tetrodotoxin as a tool to study neurophysiology5 (Narahashi et al.,
1964).
Since then, many more small molecules were developed as research tools and today,
hundreds of small molecule tools can be readily obtained from commercial vendors.
The use of small molecules to interrogate biological processes is often called chemical
genetics, in analogy to molecular genetics approaches, which use genetic perturbations to
achieve similar ends (Schreiber, 1998; Stockwell, 2000). Molecular genetics approaches
can be divided into forward- and reverse genetics approaches. Forward genetics seeks
to establish the genetic cause of an observed phenotype. In analogy, forward chemical
genetics seek to establish the mechanism by which a given small molecule induces an
observed phenotype. Reverse genetics on the other hand makes use of molecular cloning
techniques or crosses of mutant strains to introduce a targeted genetic perturbation and
then analyse the eﬀect of this perturbation on the resulting phenotype. This approach
can deliver powerful insights into the molecular biology of cells, mechanisms of disease
and development. Reverse chemical genetics introduces targeted perturbations using
small molecules with known protein targets. One important advantage of traditional
genetic approaches over chemical genetic approaches is their generality. Regardless of
which gene is being investigated, mutations can be introduced and located using the
same procedures over and over and again. Small molecules that interfere with gene
function on the other hand are only available for a small fraction of all proteins encoded
5Tetrodotoxin acts by blocking the pores in sodium channels. This prevents the formation of action
potentials, a useful condition for neurophysiological studies (Kandel et al., 2000).
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by the human genome. Further, the specificity of small molecules is often limited and
oﬀ-target eﬀects have to be accounted for. Despite these shortcomings, small molecules
are desirable research tools. Proteins that are targeted by small molecules are inactivated,
but still present in the cell, keeping it closer to its physiological state compared to genetic
knock-outs. Further, small molecules aﬀord researchers the possibility to induce reversible
and gradual perturbations of protein function. Chemical genetics approaches are also
useful to cross-validate findings from traditional genetics approaches.
Successes of chemical genetic approaches, such as the discovery of FK506, a suppressor
of calcineurin and immunosuppressant (Schreiber, 1991), or the characterisation of the
bile acid receptor FXR using chemical probes (Kliewer et al., 1999; Downes et al.,
2003) inspired calls for a generalised chemical genetics methodology. To achieve this, it
was proposed that chemical probes should be identified systematically for all proteins
(Zanders et al., 2002; Shokat and Velleca, 2002; Schreiber, 2003; Austin, 2003). Around
the same time, a big NIH-funded screening project for small molecule research tools,
called Molecular Libraries Initiative (MLI), was brought underway (Austin et al., 2004).
It involved multiple high throughput screening centres and organic chemistry divisions
with the aim of screening hundreds of thousands of compounds against a wide range of
targets and optimising initial hits towards a given target. The chemical probes identified
in this project were made available to the scientific community. The data generated
in these screens was also made available, through the PubChem Bioassay repository
(Wang et al., 2012a, http://www.ncbi.nlm.nih.gov/pcassay). The MLI did not meet
the high expectations it set out with (Kaiser, 2008) and during the years following the
initiation of this project, it became clear that HTS alone is not a recipe to obtain small
molecule tools for a genome-scale range of targets (Lazo, 2006). Increasingly, a focus
was set on HTS reporting standards (Inglese et al., 2007) and selection criteria for small
molecule research tools from HTS screening hits. A widely accepted set of rules has been
stated by Stephen V Frye (Frye, 2010):
• Molecular profiling. Suﬃcient in vitro potency and selectivity data to confidently
associate its in vitro profile to its cellular or in vivo profile.
• Mechanism of action. Activity in a cell-based or cell-free assay influences a physio-
logic function of the target in a dose-dependent manner.
• Identity of the active species. Has suﬃcient chemical and physical property data
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to interpret results as due to its intact structure or a well-characterized derivative.
• Proven utility as a probe. Cellular activity data available to confidently address at
least one hypothesis about the role of the molecular target in a cell’s response to
its environment.
• Availability. Is readily available to the academic community with no restrictions
on use.
Other experts have stated similar criteria (Workman and Collins, 2010; Cohen, 2010). In
an alternative approach, a panel of experts was asked to evaluate a set of chemical probes
produced by the MLI according to their own criteria and a consensus was determined
quantitatively (Oprea et al., 2009). Intellectual property and access issues have also been
identified as important factors for the success of small molecule research tools, especially
for use in target validation in the early stages of drug discovery (Edwards et al., 2009).
An opportunity to improve functional annotations for small molecule research tools
comes from structural biology. Eﬀorts to structurally characterise all proteins encoded
by the human genome have begun simultaneously with the MLI (Sali, 1998; Kuhn et al.,
2002) and are beginning to make an impact both in term of the number of solved
structures as well as the diversity of these structures in terms of covered protein families
(Chandonia and Brenner, 2006; Marsden et al., 2007; Gileadi et al., 2007). Crystal
structures of proteins, and especially protein inhibitor complexes provide insights into
potential and observed binding sites for small molecules (Fedorov et al., 2007b; Marsden
and Knapp, 2008). This information can be interpreted to understand and predict
patterns of selectivity between members of protein families such as kinases (Fedorov
et al., 2007a) and GPCRs (Venkatakrishnan et al., 2013). Protein structures have also
fundamentally aided the design of artificial modifications to kinases that renders them
sensitive to certain inhibitors (Bishop et al., 2000b; Bishop et al., 2000a; Eblen et al.,
2003). Using this approach, small molecule inhibitors can be used to eﬀect extremely
specific perturbations that can be spatially and temporally controlled. Similar systems
have been developed for GPCRs (Scearce-Levie et al., 2002) and the estrogen receptor
(Tedesco et al., 2001).
The selectivity of chemical probes in comparison to genetic perturbations is often
limited. This need not necessarily be a disadvantage, the broad-spectrum kinase inhibitor
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staurosporine for example has an excellent track record as a research tool (Tamaoki et al.,
1986; Tamaoki, 1991). However, to use small molecules adequately, it is absolutely vital
to have an understanding of which proteins are perturbed by a given small molecule. This
may explain the success of staurosporine as a chemical tool, as its excessive promiscuity
is well-known and understood (Karaman et al., 2008; Tanramluk et al., 2009). Selectivity
profiles of other small molecule research tools are more ambiguous and often not well
appreciated by those using them. Kinases, with their highly conserved ATP-binding
site, are particularly challenging in this respect. In early eﬀorts in the group of Phillip
Cohen, the selectivity of kinase inhibitors was probed by screens across a panel of about
30 kinases (Davies et al., 2000; Bain et al., 2003; Bain et al., 2007; Cohen, 2010). Eﬀorts
at much larger scale have followed that tested small molecules across a large fraction
of the roughly 500 kinases6 in the human proteome (Fabian et al., 2005; Fedorov et al.,
2007a; Anastassiadis et al., 2011; Posy et al., 2011; Metz et al., 2011; Davis et al., 2011;
Gao et al., 2013). A consensus forming from these experiments is that many compounds
exhibit high levels of promiscuity between related kinases, but some specific compounds
can be identified for many of the 500 kinases in the human proteome (Uitdehaag et al.,
2012).
Beyond profiling on a protein target level, small molecules are also profiled for their
activity on diﬀerent types of cell lines, for example in the anticancer drug screen of the
National Cancer Institute in the US (Shoemaker, 2006) which screens approximately
3,000 compounds per year for activity across a panel of 60 cell lines. An even larger
number of cell lines are being evaluated in the connectivity map screening at Broad
Institute (Lamb et al., 2006) and the genomics of drug sensitivity screen at the Sanger
Institute (Garnett et al., 2012). These screens are intended to assess the eﬀect of genetic
diﬀerences between cell lines on the way in which cell lines respond to small molecules. In
reverse, these screens also contain information that can be used for the characterisation
of small molecules involved in these screens.
To summarise, over the last decade, eﬀorts to obtain and characterise small molecules
as research tools have scaled up and increasingly rely on high-throughput technologies.
The specificity and universal applicability of traditional genetic methods have not been
matched, but small molecules have nevertheless been established as important research
tools in molecular biology and for the validation of targets in the early stages of drug
6See Manning et al., 2002
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discovery. Small molecule related experiments generate large amounts of data that hold
value on their own. In the following section I review approaches that integrate and
exploit data generated in the development of small molecule research tools and drugs.
1.2 Data integration in chemical biology and drug
discovery
Chemical biology and drug discovery naturally examine biological processes on multiple
levels of molecular and organismal abstraction and hence rely on data generated from a
mosaic of diﬀerent experiments. This requires an integrative approach beyond isolated
experiments or for that matter, isolated data repositories. For example, knowledge of a
binding constant of a small molecule to a protein is more useful if its role in a disease
process is also known; in other words, a piece of biological data is more meaningful if a
context is provided for it. This context can reveal links and relationships from previously
isolated data and promote new biological theories and standards (Karp, 1996). The need
for integration of data across diﬀerent resources is also illustrated by the growing number
of biologically relevant data repositories: in 1990, there were about one hundred biological
databases (Keen et al., 1992). In 2013, the database issue of Nucleic Acids Research
already listed 1,512 relevant repositories (Ferna´ndez-Sua´rez and Galperin, 2013). By
combining data from these sources, data integration supports the logical interpretation
and association of life science knowledge (Neumann and Thomas, 2002). More specifically
to drug discovery, the application of data integration promises to help understand drug
action on multiple scales, support the generation of new hypotheses, for example in target
validation or mode-of-action studies, and avoid duplication of experiments (Searls, 2005;
Loging et al., 2007).
Formally, data integration seeks to establish links between independent data reposito-
ries. Most frequently, data in such repositories is stored in relational databases (Codd,
1970), and in such cases the challenge for data integration is to establish links that are
beyond the scope of individual relational schemas. In computer science, data integration
has been an area of research for almost four decades and various technical solutions
to this problem have been proposed (Ziegler and Dittrich, 2004; Louie et al., 2007).
Solutions that have been applied in a biomedical context include link integration, view
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integration, and data warehousing (Stein, 2003; Schneider and Jimenez, 2012). Link
integration builds on the world wide web technology and refers the user between linked
documents. It requires that participating data sources maintain links to other reposito-
ries and frequently check their validity. It also enforces a sequential approach to data
integration in which links from one document direct to the next document and so forth.
The method is nevertheless successful. SRS for example is a widely used query system
that uses link integration (Zdobnov et al., 2002). View integration provides a query
interface to multiple, federated datasources. The interface acts as a mediator between
the databases and the user input. The cross-database resources Biomart (Smedley et al.,
2009) and the distributed annotation system (DAS) (Dowell et al., 2001) are examples of
view-based integration. Data warehousing seeks to integrate all relevant data sources
into one consistent database schema. A critical view of data warehousing proposes that
integration of drug discovery data into monolithic, fully linked systems are unsustain-
able and should be avoided in favour of more flexible approaches that connect multiple
knowledge systems and provide mechanisms for expert reasoning and curation (Slater
et al., 2008). One such approach, relying on ‘cubes’ of data that can be reformatted, for
example to accommodate an additional dimension, has been proposed by Millard et al.,
2011. It has also been suggested that linking of data sources by preferential attachment7
can improve the sustainability of data warehousing (Searls, 2003a). A relevant example
of a warehousing integration approach is the STITCH database, which aggregates small
molecule protein interaction data from multiple other data sources (Kuhn et al., 2012).
The use of ontologies can greatly facilitate data integration eﬀorts for all of the
approaches presented above. Ontologies provide controlled vocabulary to capture the
concepts that are relevant to a scientific discipline and the terms in such a vocabulary
are arranged in hierarchical relationships (Stevens et al., 2000). If two or more data
sources can be represented by the same ontology, they can be integrated using links
established through the hierarchy of the ontology’s controlled vocabulary. One example
in this context is the BioAssay ontology (BAO), which enables cross-analysis of diverse
high-throughput screening data sets (Schu¨rer et al., 2011).
Data integration is also facilitated by the use of reporting standards for particular types
of data. For example, the widely used integration platform for micro-array experiments,
7An integration approach using this strategy would result in a small number of densely connected
data sources and many more that only have sparse links to other data sources.
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ArrayExpress (Rustici et al., 2013), requires submitted experimental data to contain
a minimal set of annotations defined by the MIAME standard (Brazma et al., 2001).
Similarly, guidelines for submitting data of bioactive entities, including small molecules,
have been introduced under the MIABE standard in 2011 (Orchard et al., 2011).
The field of chemogenomics, which is of high relevance to both drug discovery and
chemical biology, relies heavily on the integration of biological and chemical databases
(Bredel and Jacoby, 2004; Oprea and Tropsha, 2006). The chemogenomics approach
seeks to explore the specificity of small molecule binding within protein families and
makes use of both protein- and small molecule similarity metrics to predict patterns of
specificity where no data is available (Harris and Stevens, 2006). Early work introduced
the structure-activity relationship homology concept, which proposes that patterns of
susceptibility to small molecule perturbation should, to some degree, be conserved
between one given protein and its relatives in the same protein family (Frye, 1999).
Extensive studies of the selectivity patterns of kinase inhibitors followed. In 2005, Vieth
and colleagues published a study that explored ligand profiles of therapeutically relevant
kinases and found that that kinases with ≥ 60% sequence identity are most likely to be
inhibited by the same classes of compounds (Vieth et al., 2005). In 2007, Keiser and
colleagues related 289 proteins by sets of small molecules reported to bind them (Keiser
et al., 2007). Later, this approach was developed into a fully implemented method to
predict small molecule protein interactions (Keiser et al., 2009). A study published in
2010, described the organisation of 102 class-A GPCRs according to sets of associated
ligands, thus providing an alternative to the sequence-based organisation (Horst et al.,
2010). In 2013, this approach was extended to 146 GPCRs and also evaluated overlaps
with 485 non-GPCR targets (Lin et al., 2013).
Data integration studies that go beyond the chemogenomics approach have examined
links between chemical-genetic and genetic interaction data and used these insights
successfully to identify components of cellular pathways (Parsons et al., 2004). In a
study that integrated chemical data and side eﬀect information from package inserts,
Campillos, Kuhn and colleagues have established a creative method to identify the
molecular targets of marketed drugs (Campillos et al., 2008). Also with a perspective on
side eﬀects, Tatonetti and colleagues have used patient medical records of adverse side
eﬀects to predict unknown eﬀects and interactions of therapeutic drugs (Tatonetti et al.,
2012).
14
Chapter 1. Introduction
In a 2003 review, it was proposed that drug discovery can benefit from comprehensive
analyses of the evolutionary history of proteins that are investigated as drug targets.
This approach was referred to as pharmacophylogenomics (Searls, 2003b). Pharmacophy-
logenomics is set apart from chemogenomics by its focus on evolutionary relationships,
rather than binding site similarity. In an extension of this approach, I have sought to
integrate protein evolutionary relationship data with bioactivity data. My work was
motivated by the prospect of learning about small molecule binding using evolutionary
parameters, such as the distance from a last common ancestor or the type of event that
lead to a split in the lineage. These parameters are available in increasing quantity and
detail through genome sequencing projects of diverse species (Pagani et al., 2012). In the
following sections, I give an overview of the data sources I have used to achieve this.
1.3 Bioactivity data
It was illustrated in the previous two sections that the development of small molecules
as either therapeutics or research tools requires the testing of large numbers of small
molecules. The first episode of testing in a discovery program is often a screen of
some sort to identify small molecules that exhibit a desired activity. In subsequent
steps, these molecules are validated, for example in assays that measure activity using a
diﬀerent output as well as in assays that measure oﬀ-target eﬀects. Optimisation of a
small molecule entails the synthesis and testing of derivatives. Thus, a single discovery
program can generate bioactivity data from hundreds and thousands of measurements.
As a byproduct of the discovery of drugs and research tools, this data is valuable in
itself. It helps researchers avoid duplication of eﬀorts and learn from the successes and
failures of previous strategies. Examination of such data can also help answer questions
beyond the scope of individual discovery programs. The availability of such data in the
public domain has much improved over the last years and now a number of repositories
exist for small molecule bioactivity data. The PubChem Bioassay resource hosts assay
data generated in the Molecular Libraries program introduced in the previous section
(Wang et al., 2012a). BindingDB is an academic project that focuses on bioactivity data
obtained in binding assays and includes data from the scientific literature, ChEMBL
(see below) and PubChem BioAssay (Liu et al., 2007). The PDSP Ki database is a
data warehouse that provides inhibition constants for measurements of small molecule
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binding to protein targets. These measurements derive either from the literature, or were
generated within the Psychoactive Drug Screening Program (PDSP) at the University of
North Carolina Chapel Hill (Roth et al., 2000). ChEMBL is a database of small molecule
bioactivity data that is extracted from the scientific literature and, increasingly, from
direct submissions of larger datasets generated in the pharmaceutical industry and other
research organisations (Gaulton et al., 2012). The scope of journals that routinely serve as
sources for data extraction into the ChEMBL database lies within the domain of medicinal
chemistry. The standardised assay formats and reporting techniques established in this
field facilitate both extraction and analysis of the data. As a trade-oﬀ to standardisation,
the contribution of innovative assay types to the overall make-up of the data is relatively
small. With regard to the composition of targets in cutting-edge drug discovery pipelines
this results in a bias towards proteins that are amenable to traditional assay techniques,
in particular kinases, GPCRs and proteases. This bias should be noted when interpreting
outcomes of data mining studies using ChEMBL.
In the following, I introduce in more detail the types of bioactivity data and assay
formats that are prevalent in these data resources, with a focus on the ChEMBL
database, as this is the resource that provided bioactivity data used throughout my
research. Bioactivity data hosted within the ChEMBL database is derived from a large
number of diverse assay formats. A query for assay descriptions in the ChEMBL database
(chembl_15) returns 578,979 unique terms. While many of these are variations of similar
and sometimes identical formats, the diversity of assays is nevertheless staggering. One
way of ordering this data is by the level of scale at which bioactivity is measured.
This can be on the level of molecular interactions, cells, tissues and whole organisms.
Assays on a molecular level, in the remainder of this thesis referred to as ‘biochemical’
assays, deliver outputs that are mostly independent of ‘biological’ factors such as the
distribution of receptors in a tissue or the expression levels of proteins in diﬀerent cell
types. Comparisons between measured outputs from biochemical assays are therefore
more reliable than comparisons of higher-level assays. Biochemical assays break down
further into binding and functional assays. Binding assays measure the interaction or
compounding of a small molecule and its protein target directly, while functional assays
measure this event as a function of some downstream eﬀect. The term used to describe
the strength of binding is aﬃnity, while the amplitude of downstream eﬀects elicited by
a small molecule are described as eﬃcacy.
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In the context of bioactivity measurements, aﬃnity is most commonly expressed as a
dissociation constant Kd, which derives from the Langmuir adsorption isotherm and can
be described as
Kd =
[L][R]
[LR]
, (1.1)
where [L] is the concentration of free ligand, [R] the concentration of unbound receptor and
[LR] the concentration of the ligand-receptor complex. The aﬃnity of a small molecule for
a given target is usually determined in saturation experiments. Saturation experiments
measure the occupancy of receptor sites as a function of increasing concentrations of a
small molecule. Receptor sites can be located on isolated proteins, membrane preparations
or membrane proteins on whole cells (Bylund and Toews, 2011). Assay formats that
are suitable for saturation experiments include radioligand filter binding assays (Bruns
et al., 1983), scintillation proximity assays (SPA) (Alouani, 2000), as well as fluorescence
polarisation assays (Banks and Harvey, 2002). Saturation experiments can also be carried
out using surface plasmon resonance setups (Haes and Van Duyne, 2002; Wang et al.,
2005).
Eﬃcacy can be expressed in a range of activity types. Most frequently used within the
ChEMBL database are IC50, Ki, %(inhibition) and %(potency). The latter two activity
types measure the eﬀect of a small molecule in relation to some standard of comparison,
which could be either the activity of another compound or some sort of baseline activity,
for example the substrate turnover of an enzyme. The activity type IC50 is determined
as the concentration of small molecule at which the signal, of whatever output is being
evaluated, is reduced to 50%. IC50 values can be determined in dose-response studies,
where the eﬀect of the administration of a given compound is measured in intervals of
increasing concentrations. Normally, a sigmoidal curve is fitted to the measured values
and the IC50 is determined as the concentration at which the slope of the curve is at a
maximum. Basically, IC50 depends on both the concentration of protein and substrate8,
while the value for Ki is an absolute constant. The Ki can be determined from an IC50
value and the assay-specific parameters through the Cheng-Prusoﬀ equation (Cheng and
Prusoﬀ, 1973).
Eﬃcacy can be measured using displacement binding assays, which monitor the
8Substrate in this context denotes additional molecules that constitute some form of competition
with the small molecule that is being evaluated.
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displacement of a traceable substrate, in response to increasing concentration of a given
small molecule. All methods mentioned earlier for saturation experiments are also suitable
formats for displacement assays. Other formats measure eﬃcacy further downstream
of the binding event. These include measuring the turnover of a fluorescent substrate
or radiolabeled substrate (Windh and Manning, 2002). Assays that measure eﬃcacy in
a cellular context include those that measure the levels of second messengers such as
Inositol-3-phosphate (IP3) or Ca2+ in response to a stimulus either using fluorescent
chelator dyes (Chambers et al., 2003) or the aequorin system (Le Poul et al., 2002). Small
molecule perturbations can also lead to increased or decreased transcription of specific
genes; these changes can be exploited to measure eﬃcacy using reporter gene formats, such
as β-galactosidase (Jain and Magrath, 1991), chloramphenicol acetyltransferase (Gorman
et al., 1982), firefly luciferase (Gould and Subramani, 1988), and green fluorescent protein
(GFP) (Zolotukhin et al., 1996).
When assaying the biological activity of small molecules, it is necessary to account for
a degree of ambiguity concerning the identity of the molecular target of any given ligand.
In biochemical assays, the level of certainty with which a target can be identified depends
on the procedure used to obtain pure protein. Pure protein is often obtained through
expression systems and subsequent purification using centrifugation, chromatography
or electrophoresis. Frequently used expression systems are based on bacterial and yeast
cultures or derived from insect, plant or mammalian cell lines (Baneyx, 1999; Cereghino
and Cregg, 2000; Kost et al., 2005). The use of expression systems often implies that
post-translational modifications do not correspond to the physiological state. Protein
folding can also be aﬀected in expression system that lack chaperone proteins specific to
the target organism. In many cases, expression constructs represent only a truncated
version of the original protein, containing the part that is assumed to be relevant to
small molecule binding. Ambiguity around the identity of a protein target increases
further when bioactivity is measured as a downstream signalling response in a cellular
context. Measured endpoints from cell-based assays integrate the response to small
molecule perturbation across a system of interacting components and thus obfuscate
the individual contributions of on-target eﬀects versus oﬀ-target eﬀects. Assay formats
that assess small molecule bioactivity on the levels of cell populations, tissues and whole
organisms are typically referred to as phenotypic screens. In such screens, the measured
output is an integrated response of networked interactions of cellular components as
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well as interactions between cells, tissues or whole organisms. The mechanism through
which a small molecule elicits a measured response in phenotypic screens is thus not well
defined.
For the purposes of my thesis work it was desirable to minimise the ambiguity around
the identity of a protein target in any given assay. Therefore, I used only information from
assays that measured eﬃcacy immediately downstream of the target protein. Within the
ChEMBL database, such assays carry a flag B, for binding. Queries to the database can be
further restricted using the confidence score that is assigned manually by curators. This
score evaluates the relationship between the assigned identifier and the actual identity of
the target. For example, an identifier could directly map through to the actual target
(confidence score 9) or to a homologue of the target (confidence score 8). Queries made
in the context of this thesis are presented in the methods section for each chapter and
generally are restricted to bioactivities of type B, with target identifiers mapping directly
to the actual protein used in the assay. Moving on from the small molecule bioactivity
aspect of my work, in the following I present an introduction to protein evolutionary
relationships.
1.4 Protein evolutionary relationships
In 1859, Charles Darwin published his seminal theory of the origin of species and shaped
our perception of evolution as a process of variation and natural selection of fit individuals
in a population (Darwin, 1859). On a molecular genetic level, variation is present in the
form of sequence mutations. Until the 1960s, the predominant view was that genetic
diﬀerences between species are based on mutations that improve fitness; however, this
view was challenged by the increasing availability of genomic sequence data, which showed
that synonymous mutations are much more frequent than mutations that change the
amino acid composition of a sequence. In 1968, Motoo Kimura proposed that most of
the mutations observed between species have no impact on fitness, but rather follow a
stochastic process (Kimura, 1968). The prevailing view today is that mutations between
species are fixed through both natural selection and neutral mutations, but there is still
debate about the relative contributions (Bromham and Penny, 2003). In the context of
this thesis, it is important to note that proteins, over the course of generations, undergo
sequence changes. Sequence diﬀerences between two related proteins thus reflect the
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generational distance between these proteins and their last common ancestor9. In other
words, sequence dis-similarity indicates evolutionary divergence of related proteins. In the
following sections, I introduce two main concepts that were developed on this principle
and are used to describe evolution on a molecular level, protein homology, and protein
domains.
1.4.1 Protein Homology
According to the central dogma of molecular biology, proteins are the product of transcrip-
tion into messenger RNA and subsequently translation into polypeptides. Genes coding
for functional proteins in any organism do not arise spontaneously, but rather develop
their function and patterns of expression in a long succession of subtle or sometimes
dramatic changes across many many cycles of replication (Fitch, 1970). Thus, each
gene has a line of ancestors and, through ancestral duplication, homologous relatives
evolving in parallel lineages. Gene duplication is driven by a number of mechanisms,
for example through erroneous recombination, transposable element insertion or whole
genome duplication. Genes evolving independently within the genome of one species are
called paralogs if they can be traced back to a common ancestor. Another mechanism by
which the evolution of a gene can split into independent lineages is speciation. Genes
that derive from a common ancestor, but evolve independently in two separate species
are called orthologs. Figure 1.2 provides a graphical summary of these relationships.
It is a longstanding hypothesis that the formation of functionally redundant paralogs
through duplication within a genome can catalyse the evolution of new functionality (neo-
functionalisation) or the partitioning of the the original function (sub-functionalisation)
(Hughes, 1994; Lynch, 2000; Hanada et al., 2009). Orthologs on the other hand continue
to share similar function after speciation according to this hypothesis, also known as the
‘ortholog conjecture’ (Conant and Wolfe, 2008; Studer and Robinson-Rechavi, 2009).
A famous study on functional conservation between orthologous proteins was carried
out by Max Perutz who studied the structural and functional impact of mutations of
hemoglobin in diﬀerent classes of vertebrates (Perutz, 1983). In this thesis, I examine
9Emiel Zuckerkandl and Linus Pauling predicted this relationship (Zuckerkandl and Pauling, 1965)
and Kimura incorporated it into his theory of neutral evolution (Kimura and Ohta, 1971), coining the
term of a molecular clock. It was later shown by Dickerson that the ‘speed’ of this clock diﬀers between
species. This promoted the model of a ‘relaxed’ molecular clock (Dickerson, 1971; Sanderson, 1997).
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Figure 1.2: Schematic diagram of homologous relationships. This figure illustrates a hypo-
thetical phylogenetic tree delineating the evolution of an exemplary gene A. Branchpoints in
this tree represent events where gene A is duplicated either through speciation or within a
genome. The first speciation event separates the evolution of A into a human lineage and a
lineage representing the precursor of mice and rat. In this lineage, A is duplicated within the
genome, leading to the rise of a paralog B. In this diagram, A(hsap), A(Rnor) and A(Mmus)
are orthologs. In addition, A(hsap), B(Rnor) and B(Mmus) are also orthologs, as are B(Rnor)
and B(Mmus). A(Rnor) and B(Rnor) are paralogs, as are A(Mmus) and B(Mmus).
functional conservation between orthologs and paralogs in terms of susceptibility to small
molecule binding.
1.4.1.1 Computational approaches to assign protein homologous relation-
ships
The bioinformatics task of assigning orthologous and paralogous relationships between
genomic sequences is an important and challenging problem. The enormous growth
of genomic sequencing data over the last decade requires fully automated and eﬃcient
methods. At the same time, arrangements where speciation precedes duplication, leaving
for example a single gene in one species as an ortholog to two genes in another species
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make such assignments more complicated.
Early implementations of ortholog mapping approaches relied on manual curation for
this task, as seen in the COG database of orthologous clusters in prokaryote genes and
later addition of eukaryote genes (Tatusov et al., 2001; Tatusov et al., 2003, http://www.
ncbi.nlm.nih.gov/COG/). The COG ortholog assignments are still widely used, but the
manual approach to assigning orthologs does not scale up with the exponential growth
of genome sequencing data. Automated solutions that build orthologous relationships
from reciprocal pairwise sequence alignments of the protein coding sequences in two
genomes were developed towards the end of the millenium (Overbeek et al., 1999).
These methods are now referred to as bidirectional best-hit approaches (BBH) and are
still frequently used (Overbeek et al., 1999; Wolf and Koonin, 2012). The Inparanoid
resource of orthologous groups (Remm et al., 2001, http://inparanoid.sbc.su.se/
cgi-bin/index.cgi) aligns two proteomes using the BLASTP algorithm (Altschul
et al., 1990) and uses resulting BBHs as seeds for orthologous groups. These groups
are populated with all sequences most similar to the original seed sequences. The
OrthoMCL resource determines BBHs from all-versus-all alignments of any given number
of genomes and obtains orthologous groups using a Markov chain algorithm (Dongen,
2000; Li et al., 2003, http://orthomcl.org/orthomcl/). A diﬀerent approach is taken
by the EnsemblCompara Genetrees resource (ECG, Vilella et al., 2009, http://www.
ensembl.org/info/genome/compara/homology_method.html). The algorithm relies
on multiple sequence alignments (MSAs) to infer a tree structure of protein evolutionary
relationships. In the ECG implementation, BLASTP is used for all-versus-all alignments
and clusters are formed as in previous approaches. For each cluster, M-coﬀee (Wallace et
al., 2006) is used to obtain a consensus MSA. The tree-building algorithm TreeBest (http:
//treesoft.sourceforge.net/treebest.shtml) is used to infer a gene-tree structure
from the MSA. The algorithm also incorporates a preconfigured species tree and thus
reconciles gene- and organism-level trees (Dufayard et al., 2005).
The resources described above are approaches to assign orthologous relationships
between proteins of two or more species. However, as a byproduct of the clustering or
tree inference procedures, which associate related sequences between and within genomes,
they also provide mappings of paralogous relationships. In my thesis project, I worked
with the ECG resource. Through discussions with Albert Vilella I learnt that paralogous
mappings in ECG are limited to close relatives. For my purposes, this was an advantage
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when comparing orthologs and paralogs as described in chapter 4 (see also section 4.2.3).
In a benchmarking study, ECG was found to deliver decent performance compared to
other approaches (Altenhoﬀ and Dessimoz, 2009).
1.4.2 Protein domains
Protein domains are independent folding units that form the basic evolutionary and
architectural ‘building blocks’ of proteins (Blake et al., 1967; Wetlaufer, 1973). Within a
protein sequence, domains are subsets of consecutive residues that stabilise each other in
a defined arrangement of secondary structure elements. In most cases this is achieved
through the formation of a hydrophobic core as well as electrostatic interactions on the
domain surface (Chothia, 1984; Garbuzynskiy et al., 2013). In contrast to simple protein
folding units, protein domains are by definition structurally self-suﬃcient, meaning
they would retain their three dimensional geometry and often their function if cleaved
from the rest of the protein backbone (Levitt and Chothia, 1976). While there can
be large sequence diﬀerences between members of a domain family, the fold of the
peptide backbone is generally conserved (Chothia, 1984), even though exceptional cases
of homologous proteins with diﬀering folds have been identified and discussed (Grishin,
2001).
Most proteins in eukaryotes have two or more domains (Apic et al., 2001; Chothia
et al., 2003) and it has been observed that increasing complexity on an organismal level
also confers an increase of more complex multi-domain architectures (Koonin et al., 2000).
In some eukaryotic proteins, the underlying intron-exon structure of the gene reflects
the pattern of domain segmentation, suggesting that proteins can acquire new domains
through intronic recombination (Patthy, 1996). However, this mechanism accounts for
only a fraction of protein architectures, while in most cases, domains are gained through
non-allelic homologous recombination of nearby genes (Buljan et al., 2010).
A number of evolutionary constraints that favour multi-domain architectures have
been proposed. These include the rate of protein folding and protection from mis-folding
(Han et al., 2007; Garbuzynskiy et al., 2013), increased eﬃciency of cellular processes
through ‘forced’ spatial proximity of inter-dependent functional modules (Burns et al.,
1990; Marcotte et al., 1999; Enright et al., 1999) and the ‘syntactical’ re-use of existing
domains to serve new functions in reconfigured domain assemblies (Vogel et al., 2004).
23
Chapter 1. Introduction





 


	
			
Figure 1.3: Schematic illustration of domain fusion. GalE, consisting of a Epimerase and
Epimerase_Csub Pfam-A domain (red, for simplification shown as one domain), and GalM,
consisting of a Aldose_epim (blue) domain are individual proteins in E.coli. In S. cerevesiae,
these two genes are fused to form Gal10, a protein consisting of a Epimerase, Epimerase_Csub
(red, shown as one), and Aldose_epim (blue) domain. This figure is adapted from Enright
et al., 1999.
Figure 1.3 illustrates a simple example of a domain fusion of GalE and GalM to form
the bifunctional Gal10 protein in S. cerevesiae.
1.4.2.1 Frameworks to detect and represent protein domains
A number of frameworks exist for the detection and representation of domain architectures
in protein sequences. In the following I will give an overview of three widely used
frameworks, including the Pfam collection of protein families used in the mapping
of small molecule binding to protein domains presented in this chapter. The three
frameworks, SCOP, CATH, and Pfam can be grouped into structure- and sequence-based
approaches. SCOP (Murzin et al., 1995) and CATH (Orengo et al., 1997) are prominent
implementations that define protein architecture based on hierarchical definitions of three-
dimensional structural domains, while the remaining frameworks rely on sequence-based
methods for the detection of protein domains.
In SCOP, domains in proteins with known structure are classified according to a
hierarchy that includes a species level representing individual domains, a protein level
that groups orthologous domains from diﬀerent species, a family level that establishes a
grouping based on sequence similarity, a superfamily level that aggregates these groups
further based on shared structural and functional characteristics, and finally a fold level,
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that arranges superfamilies based on shared order and topology of secondary structure
elements. All domain models in SCOP are assigned in a manual curation process, but since
2008 this process is supplemented by sequence-based clustering methods (Andreeva et al.,
2008). When first published in 1995, SCOP listed 498 domain families, 366 superfamilies
and 274 folds (Murzin et al., 1995). In its latest release in the year 2009 (version 1.75),
SCOP listed 3,902 domain families,1,195 superfamilies and 1,962 folds. Major updates
to the SCOP database have introduced stable domain identifiers, improved definitions of
family and superfamily models, and addressed challenges imposed by the rapid growth
of structural data in recent years (Lo Conte et al., 2002; Andreeva et al., 2004; Andreeva
et al., 2008). In an extension to the manual approach of assigning SCOP classifications,
SCOPe is a framework for automated curation that achieves higher coverage of structures
in the protein data bank (PDB, Berman et al., 2007) compared to SCOP (Fox et al.,
2014).
CATH is another structure-based framework that uses a hierarchy of structural ab-
straction levels for the classification of proteins with known structure. Unlike SCOP,
which relies on manual curation, the classification of proteins with known structure in
CATH is carried out using a semi-automated procedure that operates on atomic coordi-
nates obtained from entries in the PDB. (Orengo et al., 1997). The hierarchy in CATH
is defined by homologous superfamilies at the most distributed level, where domains are
aggregated by sequence, much like the family level in SCOP. In the next higher order level,
termed topology, or T-level, domains are grouped by the arrangement and connectivity
of secondary structure elements. The architecture level further aggregates domains by
shape and orientation of structural elements with no constraints on connectivity. The
most general level in CATH is the class level, that abstracts protein domains to their
secondary structure content without further constraint (eg. all-alpha, alpha-beta, etc.).
The latest version of CATH contains 2,626 homologous superfamilies, 1,313 topologies,
40 architectures and 4 classes (Sillitoe et al., 2013). Recently, a genome annotation
approach has been launched that uses a combination of SCOP and CATH domains and
derived structure-prediction tools to provide protein-function predictions for proteins
with unknown structure (Lewis et al., 2012).
The concept of protein domains can be thought of as an extension of the homology
concept: While in most cases, protein sequences belonging to the same domain family
can not be related to each other through conventional sequence similarity methods,
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they are nevertheless expected to share a common ancestor. Structure-based domain
annotation methods such as CATH and SCOP make use of the greater conservation of
structure over sequence to assign protein sequences with known function to structural
domains. However, this is not an option for proteins with unknown structure. About two
decades ago, Krogh et al. reported the application of hidden Markov models (HMMs)
to address this protein classification problem (Krogh et al., 1994). HMMs have since
been successfully applied to discover relationships between remotely related sequences
with greater performance than traditional methods such as pairwise or multiple sequence
alignments (Park et al., 1998; Eddy, 1998; Lindahl and Elofsson, 2000). HMMs can also
be applied to other problems, such as the prediction of membrane-spanning sequences
(Krogh et al., 2001) Two popular implementations of HMM-based sequence homology
detection are SAM (Karplus et al., 1997; Karchin and Hughey, 1998) and HMMER3
(Eddy, 2008).
A number of methods to detect structural domains and functional motifs in sequences
are aggregated in Interpro, a service often used as a first point of reference in the
annotation of protein sequences with unknown function (Hunter et al., 2012). The
mapping of small molecule binding to protein domains described in this chapter uses
Pfam-A domains. Pfam-A domains are a set of manually curated HMM models of protein
domains that can be obtained from the Pfam database10 (Sonnhammer et al., 1997;
Sonnhammer et al., 1998). Since 2010, Pfam uses the HMMER3 algorithm to build
HMMs and query sequence databases (Finn et al., 2010). Functional annotations and
HMM seed alignments for Pfam-A domains are curated manually, and HMM models
are subsequently used to query the UniProtKB database (Magrane and Consortium,
2011) for additional homologs of a given Pfam-A domain. Pfam-A domain models
provide excellent annotation quality that has recently been integrated with the online
encyclopedia Wikipedia (Punta et al., 2012). The coverage of most sequenced genomes is
incomplete, but good in comparison with other annotation tools (Rekapalli et al., 2012;
Mistry et al., 2013). A further benefit of Pfam-A is the manual revision process of seed
alignments and the hidden markov models that ensures that Pfam-A domain annotations
are to the greatest extend non-overlapping (Finn et al., 2006). The non-overlapping
architectures described by Pfam-A models along with rich functional annotations for
each model made Pfam-A an ideal choice for the mapping presented in this Chapter.
10In addition to Pfam-A models, Pfam also provides Pfam-B models, which are not manually curated.
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1.5 Aims of the analyses
In this thesis I describe an integration approach of small molecule bioactivity data and
protein evolutionary information. The analyses were carried out with the aim to explore
the linkage between variation in the chemical and biological world through systematic
indexing and organisation of data from both domains. Two use cases, one revolving
around domain annotations from the Pfam database and the other around homology
relationship types extracted from the EnsemblCompara Genetrees resource demonstrate
that integration of bioactivity data can facilitate chemogenomics queries and answer
biologically relevant questions.
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Mapping of small molecule binding
to protein domains
2.1 Introduction
With the beginning of the molecular biology revolution, researchers acknowledged the
value of studying drug mechanisms as the interaction of a small molecule with specific
parts of a protein, often referred to as a binding site or binding pocket. An array
of techniques had become available through innovations in gene cloning and artificial
expression systems to study these interactions. They include site-directed mutagenesis,
alanine scanning, and increasingly, X-ray crystallography, and nuclear magnetic resonance
(NMR) techniques. Diverse as they are, the common objective of studies using these
techniques is to determine the binding mode or in other words the location and relative
orientation that a drug assumes when forming a bioactive complex with a protein. Studies
of binding modes have yielded detailed insights into the mechanisms of drug action and
have laid out the basis for virtual drug screening techniques such as molecular docking and
pharmacophore modelling. However, compared to biochemical and cell-based assays of
drug potency, technologies to determine the binding mode are relatively low in throughput
and thus for many pairings of small molecules and proteins, there is information about
the potency of the small molecule, but not its binding mode. This is also reflected in the
data available in ChEMBL, where most measured potencies have no complement in the
world’s largest repository of protein structures, the protein data bank (PDB, Berman
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et al., 2007). Knowledge of the binding mode is arguably the pinnacle of many drug
discovery programs, but for other applications less stringent definitions of the binding
site may be suﬃcient.
One such definition is provided by the concept of protein domains, which constitute
smaller subunits of proteins that fold independently. A view of small molecule binding
on the level of protein domains has lower resolution compared to a residue-level binding-
mode, but it provides an evolutionary context together with the sequence segment that is
most relevant to binding. An example where a domain-based annotation of small molecule
binding can be useful is the screening of newly sequenced pathogen genomes for potential
drug targets by sequence similarity searching (Tsai et al., 2013). Here, knowledge of where
approximately a small molecule binds a protein sequence helps limit the query sequence
to relevant protein domains. This reduces the query space and reduces false sequence
matches. Machine learning applications in drug discovery often seek to exploit sequence
information from proteins, genomes, and sometimes whole populations of genomes to
predict drug-protein interactions; these applications could likely also benefit from using
refined regions, such as the binding domain, as descriptors in their respective modelling
approaches.
For this chapter of my thesis I have implemented a mapping of the small molecule
binding events recorded in ChEMBL to protein domains as described by the Pfam
collection of protein families. Protein domains and their representation in the Pfam
database are introduced in more detail in section 1.4.2. In the following, I will discuss
the significance of the protein domain concept to drug discovery (see section 2.1.1 below)
and provide an overview of the mapping heuristic proposed in this chapter (see section
2.1.2).
2.1.1 The protein domain concept in drug discovery
Protein domain annotations have long been used to assign categories to drug discovery
projects and as a valuable resource in the assessment of novel drug targets (Breinbauer et
al., 2002). The interplay between molecular structure and function is generally appreciated
in the field of drug discovery and frequently applied in the prioritisation of screening
compounds and optimisation of lead structures (Johnson and Maggiora, 1990; Martin
et al., 2002; Eckert and Bajorath, 2007). Drug discovery approaches are not limited to
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the exploitation of similarities between ligand structures; similarities in protein structure
can equally be exploited to infer characteristics of potential drug targets, often also with
regard to small molecule binding properties. In this context, protein domains provide a
more systematic view of small molecule bioactivity that is underpinned by the theory of
molecular evolution. This is useful when inferring function and shared ligands beyond
the limits of pairwise similarity detection (Martin et al., 1998; Orengo et al., 1999).
A prominent example in this context is the unification of urease, phosphotriesterase,
aminodeaminase and other enzymes in a novel amidohydrolase superfamily with shared
active site characteristics (Orning et al., 1991; Jabri et al., 1995; Holm and Sander, 1997).
The domain perspective also provides examples of evolved structure-activity relationships,
as observed between the lactonizing enzyme, the mandelate racemase and enolase and
their respective ligands (Hasson et al., 1998).
With the advent of the genomics era, domain annotations have also been used to
quantify the content of the human genome in terms of ‘druggable’ domains (Hopkins and
Groom, 2002; Russ and Lampel, 2005). Hopkins and colleagues estimated the number of
genes encoding druggable proteins at around 3,000. Russ and colleagues proposed 2,200
druggable genes in a conservative estimate, and 3,000 in a more permissive estimate, albeit
with diﬀerent composition of domain types compared to Hopkins’ study. These studies,
while often limited by availability of data, have also shown clearly that the bulk of current
drug discovery eﬀorts is not uniformly distributed across domain types encountered in
the human genome, but rather, that there is a privileged subset of domains that are
more relevant in drug discovery. The mapping presented in this chapter capitalises on,
and significantly extends this finding, as described in the next section.
The protein domain concept also finds applications in the early stages of drug discovery.
Newly sequenced pathogen genomes are frequently scanned for genes encoding ‘druggable’
domain types (Berriman et al., 2009; Tsai et al., 2013) in order to identify potential
drug targets, or to identify proteins that can be targeted with existing drugs. In this
context, domain-based queries can help avoid a phenomenon I will in the following
refer to as ‘domain poisoning’, which occurs when the presence of a common ’spectator
domain’ links together targets on the basis of sequence searches, but the ligand-binding
domain is absent from the identified homologue. In this case, a database search for
potential ligands might result in a deluge of irrelevant compounds and thus ‘poison’ the
query and complicate subsequent analysis. Figure 2.1 illustrates an example of domain
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poisoning. The occurrence of domain poisoning when using whole sequences to query can
be overcome by very conservative cut-oﬀs for sequence similarity (Berriman et al., 2009).
Another solution would be a domain based query, however, this requires knowledge of
the binding domain for all proteins that are used to query a new genome (Tsai et al.,
2013). The mapping heuristic presented in this chapter was motivated in part by this
requirement.
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Figure 2.1: Domain poisoning of sequence-based queries. The schematic shows the domain
structure of a protein in a hypothetical query - the rat Tyrosine-protein phosphatase Syp
(P35235) - and one of the hits, retrieved from a BLAST query against the ChEMBL target
dictionary - the rat Tyrosine-protein kinase SYK (Q64725). The significant e-value for this
query results from high scoring alignments of the SH2 domains. At the same time, the overlap
between small molecules binding both proteins is expected to be low.
2.1.2 A heuristic mapping that relies on domain-based annota-
tion transfer
The domain concept introduced in the previous section provides numerous benefits
when applied in a drug discovery context. One of them is a more systematic view of
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small-molecule bioactivities, and another the possibility of linking potential drug targets
beyond pairwise sequence-similarity. To realise these benefits, it would be desirable to
annotate small molecule bioactivities with information about the domain or domains
that mediate small molecule binding. In a typical drug discovery project that focusses
on one or few targets, this task is often so trivial that knowledge of the binding domain
remains implicit. On the other hand, in data-mining approaches, this lack of explicit
knowledge of the binding domain is often insurmountable due to the sheer number of
interactions that need to be examined. One of the goals of my work is therefore to provide
this annotation for bioactivities stored in the ChEMBL database using a generalisable
mapping procedure.
The mapping heuristic presented here is based on a corpus of protein domains with
known small molecule interactions. This corpus is derived from single-domain proteins
with measured small molecule interactions in the ChEMBL database. In theory, it could
however be replaced by any other catalogue of domains. This catalogue can then be
projected onto small-molecule protein interactions, in this case, measured bioactivities
stored in the ChEMBL database. Figure 2.2 provides a schematic illustration of this
process and highlights constellations that may cause issues when this mapping is applied
to measured activities. In one of these constellations, the mapping is not applicable to
a protein sequence because there is no overlap between domains in the sequence and
domains in the catalogue. In the other constellation, more than one domain in the protein
sequence of interest is present in the catalogue, resulting in a conflicting mapping. In
sections 2.2.4 and 2.3.3, the impact of these constellations on the mapping process will
be presented in detail.
The design and implementation of the mapping was inspired by homology-based
annotation transfer, a methodology that is frequently used in bioinformatics to provide
functional annotations for new protein- or nucleotide sequences. Homology-based an-
notation transfer can result in inaccurate or incorrect annotations, but, owing to its
high coverage, often remains as the only feasible solution for large data sets (Hegyi
and Gerstein, 1999; Devos and Valencia, 2000). In analogy to the transfer of functional
annotation between homologous proteins, the mapping heuristic was envisaged to trans-
fer binding site annotations between protein domains. I deemed this transfer justified
because it is known from molecular dynamics simulations that conformational variability
between homologous proteins is often within the bounds of the dynamic conformations
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Figure 2.2: Schematic illustration of homology-based transfer of binding annotation. The
schematic shows how a catalogue of Pfam-A domains with known small molecule interactions
was created from the corpus of single-domain proteins within the ChEMBL database. In a
second step, this catalogue was projected onto protein sequences matching more than one
Pfam-A models. Three possible outcomes are: i) A successful mapping if exactly one of the
Pfam-A domain models from the catalogue matches the sequence; ii) No mapping if none of
the Pfam-A domain models from the catalogue match the sequence; iii) A conflicting mapping
if multiple domain models from the catalogue match the sequence.
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assumed by a protein in solution (Elber and Karplus, 1987). Further, from studies of
functional conservation within domain families, it is known that the presence of a binding
site is conserved in most cases, even though conservation of ligand specificity may vary
(Martin et al., 1998; Tanramluk et al., 2009). It has further been shown that protein
surfaces as well as small molecule interaction sites are conserved within domain families
(Zhang et al., 2010; Davis and Sali, 2010; Kufareva et al., 2012) and an application of
domain-based annotation transfer has previously demonstrated that this method can
be used to make proteome-wide predictions of small molecule and protein binding sites
(Davis, 2011). Thus, I present here a novel and fully implemented mapping heuristic
inspired by homology-based transfer of functional annotations.
Previous computational approaches have linked small molecule binding to protein
domains. In 2006, Snyder and colleagues used crystallographic structures from PDB and
domain annotations derived from the conserved domain database (CDD) to obtain a set
of ligand-domain interactions (Snyder et al., 2006). These interaction were used to build
profiles of ‘position specific’ binding sites that map small molecule binding to a domain
rather than protein sequence. Remarkably, Snyder et al. demonstrate that this approach
can be useful for drug repurposing approaches. The mapping produced in this chapter
diﬀers from Snyder’s work in that it relies on potency measurements retrieved from the
ChEMBL database to assign small molecule-domain interactions.
In 2009, Bender and colleagues described a method to predict protein targets for active
compounds that was based on statistical associations of Interpro domain annotations
and small molecule binding events recorded in the WOMBAT database (Bender et al.,
2009). The representation of small molecule-domain interactions in this approach is more
abstract than the direct mapping presented here and includes weighted contributions
of domains that do not physically interact with a given small molecule. In 2011, Davis
published the binding site prediction method discussed above (Davis, 2011). The same
year, Yamanishi and colleagues proposed the use of sparse canonical correspondence
analysis, a statistical approach that extracts combinations of chemical substructures
and Pfam domains as features to model and predict small molecule-domain interactions
(Yamanishi et al., 2011). In 2012, Wang, Nacher, and colleagues published a method
that predicts drug targets based on drug-protein interactions recorded in DrugBank
(Wang et al., 2012b). Later that year, an initial implementation of the mapping presented
here was published (Kruger et al., 2012) and Li and colleagues published a mapping
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of small molecule binding to protein domains that was based on interactions obtained
from the inferred biomolecular interaction server (IBIS, see Shoemaker et al., 2010)
(Li et al., 2012). Li and colleagues use this mapping to analyse a network of protein
domains that are joined through shared ligands. In an analysis similar to Li and Nacher’s
approach, Moya-Garc´ıa et al. used interactions from DrugBank to construct a network
of drug-domain interactions in a analysis published in 2013 (Moya-Garc´ıa and Ranea,
2013). Thus, there has recently been a large amount of development in the area of small
molecule-protein domain interactions and it gives reason to hope that the foundation-work
presented in many of these studies will find use in future drug discovery applications.
2.1.3 Outline
In this chapter of my thesis, I present an approach to map small molecule binding recorded
in the form of potency assays within the ChEMBL database to confined regions within a
protein. These regions stem from annotations provided through the Pfam-A collection
of protein domain models (see section 1.4.2.1). Pfam domain annotation is automatic
and based on protein amino acid sequence; it does not require knowledge of the three-
dimensional structure of a protein. In a wider sense the aim was to obtain a catalogue of
protein domains with observed small molecule interactions that are meaningful in a drug
discovery context. The performance of the mapping was evaluated against binding site
annotations extracted from PDBeMotif (Golovin and Henrick, 2008), a protein structure
resource, and against UniprotKB (Magrane and Consortium, 2011), a protein sequence
and annotation repository. The work presented in this chapter was also an eﬀort to
provide annotations of the binding region for activities stored in the ChEMBL database
to the research community. The implementation and devised delivery of this mapping is
described in chapter 3.
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2.2 Results
2.2.1 Small molecule binding within the boundaries of Pfam-A
domains
In this section, I present an analysis of the occurrence of small molecule binding sites
and Pfam-A domain models. This analysis was carried out to verify a prerequisite for my
mapping heuristic: The notion that small molecule binding takes place within structured
regions in a protein that are covered by Pfam-A models. To probe this hypothesis I
used binding site information available from two bioinformatics resources, PDBeMotif
and the Uniprot database. I retrieved binding site information from PDBeMotif where
interactions corresponding to a given complex of protein and small molecule were also
recorded in ChEMBL (release chembl 13, for details see Methods section 2.5.6 and 2.5.8).
In total I obtained binding site information for 496 complexes. Some of these complexes
are represented in the PDB by multiple entries, so this corresponds to 3,341 individual
PDB entries. For each complex I assessed a measure k defined as:
k =
n(BSRPfam-A)
n(BSR)
, (2.1)
where n(BSRPfam-A) is the number of binding site residues that fall within the boundaries
of any Pfam-A domain and n(BSR) is the number of all binding site residues (see Methods
section 2.5.11). Thus, for each complex, k indicates to which degree small molecule
binding is tied to specific Pfam-A domains.
To compare residue positions obtained from PDBeMotif with domain boundary
positions from Pfam, the SIFTS mapping (Velankar et al., 2013) was used to translate
residue positions between the two resources (see Methods section 2.5.10). As a threshold
for a strong association between a small molecule binding site and a domain described
by a Pfam-A model, I chose 0.5. This choice is arbitrary, but I am confident that it gives
a good indication that the binding of a small molecule is mediated through this domain,
even if not all residues interacting with the molecule are part of the Pfam-A model. I
found that at this threshold, small molecule binding was associated with Pfam-A domains
for 477 small molecule-protein complexes, or 96.2% of all examined complexes from
PDBeMotif. When shifting the threshold up or down to 0.25 or 0.75, the corresponding
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numbers of entries are 487 (98.2%) and 447 (90.1%), respectively. Figure 2.3A provides a
graphical summary of the coincidence of Pfam-A domains and residues involved in small
molecule binding.
I also retrieved binding site information from the Uniprot database (see Methods
section 2.5.7). Binding site annotation in Uniprot is mostly focussed on key residues
interacting with natural ligands, such as catalytic centres, and residues that leverage
conformational changes upon ligand binding. Uniprot is a protein-centric database and
entries for some of the proteins provide binding site annotation for multiple ligands
simultaneously. In some cases, the ligand is not explicitly specified and more often is
referred to by a trivial name or an acronym. It is diﬃcult to relate these identifiers to
small molecules in the ChEMBL database. For this reason, I limited my survey to protein
sequences from the ChEMBL target dictionary, but did not further limit this set to small
molecule-protein complexes with corresponding entries in the ChEMBL database. In
total, I obtained binding site annotations for 1,460 Uniprot entries. Again, for each entry
I assessed a measure k as defined in equation 2.1. The number of binding sites with
k ≥ 0.5 was 1,418, corresponding to 97.1% of all examined entries. At k = 0.25 and
k = 0.75, the correspondong numbers were 1,424 (97.5%) and 1,330 (91.1%). Figure 2.3B
provides a graphical overview of all possible threshold values for k. Both the coordinate
data from the crystallographic structures accessed through PDBeMotif as well as the
manual annotations accessed through Uniprot indicate that small molecule binding is
limited in the vast majority of cases to those regions in protein sequences that are covered
by Pfam-A models. Thus, a first requirement for the mapping presented in this chapter
withstood a test constructed from publicly available binding site data. In the following
section I present an investigation of the coverage on Pfam-A models for proteins in
ChEMBL to probe a second requirement for the mapping.
2.2.2 Domain coverage of the human genome and ChEMBL
target dictionary
One other prerequisite of the mapping heuristic that I present in this chapter is suﬃcient
coverage of target proteins by the conserved regions that constitute Pfam-A families.
To probe this, I investigated Pfam-A coverage both for the human proteome as well as
proteins in the ChEMBL target dictionary (release chembl 13). Uniprot accessions for
38
Chapter 2. Mapping of small molecule binding to protein domains





     





   
	
			
	
	

 
!"	
 
##

	$
	
%!
	

 
!"	
 
##

	$
	
%!
	$	%& 	$	%	
 
Figure 2.3: Small molecule binding within Pfam-A domains. Panel A depicts binding of small
molecules within Pfam-A domains for protein-ligand complexes obtained from PDBeMotif. The
measure k shown on the y-axis describes the fraction of binding-site residues within a Pfam-A
domain over all binding site residues. The plot shows k as a cumulative distribution function of
the number of entries having a value of at most k as indicated on the y-axis. Panel B illustrates
the cumulative distribution function of the same measure for binding site annotations retrieved
from Uniprot. Dashed horizontal lines represent the threshold value for k that indicates strong
association of a domain and a site for small molecule binding.
39
Chapter 2. Mapping of small molecule binding to protein domains
the human proteome were retrieved from the Ensembl Biomart as described in Section
2.5.2. In total, I obtained 18,932 Uniprot accessions, representing all recorded proteins
and protein isoforms encoded by the human genome. I retrieved Pfam-A annotations for
all protein sequences associated with these Uniprot identifiers from the Pfam database
(release Pfam 26.0, see Methods section 2.5.1). Further, I obtained Pfam-A annotations
for 3,075 non-human proteins in the ChEMBL database target dictionary. A number of
Uniprot identifiers had to be discarded because requests to the Pfam API returned empty
documents for these identifiers. The errors I encountered were due to the asynchronous
release cycles of the Ensembl Biomart and Pfam resources. Uniprot identifiers that have
been generated after the release of the latest Pfam version do not have corresponding
entries in Pfam and hence requests for these identifiers return an empty document. Of
the initial 22,020 submitted Uniprot identifiers, 277 returned empty documents, leaving
21,743 proteins for the analysis. I then determined the number of Pfam-A domains for
each protein sequence. 12.3% of all human proteins have no mapped Pfam-A domain,
corresponding to a number of 2,305 proteins. By contrast, in the ChEMBL target
dictionary, this fraction is only 1.0%, which corresponds to 58 sequences with no Pfam-A
domain. For the subset of ChEMBL target proteins of human origin, this fraction is 1.2%,
corresponding to 31 sequences with no Pfam-A domain. Figure 2.4A gives an overview of
the distribution of domain numbers for each data set. I also determined for each protein
the coverage by Pfam-A domain models. To this end, I determined a measure ρ of the
coverage for each protein sequence:
ρ =
nPfam-A
nall
. (2.2)
Here, nPfam-A is the number of residues covered by Pfam-A models and nall the number
of all residues in a sequence. Figure 2.4B summarises values of the coverage ρ for all
sets of proteins. For the entire set of human-derived proteins, the coverage varied highly
between diﬀerent proteins, with a median ρ of 0.53. The outer limits of the second and
third quartile were located at ρ = 0.25 and ρ = 0.77. The coverage for ChEMBL targets
is again significantly higher, with median ρ = 0.74 and ρ = 0.71 for all ChEMBL proteins
and the subset of human proteins, respectively. Outer limits of the second and third
quartile are located at 0.58 and 0.87 for all ChEMBL proteins and 0.53 and 0.86 for
the subset of human proteins in ChEMBL. Thus, Pfam-A coverage of proteins from the
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ChEMBL target dictionary is significantly higher than coverage of the human genome.
This finding is discussed in section 2.3.1.2.
2.2.3 A catalogue of protein domains with known small molecule
interactions
Having established that small molecule binding as reported in ChEMBL is well covered
by Pfam-A annotations, I devised a simple heuristic to infer a catalogue of Pfam-A
domains with known small molecule interactions. To achieve this I examined single-
domain proteins and assessed whether Pfam-A domains in these proteins could be added
to the catalogue through homologous transfer. Pfam-A domains from protein sequences
with only a single Pfam-A domain model were added to the catalogue if evidence of
small molecule binding was recorded in the ChEMBL database. Evidence was collected
from the ChEMBL database (release chembl_13) by screening for measured activities
from binding assays that could be mapped to a protein sequence without ambiguities.
Methods section 2.5.3 describes the process of obtaining evidence for small molecule
binding in detail. It should be pointed out that in a manual curation step, a number
of single-domain proteins that constitute fragments of longer sequences were flagged to
be ignored when compiling the list of Pfam-A domains. This was done to ensure only
Pfam-A domains that mediate the interaction with small molecules are incorporated into
the catalog. Methods section 2.5.4 describes this step in detail.
The initial catalogue was assembled from 1,161 single-domain proteins with small
molecule interactions measured in cell-free assays with unambiguously defined protein
targets (for details see Methods section 2.5.3). This process yielded a list of 274 Pfam-A
domain types. This list did not include the Pkinase Tyr domain because this type of
domain does not occur in single-domain proteins, but always in combination with at
least one other domain. Given the ample evidence for small molecule binding for this
type of domain, I added it manually to the catalogue (for details refer to section 2.3.3.1).
The complete catalogue from the first implementation of the mapping thus consisted
of 275 Pfam-A domain types. A full listing of identifiers is provided in the Appendix
section 5.3. Six exemplary Pfam-A domains from this set are discussed in section 2.3
together with the associated evidence of small molecule binding.
In addition to Pfam domain models, the Pfam database provides a grouping of
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Figure 2.4: Overview of Pfam-A coverage. Panel A illustrates Pfam-A coverage on a per
protein sequence level. The histogram bars represent fractions of protein sequences with n
Pfam-A models, where n is the position of a bar on the x-axis. Pfam-A coverage on a protein
sequence level is shown for all proteins in ChEMBL (orange), the subset of human proteins
in ChEMBL (green) and the human proteome as retrieved from the Ensembl biomart (blue).
Panel B shows Pfam-A coverage on a residue level, indicating for each protein the fraction of
residues that are covered by Pfam-A models. The data for each set are summarised in box plots
where the mid-line indicates the median, lower- and upper hinge the 25th and 75th percentile,
and whiskers extend to 1.5 multiples of the interquartile range, with data points outside of
these ranges plotted as outliers. Colour coding is the same as in panel A.
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Table 2.1: The ten most frequent Pfam domain clans in the catalogue of Pfam-A domains with
known small molecule interactions. This table lists the ten most frequent Pfam domain clans in
the catalogue of Pfam-A domains with known small molecule intercations. The clan names in
the first column were obtained from the clan_id field in Pfam. Counts of individual Pfam-A
domains assigned to each clan are provided in the second column and a short description
obtained from Pfam is presented in the third column.
Clan name count description
NADP Rossmann 14 FAD/NAD(P)-binding Rossmann fold superfamily
Glyco hydro tim 11 Tim barrel glycosyl hydrolase superfamily
AB hydrolase 9 α/β hydrolase fold
P-loop NTPase 8 P-loop containing nucleoside triphosphate hydrolase su-
perfamily
TIM barrel 8 Common phosphate binding-site TIM barrel superfamily
MFS 5 Major Facilitator superfamily
PLP aminotran 5 PLP dependent aminotransferase superfamily
Beta-lactamase 4 Serine β-lactamase-like superfamily
HUP 4 HIGH-signature proteins, UspA, and PP-ATPase.
Peptidase CA 4 Peptidase clan CA
Pfam-A domains into clans, or collections of similar Pfam-A domains. I assessed the
clan associations among the 275 Pfam-A domain types and found that most of the 102
identified clans are occupied by one or two Pfam-A domain types. There was only a
small number of clans with more than two representatives in the catalogue. The ten
most frequent clans are listed in table 2.1. It is important to note that this rather
uniform distribution across clans does not reflect the distribution of measured activities
- as described in Chapter 3, the distribution of activities over domain types follows a
distribution that is much more polarised.
2.2.4 Mapping small molecule binding by domain-based anno-
tation transfer
In the previous section I described how I established a preliminary catalogue of Pfam-A
domains with known small molecule interactions. In this section I describe how I used
this catalogue to infer regions mediating small molecule binding in protein sequences
matching one or multiple Pfam-A domain models. The latter will in the following be
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referred to as multi-domain sequences, even though it is expected that a number of those
protein sequences that match only a single Pfam-A domain model are also multi-domain
proteins. Mapping was attempted for protein sequences that were unambiguously defined
as targets of a binding assay with at least one active compound (using the same criteria
as described in Methods section 2.5.3). I inferred regions of small molecule binding for all
eligible protein sequences by domain-based annotation transfer. In practice, this entailed
a projection of the catalogue of validated domains onto eligible sequences. Figure 2.2
shows a schematic representation of this process. For each protein sequence subject to
the mapping, three outcomes are possible:
(i) One of the catalogue domains could be matched to a domain in the protein sequence
and small molecule binding was mapped to this Pfam-A domain.
(ii) None of the Pfam-A domains in the catalogue matched the protein sequence and
no mapping was made.
(iii) More than one Pfam-A domain from the catalogue matched the sequence and the
sequence was annotated with a conflicting mapping.
The third outcome was treated as if no mapping had been assigned, but the protein
sequence would be flagged for manual curation. Manual curation would be carried out
using the curation interface described in chapter 3. The mapping was applied to 2,436
proteins with measured activities in the ChEMBL database (version chembl 13) and
yielded mappings for 1,740 protein sequences (or 71.4%), of which 579 were multi-domain
proteins. From the catalogue of 274 Pfam-A domain models with known small molecule
interactions, only 59 were projected onto multi-domain proteins. Kinase domains were
among the most frequently projected, followed by the ANF receptor and Ion trans
domains. Table 2.2 lists the ten most frequently projected domains and summarises the
number of targets and activities covered by this projection. Appendix table 5.3 provides
a full list of the projected domains. (See methods section 2.5.5)
To validate the mappings, I again used binding site annotations obtained from
PDBeMotif and Uniprot. For each sequence with an assigned mapping, I compared the
overlap of annotated binding site residues and the mapped Pfam-A domain (see Methods
section 2.5.11). A measure kpred of the prediction coverage was determined for each
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Table 2.2: Pfam-A domain types projected onto multi-domain proteins. The table summarises
all Pfam-A domain types from the catalogue of Pfam-A domains with known small molecule
interactions that were projected onto multi-domain proteins. The column headed ‘mapped
proteins’ provides the number of multi-domain proteins a given Pfam-A domain was projected
onto, the column headed ‘mapped activities’ the number of corresponding measured activities.
Pfam-A mapped proteins mapped activities
Pkinase Tyr 90 9,877
Pkinase 75 4,027
ANF receptor 48 2,358
Ion trans 46 3,889
Hormone recep 45 7,386
Neur chan LBD 33 1,163
Peptidase C1 30 4,069
Trypsin 26 3,808
Peptidase M10 21 4,053
PDEase I 17 724
protein sequence:
kpred =
n(BSRpred)
n(BSR)
, (2.3)
where n(BSRpred) is the number of binding site residues that fall within the boundaries
of the predicted Pfam-A domain and n(BSR) is the number of all binding site residues.
For each complex, the measure kpred thus indicates the degree to which small molecule
binding is associated with the predicted domain. I once again argued that at kpred = 0.5,
a mapping can be considered correct because small molecule binding is clearly associated
with a domain. The analysis of the prediction coverage was split according to whether a
protein sequence matched one or multiple Pfam-A domain models. For small molecule-
protein complexes with binding site annotations from PDBeMotif, 96.9% of single-domain
complexes and 88.8% of multi-domain complexes had correctly assigned binding sites at
this threshold. For proteins with Uniprot binding site annotations, 97.5% of single- and
87.2% of multi-domain proteins had correctly assigned binding sites. As expected, the
mapping results are thus better for single-domain proteins over multi-domain proteins,
but overall satisfactory for either category. A graphical summary of the mapping’s
performance under diﬀerent thresholds is given in Figure 2.5.
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Figure 2.5: Small molecule binding within Pfam-A domains. Panel A depicts binding of small
molecules within Pfam-A domains for protein-ligand complexes obtained from PDBeMotif.
The measure kpred shown on the y-axis describes the fraction of binding-site residues within a
Pfam-A domain over all binding site residues. The plot shows kpred for single- (blue line) and
multi-domain proteins (red line) as a cumulative distribution function of the fraction of entries
having a value of at most k as indicated on the y-axis. Panel B illustrates the cumulative
distribution function of the same measure for binding site annotations retrieved from Uniprot.
Dashed horizontal lines represent the value for kpred that indicates strong association of a
domain and a site for small molecule binding.
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Table 2.3: Detail view of mapping evaluation. The table summarises the outcome of the
mapping evaluation for individual target classes. Results are split by single- and multi-domain
proteins. The column ‘kpred’ indicates the average across all assessed complexes in a protein
class. The column ‘count’ indicates the number of assessed complexes in a class. ‘LGIC’ -
ligand gated ion channel; ‘None’ - proteins without assigned target class.
PDBeMotif Uniprot
single multi single multi
protein class kpred count kpred count kpred count kpred count
7TM1 0.50 2 0.41 1 1.00 18 1.00 1
7TM3 - - - - - - 0.80 3
Cytochrome P450 1.00 1 - - 1.00 2 - -
Kinase 1.00 16 0.89 29 1.00 72 0.94 156
LGIC - - 0.14 7 - - 0.00 16
None 0.92 97 0.79 11 0.94 177 0.69 23
Nuclear Receptor - - 0.92 20 - - 0.84 13
Phosphatase 0.97 1 1.00 1 1.00 5 0.88 4
Phosphodiesterase 1.00 4 1.00 2 1.00 5 0.61 7
Protease 0.96 7 0.98 19 1.00 5 0.62 4
For a more detailed view of the mapping perfomance, results of this evaluation were
split into a human and non-human set and further categorised by the ‘class’ of the
protein, as described by the L2 field in the target_class table of the ChEMBL database.
Results are summarised in Table 2.3. Across a range of protein classes, the mapping
performed well, with average values for kpred well above the threshold of 0.5. However, I
observed poor mapping performance for the class of ligand-gated ion channels. Factors
contributing to poor performance for this class may be the complex architecture of these
channels and the presence of multiple ortho- and allosteric binding sites. In section 2.3.3,
I discuss some configurations that impose obstacles to accurate mapping and may in part
explain the poor performance of the mapping on the class of ligand-gated ion channels.
Overall, the mapping had acceptable performance for multi-domain proteins and good
performance for single-domain proteins.
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2.3 Discussion
2.3.1 Prerequisites of the mapping heuristic
The implementation of the mapping heuristic presented in this chapter is straight-forward.
A catalogue of Pfam-A domains with known small molecule interactions was constructed
from a list of single-domain proteins in the ChEMBL target dictionary. In a second step,
this catalogue was projected onto multi-domain proteins. The mapping heuristic relied
on three prerequisites. These were:
(i) Small molecule binding takes place within those regions in a protein sequence that
are covered by Pfam-A domains.
(ii) Pfam-A annotations have good coverage on protein sequences that are subject to
the mapping.
(iii) Pfam-A annotations do not overlap.
The first requirement is easily explained: If small molecules routinely bind regions not
covered by Pfam-A models, there is no point in mapping small molecule binding to
Pfam-A domains. The second prerequisite is an extension of the first. In the first
step of the mapping, a catalogue of Pfam-A domains with proven capability of small
molecule binding was constructed from single-domain proteins. If structured regions
in these proteins remain uncovered by Pfam-A models, then the possibility that small
molecules could bind through these regions reduces confidence in the mapping. The
third prerequisite ensures that there are no constellations of overlapping domains that
confound the mapping. It also makes it easier to understand and interpret the mapping.
Pfam-A models are curated to be non-overlapping (Sonnhammer et al., 1998) and within
the ChEMBL dataset I discovered no overlaps apart from a few instances of overlap at
the very margins of two Pfam-A models (data not shown). In the following, I discuss the
first and second prerequisite in the light of my findings from sections 2.2.1 and 2.2.2.
2.3.1.1 Small molecule binding within the boundaries of Pfam-A domains
The first prerequisite for mapping small molecule binding to Pfam-A domains is that small
molecules actually bind proteins through regions that are covered by Pfam-A domains.
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There are a number of arguments to support this notion. Small molecule binding to
proteins has been studied mostly at sites that are evolutionary conserved (Lichtarge
et al., 1996) and therefore more likely to be covered by Pfam-A models. Whether this is
due to a bias in drug discovery for ‘easier’ targets or whether it reflects an underlying
propensity for small molecule binding to take place in structured regions in a protein is an
important consideration (Metallo, 2010). In the context of this mapping this point is less
important because the data I used to carry out the mapping is almost entirely derived
from traditional drug discovery projects. To support my argument further, I tested it
against binding site annotations from two public resources, Uniprot and the PDBe as
described in section 2.2.1. The results of this analysis demonstrated a high coincidence of
sites for small molecule binding and Pfam-A domains. 96.2% of protein-ligand complexes
from PDBe had at least half of all binding site residues within a region covered by a
Pfam-A model. For binding site residues obtained from Uniprot, the same measure was
97.1%. Binding site annotations from PDBeMotif are derived from structure coordinate
data and typically comprise between 8 and 15 residues. Binding site annotations from
Uniprot are assigned manually and mostly focussed on a small number of key residues,
such as catalytic centres of enzymes or attachment sites for covalent ligands (personal
communication Ursula Hinz, SIB, Geneva). Annotations from both data sources are
therefore somewhat complementary. These diﬀerences are also reflected in the diﬀerent
shapes of the cumulative distribution functions shown in Figure 2.3. Taken together,
considerations from first principles and the results presented in section 2.2.1 support
strongly the prerequisite that small molecule binding (as encountered in the ChEMBL
database) is confined to those regions in protein sequences that are covered by Pfam-A
models.
2.3.1.2 The implications of Pfam-A model coverage
Of crucial importance to the mapping presented in this chapter is the coverage of proteins
in the ChEMBL target dictionary with Pfam-A domains. This is important because
evidence of small molecule binding for individual Pfam-A domains was collected under the
premise that proteins with only a single Pfam-A annotation do indeed not contain other
domains through which small molecule binding could take place. In section 2.2.2, I have
presented an assessment of the coverage on Pfam-A models. I found that on a protein
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level, about 99% of proteins in the ChEMBL target dictionary have been annotated with
at least one Pfam-A domain. This is in contrast to the entire set of human proteins,
where less than 88% of proteins have Pfam-A annotations. Taken together, these findings
indicate that proteins in the ChEMBL target dictionary generally have good annotation
with Pfam-A domains. The findings also suggest that with regard to Pfam-A annotations,
proteins in ChEMBL constitute a privileged set compared to the entirety of the human
proteome. On a residue level, the median coverage of the human proteome is 0.5, but
with considerate variation for individual proteins, with an interquartile range of 0.52.
For proteins higher in the spectrum of Pfam-A coverage, it appears likely that uncovered
residues constitute N- and C-terminal extensions of Pfam-A domains beyond the borders
of the HMM. In addition, these regions can represent flexible loops linking separate
domains. For those proteins lower in the spectrum of Pfam-A coverage, it appears more
likely that some structured regions have missing Pfam-A domain annotation, especially if
one assumes that most proteins are fully structured, as previously proposed (Apic et al.,
2001). A recently published study reviews the coverage of the human genome by Pfam-A
and Pfam-B models and the results with regard to residue-level coverage are very similar
to the results presented in this chapter (Mistry et al., 2013). The authors of the study
suggest that un-annotated regions might represent a highly diverse set of families as well
as unstructured regions. With regard to the mapping heuristic, neither of these types of
regions are likely to mediate small molecule binding as reported in ChEMBL. Remarkably,
coverage of proteins in the ChEMBL target dictionary is significantly higher compared to
the human proteome and seems near-complete for the majority of proteins, with a median
coverage of 0.75 and a much lower interquartile range of 0.29. It further is likely that
Pfam-A domains that are relevant to small molecule binding have been prioritised during
the manual process of model creation and annotation. The prioritisation of Pfam-A
domain types occurring in proteins of high scientific interest, such as known and potential
drug targets is stated as an explicit goal of the Pfam-A curation eﬀort (Mistry et al.,
2013; Punta et al., 2012). I am therefore confident that for most single-domain proteins,
which are so crucial to the mapping, the coverage with Pfam-A models is near-complete
with few omissions, that are mainly structured or unstructured regions not involved in
small molecule binding.
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2.3.2 Small molecule binding to Pfam-A domains and evidence
from ChEMBL
The initial implementation of the mapping heuristic yielded a catalogue of 274 Pfam-A
domains with evidence for small molecule binding. This catalogue was described in a
conference supplement (Kruger et al., 2012) and used as the starting point for curation
and analysis described in this thesis chapter. Given that the human proteome counts
5,494 individual domains and ChEMBL has 1,771 individual domains, the relatively small
count of 275 suggests that there is a privileged subset of domains that are targeted in
drug discovery programs. The number of domains in the catalogue is too large to discuss
each individually, but in the following I discuss three exemplary Pfam-A domains and
the associated evidence for small molecule binding. These three domains were selected
to convey a glimpse at the underlying data set and to show that the body of evidence
for small molecule binding diﬀers between domain types. Evidence for small molecule
binding to four additional Pfam-A domains is presented in the Appendix figures 2, 3, 4
and 5. Evidence for small molecule binding was collected from the chembl_15 release of
the ChEMBL database.
2.3.2.1 The HN domain
The HN Pfam-A model represents a subfamily of glycoside hydrolases termed family
83. This family belongs to the clan of Sialidases, which are enzymes that catalyse the
the removal of sialic acid from glycoproteins. They are found in many species, but
are especially well known as virulence factors produced by bacteria and viruses. The
glycoside hydrolase family 83 is found across a wide range of viruses and its members
function in the virus’ attachment and fusion to the host cell (Taylor, 1996). A number of
crystal structures of proteins containing this domain type have been determined. The
earliest structure is that of the hemagglutinin-neuraminidase of the Newcastle disease
virus in the year 2000 (Takimoto et al., 2000). Multiple drugs have been developed that
exert an antiviral eﬀect though inhibition of proteins containing the related Neur Pfam-A
domain, including oseltamivir, zanamivir, laninamivir and peramvir.
Evidence for small molecule binding to the HN domain is provided in Figure 2.6 and
comes from two publications recorded in the ChEMBL database . In total, there were
16 compounds with 16 measured interactions for this domain. The protein targets for
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these compounds are the hemagglutinin-neuraminidase from the human parainfluenza
virus 1 and glycoprotein G from the Nipah virus. Evidence shown here comes from two
publications (Nishino et al., 2011; Niedermeier et al., 2009). Only 6 of 16 tested compounds
have a measured IC50 or comparable activity type of 1 µM or more potent. These 6
compounds demonstrate that small molecule binding to the HN domain is possible, but
the evidence is scarcer than for other domain types, as for example the Carb_anhydrase
domain discussed below.
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Figure 2.6: Evidence for small molecule binding to the HN domain. Measured interactions
are shown for six molecules. Molecules are identified as in the molregno database field and
measured potencies expressed as pIC50 values. Two exemplary ligand structures are provided
in the right plot margin.
2.3.2.2 The Carb_anhydrase domain
The Carb_anhydrase Pfam-A model represents the catalytic domain of a large family
of the enzyme family of carbonic anhydrases. The Carb_anhydrase is not part of a
higher order clan, but comprises more than 3,000 protein sequences across almost one
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thousand diﬀerent species according to the Pfam website. It is found in species from all
branches of the tree of life with wide-spread occurence in prokaryotes and virtually all
metazoans (Smith et al., 1999). The enzyme catalyses the hydration of carbon dioxide
to form bicarbonate, as well as the reverse reaction, and plays a crucial role in acid-
base homeostasis. An abundance of crystal structures of proteins with Carb_anhydrase
domains have been determined (in excess of 500) starting with the structure of the human
erythrocyte carbonic anhydrase C in 1972 (Kannan et al., 1972). The human carbonic
anhydrase has been exploited as a drug target for a number of indications including
glaucoma, hypertension and epilepsy. Approved inhibitors of carbonic anhydrase on
market are acetazolamide, methazolamide, dorzolamide and topiramate.
Evidence for small molecule binding to this domain is provided in Figure 2.7 and
comes from 200 publications recorded in the ChEMBL database. In total, there were
1,882 compounds with 12,008 measured interactions for this domain. Protein targets
for these compounds are 21 carbonic anhydrases from a number of species including
H. sapiens, M. musculus, B. taurus, S. pistillata (smooth cauliflower coral) and others.
One additional target is the human receptor-type tyrosine-protein phosphatase γ, a
receptor-like protein that contains both a Carb_anhydrase as well as regions that are
matched by Y_phosphatase Pfam-A domain model. The Carb_anhydrase domain is
one of the highest ranking domains in terms of ligand counts and there is substantial
evidence for small molecule binding to this domain for ligands of various chemotypes.
2.3.2.3 The Pantoate_ligase domain
The Pantoate_ligase Pfam-A model describes a catalytic domain that is found in the
the Pantoate-beta-alanine ligase enzyme (PL) in bacteria, plants and fungi. It catalyses
a condensation reaction of β-alanine and pantoate which results in the formation of
pantothenate or Vitamin B5 (Maas, 1952). Mammals do not have a functional PL enzyme
and obtain Vitamin B5 through dietary uptake. The PL of M. tuberculosis has been
described as a potential drug target for the treatment of tuberculosis (Sambandamurthy
et al., 2002) and a number of drug discovery programs have been launched to investigate
lead compounds for the PL (Velaparthi et al., 2008; Ciulli et al., 2008; Hung et al.,
2009). Crystal structures of the PL have been obtained for multiple species, including M.
tuberculosis (Wang and Eisenberg, 2003), E. coli (Delft et al., 2001) and S. aureus (Satoh
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Figure 2.7: Evidence for small molecule binding to the Carb_anhydrase domain. Measured
interactions are shown for ten molecules. Molecules are identified as in the molregno database
field and measured potencies expressed as pIC50 values. Three exemplary ligand structures are
provided in the right plot margin.
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et al., 2010). Evidence for small molecule binding to this domain is provided in Figure
2.8 and comes from 2 publications recorded in the ChEMBL database. In total, there
were 18 compounds with 20 measured interactions for this domain. The protein target
for these compounds is the PL from M. tuberculosis. The evidence for small molecule
binding to this domain comes from two independent publications (Velaparthi et al., 2008;
Yang et al., 2011) and measured potencies are largely within an acceptable range.
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Figure 2.8: Evidence for small molecule binding to the Pantoate_ligase domain. Measured
interactions are shown for ten molecules. Molecules are identified as in the molregno database
field and measured potencies expressed as pIC50 values. Three exemplary ligand structures are
provided in the right plot margin.
2.3.3 Limitations of a widely applicable mapping heuristic
I presented the results of an evaluation of the mapping in section 2.2.4. Generally,
the performance of the mapping was good for single-domain proteins and, with a few
exceptions, at least acceptable for multi-domain proteins. It should be noted that, due
to limited availability of binding site annotations, the evaluation was carried out on a
small subset of the protein-ligand pairs to which the mapping was applied. Further,
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the scope of the mapping is very wide, encompassing virtually all proteins that are of
current or past relevance to drug discovery. The advantage of the proposed mapping
is that it is simple and almost universally applicable. However, the simplicity of the
process also results in generalisations that may limit the validity of the mapping for some
constellations. In the following I will discuss two of these problematic constellations and
their impact on the mapping presented in this chapter.
2.3.3.1 Uncatalogued Pfam-A domains
In section 2.2.3, I describe how I compiled a catalogue of Pfam-A domains with known
small molecule interactions from single-domain proteins. In a second step, described
in section 2.2.4, small molecule binding was projected onto proteins in ChEMBL using
homologous transfer. I observed that homologous transfer was not applicable to 16.5%
of proteins with measured binding activities in the ChEMBL. This was in one part due
to conflicting mappings, and in the other part due to multi-domain architectures that
consist entirely of domains not listed in the catalogue of Pfam-A domains with known
small molecule interactions. Domains forming part of such architectures would not be
catalogued because they do not occur in single-domain proteins. In this part of the
discussion, I present the most frequently encountered domains in Pfam-A architectures
and evaluate whether they have been adequately processed in the mapping heuristic.
As a basis for this discussion, I extracted Pfam-A domains from proteins with measured
activities in ChEMBL. Table 2.4 lists the 15 most frequently encountered Pfam-A domains
from multi-domain proteins in this set. The full list of domains occurring in multi-domain
proteins comprises 813 domains. Most Pfam-A domains occur only once or twice (64%
of the total), but the most frequent domain, Pkinase, occurs 122 times in multi-domain
proteins with measured activities in ChEMBL. To make most eﬃcient use of the space
available, this discussion will assess only the 15 most frequently encountered domains,
which cover a large fraction of the multi-domain proteins in ChEMBL.
The most frequent Pfam-A domain in multi-domain proteins is the Pkinase domain,
a domain that was correctly included in the catalogue by homologous transfer from
single-domain proteins. With a count of 109, the Pkinase_Tyr domain was initially not
catalogued among Pfam-A domains with known small molecule interactions. However,
given the ample evidence for small molecule binding at this domain from other sources,
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it was included manually. This manual amendment was somewhat inconsistent with
the mapping, but brought great practical improvements. It was the only amendment
made to the initial version of the catalogue because the cost of violating consistency
was significantly oﬀset by the benefit of mapping activities to this very relevant Pfam-A
domain. Like the Pkinase_Tyr domain, the SH2 domain does not occur in single-domain
proteins in the ChEMBL database. The SH2 domain functions as a universal adapter
in cell signalling and frequently co-occurs with the Pkinase_Tyr domain. Most drug
discovery programs in this area would aim to inhibit the kinase domain, but a few small
molecule inhibitors of the SH2 domain exist (Machida and Mayer, 2005; Song et al., 2005;
Siddiquee et al., 2007; Page et al., 2012). Despite this evidence, I decided not to include
the SH2 domain in the initial catalogue. This was to avoid conflicting mappings. Because
of its heavy co-occurrence with the Pkinase_Tyr domain, all activities against proteins
containing both domains would be lost, while, in practice, the vast majority of activities
would be measured at the kinase domain. In chapter 3, I present a curation interface
that is suitable to resolve this issue in a more coherent way, but for this part of the
analysis, no further manual amendments were made. A number of other domains were
not catalogued, namely the Pkinase_C, zf-C4, SH3_1, fn3 and C1_1 domains. These are
frequently occurring adapter domains that are not expected to mediate small molecule
binding. There was no evidence for small molecule binding from single-domain proteins
and the inference that there is no small molecule binding in multi-domain proteins is
adequate. The Neur_chan_memb domain is also not expected to mediate small molecule
binding. Ligand-gated ion channels, the family of proteins where Neur_chan_memb occurs,
bind small molecules mainly through the Neur_chan_LBD domain. The Lig_chan domain
on the other hand is a good example of a domain that was ignored by the mapping
heuristic, but is known to bind small molecules. The inference that, by lack of evidence
from single-domain proteins, there should also not be interactions for this domain-type
in multi-domain proteins is incorrect.
This overview could be continued beyond the first 15 Pfam-A domains, but for the
purpose of this discussion it suﬃces to show that many, but not all constellations are
processed adequately in the mapping heuristic. Arbitrary adjustments, such as the
manual inclusion of the Pkinase_Tyr domain can alleviate the problem of uncatalogued
Pfam-A domains superficially, but have the potential to give rise to conflicting mappings
for example through clashes with the SH2 domain. It is clear that for some constellations,
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Table 2.4: Most frequently encountered
Pfam-A domains in multi-domain proteins
from the ChEMBL target dictionary. The
column ‘count’ provides the number of
time an architecture occurred in ChEMBL.
The column ‘mapped’ indicates whether
a domain was included in the initial cat-
alogue of Pfam-A domains, which was
assembled using homology transfer from
single-domain proteins.
architecture count mapped
Pkinase 122 Yes
Pkinase Tyr 109 No
SH2 52 No
Pkinase C 46 No
zf-C4 42 No
Hormone recep 42 Yes
ANF receptor 41 Yes
SH3 1 31 No
Ion trans 29 Yes
fn3 27 No
Neur chan LBD 26 Yes
Peptidase C1 26 Yes
Neur chan memb 26 No
Lig chan 25 No
C1 1 23 No
mappings to more than one domain are possible, depending on the ligand. A solution
to this problem is presented in chapter 3 in form of a manual curation platform, where
each activity can be mapped individually. Other ways of overcoming this problem can be
envisaged, maybe most suitably machine learning approaches. However, even a successful
implementation would require at least a limited amount of manual curation for validation
purposes.
2.3.3.2 Small molecule binding at domain interfaces
The aim of the mapping was to assign small molecule binding to a Pfam-A domain for
each measured activity in the ChEMBL database. One of the underlying assumptions
here was that small molecule binding is tied to one domain, rather than several. This is
a simplification that facilitates the mapping and also its interpretation, for example for
similarity estimations of protein targets, or for the detection of potential drug targets in
newly sequenced pathogen genomes. There are however known cases of small molecule
binding at the interface of protein domains where contributions from both domains are
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Table 2.5: Domain architectures with small molecule binding at domain interfaces. The
architectures are derived from PDB entries with correlates in the ChEMBL database. The
column ‘Architecture’ designates the Pfam-A domains involved in small molecule binding,
the columd ‘ligand’ the three letter code of the ligand. If structures with other ligands are
present in the PDB this is indicated with [...]. The column ‘PDB IDs’ summarises up to three
corresponding structures and ‘n’ indicates the number of proteins in the ChEMBL database
that have the same archtitecture.
architecture ligand PDB ratios n
ADH N, ADH zinc N CCB [...] 1u3t 0.53, 0.33 21
GST C, GST N D27 [...] 2vd0 0.59, 0.35 23
Guanylate cyc, DUF1053 FOK 1ab8, 1cjk, 1cul 0.63, 0.33 18
Hexokinase 1, Hexokinase 2 LOI [...] 3goi 0.56, 0.39 14
Mur ligase C, Mur ligase 1LG [...] 2am1 0.36, 0.36 6
NMT, NMT C MIM 2nmt 0.43, 0.40 6
OTCace, OTCace N PAO 1oth 0.50, 0.50 3
PH, Pkinase IQO 3o96 0.29, 0.71 16
Peptidase M4, Peptidase M4 C TIO [...] 1zdp 0.50, 0.50 2
Peptidase S9, DPPIV N 605 [...] 3d4l 0.53, 0.42 10
Prenyltrans 2, Prenyltrans FPP 1mzc, 1jcq, 1sa4 0.46, 0.33 9
S-AdoMet synt N, S-AdoMet synt C ATP 1o93, 1o9t 0.40, 0.44 2
crucial for the interaction. These interactions cannot adequately be represented in the
mapping presented in this chapter. In the following I give an overview of architectures
that one should be aware of when interpreting analyses derived from the mapping
presented in this chapter. Architectures were systematically queried using PDBeMotif as
described in Methods section 2.5.12. Ligand binding at multiple domains was detected
using two thresholds, nmin ≥ 5 for the minimum number of residues involved in ligand
binding and rmin ≥ 0.3 for the proportional contribution of each domain to ligand binding.
These values were chosen arbitrarily, but to my judgement they give a good indication
whether a domain contributes significantly to ligand binding or not. Table 2.5 gives
a summary of all identified architectures. To the largest extent, the architectures I
identified represent enzymes. In many cases, the regions described by diﬀerent Pfam-A
models represented a single functional unit, such as for example the N- and C-terminal
domain of the Gluthatione-S-transferase (GST_N and GST_C). This means that while these
units may have diﬀerent sequence profiles and be structurally independent, they still
co-occur in most cases because they rely on each other to exert their function. One
59
Chapter 2. Mapping of small molecule binding to protein domains
striking example is the architecture of the PDB entry 3goi, representing a complex of the
human glucokinase with an allosteric inhibitor (LOI) (Mitsuya et al., 2009). It consists of
two Pfam-A domains, Hexokinase_1 and Hexokinase_2, which are structurally similar
and form a complimentary and interlocking interface. It is this interface where both
glucose and the allosteric inhibitor bind the protein. The catalytic site lies in the cleft
between the two Pfam-A domains, an arrangement that is also observed in other enzymes.
In the following, I refer to arrangements of this type as ‘enzyme doublets’. Figure 2.9
illustrates four examples of small molecule binding at domain interfaces that fall into
this category of ‘enzyme doublets’. In addition to these four, I attributed six other
architectures to this category. All of the architectures in this category occur in multiple
proteins with measured activities in the ChEMBL database.
The functional dependence of Pfam-A domains in enzymatic doublets imposes an
obstacle to independent evolution of these Pfam-A domains and the expectation is that
they occur only very rarely without their counterpart. Instead, they are expected to occur
together in most if not all instances. This renders them a special case of the mandatory
multi-domain architectures discussed in the previous section. This idea is supported by
the fact that, exempting the Prenyltrans domain, none of these domains were detected
when compiling the catalogue of Pfam-A domains with known small-molecule interactions
(which were derived from single-domain proteins). A practical way of accommodating
these architectures in the mapping presented in this chapter could be to add one domain
from an enzyme doublet as a proxy for both domains.
I detected two architectures that did not assort with the ‘enzyme doublet’ category.
The first of these was a combination of a protein kinase domain Pkinase and the
pleckstrin-homology domain PH. The ligand is a recently discovered allosteric kinase
inhibitor. The contributions of the PH domain are smaller than those of the Pkinase
domain, but several literature sources state that the PH domain is required for inhibiton
(Calleja et al., 2007; Calleja et al., 2009; Wu et al., 2010). In the current implementation
of the mapping heuristic, inhibition would be mapped to the Pkinase domain alone. It
is thus a clear limitation of the mapping heuristic that it cannot represent this type of
kinase inhibition adequately. Figure 2.10A and B illustrate the layout of this architecture.
Another architecture, consisting of a combination of the adenylate and guanylate
cyclase catalytic domain (Guanylate_cyc) and a domain of unknown function (DUF1053),
appeared to mediate small molecule binding at least in part through the DUF1053 domain.
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Figure 2.9: Four examples of small molecule binding at domain interfaces of ‘enzyme doublet’
architectures. Residues within binding domains are shown in space-filling representation,
residues outside of these domains are shown in cartoon representation. Panel A captures
the binding of the artificial inhibitor N-cyclobutyl-N-cyclopentyl-formamide (CCB) to the
active site of human alcohol dehydrogenase β-1-β-1 isoform (pdb: 1u3t). Binding takes
place at the interface of the alcohol dehydrogenase GroES-like domain (ADH_N, green) and
the zinc-binding dehydrogenase domain (ADH_zinc_N, red). Panel B depicts binding of the
inhibitor tranilast (D27) at the interface of the glutathione S-transferase N- and C-terminal
domains (GST_N and GST_C) of the human glucosylceramidase (pdb: 2vd0). Panel C captures
binding of the allosteric inhibitor N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-
3-yl)sulfanyl]-2-(methylamino)benzamide (LOI) at the interface between the Hexokinase_1
and Hexokinase_2 domains of the human glucokinase (pdb: 3goi). Panel D captures binding
of the inhibitor 4’-[(1R)-1-Amino-2-(2,5-difluorophenyl)ethyl]-3-biphenylcarboxamide (605) at
the interface of the dipeptidyl-peptidase IV domain (DPPIV_N) and the prolyl oligopeptidase
domain (Peptidase_S9) of the human dipeptidyl peptidase IV (pdb: 3d4l).
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This information was mined from a number of PDB entries including 1cjk and 1cul,
which represent the enzyme adenylyl cyclase. This was unexpected, because the adenylate
cyclase function depends on the presence of two Guanylate_cyc domains that form an
active site at their interface, much like the enzyme doublets discussed in the previous
section (Tesmer, 1999). A closer analysis of the structure revealed that the protein
used in the underlying crystal structures was a fusion construct of a dog and a rat
Guanylate_cyc domain (see Figure 2.10C, D). When translating between Uniprot and
PDB residue coordinates, this was not taken into account by the automated script used
for the analysis. Pfam annotations were obtained for the sequence of the dog protein,
but parts of it should have been matched to the rat protein. The correct architecture for
this entry is a combination of two Guanylate_cyc domains. This architecture assorts
with the ‘enzyme doublet’ category. As for other Pfam-A models from this category,
the Guanylate_cyc domain was not picked up when compiling the catalogue of domains
with known small molecule interactions. In this discussion, the seemingly unexpected
architecture also serves as a reminder that it is challenging to anticipate all edge cases
that may occur in large-scale analyses and underlines the importance of cross-checking
results.
2.4 Conclusion
In this chapter, I have laid out a mapping heuristic that can be used to annotate measured
activities in the ChEMBL database with the Pfam-A domain that likely mediates the
interaction. The procedure is based on the transfer of binding site annotations from Pfam-
A domains with known small molecule interactions onto protein sequences containing
a given Pfam-A domain. To this end, a catalogue of Pfam-A domains with evidence
for small molecule binding has been collated using ChEMBL potency measurements. A
validation of this procedure against binding-site information from Uniprot and the PDB
showed that this procedure performs well for most domain architectures. A number of
domain architectures have been identified that can not be adequately processed using the
mapping. Such architectures generally represent constellations where either no domain
in a protein or more than one domain result in hits from the catalogue. As discussed
in the following Chaper 3, the performance of the mapping for such instances could
be improved by adding ‘missing’ domains to the catalogue and by resolving conflicting
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Figure 2.10: Small molecule binding at the interface of two unusual architectures. Residues
within binding domains are shown in space-filling representation, residues outside of these
domains are shown in cartoon representation. Panel A and B depict the binding of the allosteric
inhibitor Akt Inhibitor VIII (IQO) at the interface of the Pkinase and PH domain of the protein
kinase AKT1 (pdb: 3o96). Panel C and D depict binding of the inhibitor Forskolin (FOK) at
the interface of two guanylate_cyc domains, which form a chimeric version of the mammalian
adenylyl cyclase. The guanylate_cyc domains in this PDB entry (1cjk) were derived from
two species, C. familiaris, and R. norvegicus.
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mappings. The mapping will be useful for data-mining applications that have no access
to implicit knowledge about binding domains and will also help disambiguate queries
that seek to relate small molecule ligands for an established protein target to protein
targets of unknown function, for example from newly sequenced genomes.
2.5 Methods
2.5.1 Retrieval of Pfam-A annotations
I wrote a python script to retrieve Pfam-A annotations using the RESTful API pro-
vided by the pfam web servers at http://pfam.sanger.ac.uk. Uniprot accessions of
query proteins were used to generate a request of the form: http://pfam.sanger.ac.
uk/protein/*/Uniprot/*?output=xml, where */Uniprot/* corresponds to the query
protein. Queries were then submitted using the python module urllib. The XML
document returned by the Pfam API was parsed to extract all Pfam-A domains and
associated start- and end positions (as defined by the start and end tags in the
XML qery output) using the python module xml. At the time this study was con-
ducted, the Pfam API was exposing the Pfam release 26.0. The script is available at
https://github.com/fak/mapChEMBLPfam/blob/master/getPfamDomains.py.
2.5.2 Retrieval of protein coding genes in human genome
An R script was used to obtain Uniprot accessions and amino acid sequences of protein
coding genes in the human genome. I used the R package biomaRt to query the Ensembl
dataset hsapiens_gene_ensembl and filtered for entries of the type protein_coding
with the feature with_uniprotswissprot. The query was carried out once and results
written to a tab-separated text file. The script is available at https://github.com/
fak/mapChEMBLPfam/blob/master/queryBioMaRt.R.
2.5.3 Evidence of small molecule binding for single-domain pro-
teins
Evidence of small molecule binding was collected for proteins that have only a single-
domain mapped to their Uniprot sequence. Measured potencies and ligands were retrieved
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for each single-domain target (excluding five protein fragments, see section 2.5.4) using a
SQL statement and filtered to include only activities of the type Ki, Kd, IC50, EC50,
-Log Ki, pKd, pA2, pI, pKa. To obtain only results from biochemical assays where the
value of the assay type field equals B. To ensure that the assay maps to a protein target
directly and without ambiguity, I included a requirement for the multi and complex
flags to hold the value 0 and the relationship type attribute to hold the value D, which
signifies that the assay target is mapped unambiguously to a Uniprot identifier. Measured
activities themselves were required to meet a given potency threshold, which was set to 50
µM in this study. Evidence for individual protein was then grouped according to the Pfam-
A domains. Pfam-A domains with evidence for small molecule binding were assembled
into a list of ‘validated’ domains. A script used to carry out these steps is available at
https://github.com/fak/mapChEMBLPfam/blob/master/singleDomain.py.
2.5.4 Removal of protein fragments
In some cases, small molecule bioactivities reported in ChEMBL are mapped to Uniprot
identifiers that represent fragments of a protein. This might be due to annotation errors,
or the lack of a Uniprot entry representing the full-length protein. Pfam-A domains from
such fragments might not bind small molecules, yet they would enter the catalogue of
small molecule-binding Pfam-A domains through association with a recorded activity.
When projected onto multi-domain proteins, those Pfam-A domains without evidence of
small molecule binding can lead to false mappings and therefore need to be excluded. I
identified five critical protein fragments in the ChEMBL target dictionary. Activities
associated with these fragments were excluded during the assembly of the catalogue of
small molecule-binding Pfam domains outlined in Section 2.5.3. The list below provides
the Uniprot names of the individual fragments and explanations to why they have been
excluded.
• Fourteen activities extracted from an article about cytotoxic analogs of etoposide
(Pubmed: 9804687) map to O46399, a fragment of sheep Tubulin that contains
only a Tubulin C domain. Nothing indicates that only a fragment of the protein
was used in the assays specified and I attributed small molecule binding to the
Tubulin domain, not the Tubulin C domain, as would be expected for analogs of
Etoposide.
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• 237 activities extracted from eleven articles on phosphodiesterase inhibitors (PubMed:
8388468, 8709099, 10891111, 8201604, 9719589, 12570368, 8120866, 8027992,
8254606, 15780616) map to the Uniprot identifier Q864F1. This identifier represents
an N-terminal fragment of the pig phosphodiesterase 5, containing only the GAF
domain and, crucially, missing the PDEase_I domain. Thus, I excluded the GAF
domain from the catalogue.
• In chembl 13, eight activities extracted from an article on excitatory amino acid
receptor ligands (Pubmed: 9526567) were mapped to Q80T35, a fragment of the
mouse metabotropic glutamate receptor 6, which contains only a 7tm_3 domain.
Nothing in this article indicates that only a fragment of the protein was used and I
attributed small molecule binding to the ANF_receptor domain and excluded the
7tm_3 domain from the catalogue of small molecule-binding Pfam-A domains.
• Six activities extracted from an article on GluR5 ionotropic glutamate receptor
agonists (Pubmed: 12672235 ) map to Q91755, a fragment of the frog ionotropic
glutamate receptor, which contains only a Lig_chan domain. Nothing in this article
indicates that only a fragment of the protein was used in the assays specified and I
attributed small molecule binding to either the ANF_receptor or Lig_chan_Glu_bd
domain and not the Lig_chan domain.
• In chembl 13, 49 activities extracted from one of three articles on cancer therapeutics
(Pubmed: 19610618, 20188579, 16415863) were mapped to A1Z199 a fragment of
the human BCR/ABL p210 fusion protein which contains only a SH3_1 domain.
Nothing in the articles indicates that only a fragment of the protein was used in
the assays specified and I attributed small molecule binding to the Pkinase_Tyr
domain, not the SH3_1 domain.
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2.5.5 Count of projected domains
The count of projected domains and activities that are summarised in table 2.2 and
appendix table 5.3 were obtained using a SQL statement against the ChEMBL database
(version chembl_13):
SELECT domain, COUNT(DISTINCT protein_accession), COUNT(DISTINCT activity_id)
FROM map_pfam
WHERE mapType = ‘multi’
GROUP BY domain;
2.5.6 Protein-ligand pairings in PDBe
To obtain all protein-ligands pairings from ChEMBL that could potentially be indexed
by PDBeMotif, I used a SQL statement to query the database for all activities that
are linked to a target with a Uniprot identifier and linked to a molecule with molecular
weight lower or equal to 1,000 Da. In addition, the query was limited to molecules whose
ChEMBL identifiers mapped to PDBe three-letter codes. The obtained pairings were
stored in a python hash-table and used to query PDBeMotif. The script used to obtain
protein-ligand pairings is available at https://github.com/fak/mapChEMBLPfam/blob/
master/getIntactDict.py.
2.5.7 Retrieval of ligand binding residues from Uniprot
To assess the proportion of binding residues that fall into Pfam-A boundaries, I also
retrieved binding site residues provided by the ‘Sites’ feature of the sequence annotation
section provided on the Uniprot servers. Uniprot accessions were retrieved for all
ligand pairings identified as described in Section 2.5.6. In many cases, a single Uniprot
identifier would occur multiple times because the corresponding protein was used in
assays of diﬀerent small molecules. Therefore, RESTful queries were constructed for a
non-redundant list of Uniprot identifiers and took the form: http://www.uniprot.org/
uniprot/*/Uniprot/*.xml, where */Uniprot/* corresponds to the Uniprot identifier.
They were submitted using the python module urllib and the resulting XML documents
were parsed using the python module xml to extract the position numbers and ligand
information. The script used to send and retrieve queries is available at https://github.
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com/fak/mapChEMBLPfam/blob/master/queryUniprot.py.
2.5.8 Retrieval of ligand binding residues derived from PDBe-
Motif
To assess the proportion of binding residues that fall into Pfam-A boundaries, I retrieved
binding site residues from PDBeMotif, a search tool for PDBe. Queries were constructed
for each pairing of protein and small molecule that were specified in 2.5.6, using the
Uniprot accession to represent the protein and the PDBe three-letter code to identify
the ligand. Resulting queries were of the form:
requestXML=
<!DOCTYPE query SYSTEM "http://www.ebi.ac.uk/pdbe-site/pdbemotif/query.dtd">
<query>
<declaration>
<uniprot name="p">*/Uniprot/*</uniprot>
<ligand name="l1">*/TLC/*</ligand><aminoacid name="a1">X</aminoacid>
</declaration>
<bond name="b1" a="l1" b="a1"/>
</query>
where */Uniprot/* corresponds to the protein and */TLC/* to the ligand for each
pairing. The queries were submitted to http://www.ebi.ac.uk/pdbe-site/pdbemotif/
hitlist.xml using the python module urllib2 and the XML documents returned by
the server were parsed using the python module xml to extract the positions of the amino
acid residues that are involved in the binding of the specified small molecule. In a later
step, residue positions provided by PDBeMotif were translated to match position numbers
of the Uniprot protein sequence repository (see Methods section 2.5.10). The script used
to send and retrieve queries is available at https://github.com/fak/mapChEMBLPfam/
blob/master/queryPDB.py.
2.5.9 Mapping ChEMBL compounds to PDBe identifiers
PDBe identifiers were obtained for compounds in the pairings generated as described
in Section 2.5.6 using mappings provided by the Unichem resource (Chambers et al.,
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2013). A tab-separated table of all mappings between small molecules in the PDB
and compounds in the ChEMBL database and can now be downloaded from https:
//www.ebi.ac.uk/unichem/wholesourcemap. At the time I carried out this study, the
mapping was made available on request by Jon Chambers (EBI, Hinxton, UK) in a
slightly diﬀerent format. The mappings were parsed with a custom script and used to
identify protein-ligand complexes that are indexed by PDBeMotif and correspond to
measured activities in the ChEMBL database as described in Section 2.5.6. The script for
parsing the mappings is available at https://github.com/fak/mapChEMBLPfam/blob/
master/parseUniChem.py.
2.5.10 Translation of residue numbers between PDBeMotif and
Uniprot
I used the Structure Integration with Function, Taxonomy and Sequences resource
(SIFTS) (Velankar et al., 2013) to translate between residue numbers obtained from
PDBeMotif and residue numbers in Uniprot that were used as coordinates for the mapping
presented in this chapter. A look-up table was downloaded from ftp://ftp.ebi.ac.uk/
pub/databases/msd/sifts/csv/pdb_chain_uniprot.csv on August 2nd, 2012 and the
oﬀset between numbering in the PDB sequence and corresponding Uniprot sequence was
calculated as the relative diﬀerence between the start position in the Uniprot sequence
and the start position in the PDB sequence. This oﬀset was later added to residue
numbers extracted from PDBeMotif as described in Section 2.5.9. The script is available
at https://github.com/fak/mapChEMBLPfam/blob/master/coordMap.py.
2.5.11 Small molecule binding within the boundaries of Pfam-
A domains
To assess how frequently small molecules bind within the boundaries of Pfam-A domains
rather than outside of these annotated regions, I evaluated the overlap of binding residues
extracted from Uniprot and PDBe with the domain boundary data obtained from the
Pfam web services. The procedure was the same for Uniprot and PDBe and can be
outlined as follows: For each residue, I assessed whether it lies within the boundary of
any Pfam-A domain and a boolean True was assigned if that was the case, or else the
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boolean was set to False. The fraction k of residues that are involved in small molecule
binding and lie within a Pfam-A domain was expressed as
k =
n(BSRPfam-A)
n(BSRall)
,
where n(BSRPfam-A) is the number of binding site residues that fall within the bound-
aries of ant Pfam-A domain and n(BSRall) is the number of all binding site residues. In
cases where multiple entries representing a small molecule-protein pair were retrieved
from PDBe, k was calculated for a hypothetical binding site accumulating residues
from all models. While n(BSRPfam-A) and n(BSRall) thus increased as multiples of
the number of retrieved entries, k would remain unaﬀected by the number of models
representing a small molecule-protein pair. Fractions for individual protein-small molecule
pairs were then summarised in an empirical cumulative distribution plot produced using
the R library ggplot2. The corresponding python and R are functions are available
at https://github.com/fak/mapChEMBLPfam/blob/master/matchData.py, https://
github.com/fak/mapChEMBLPfam/blob/master/evaluatePred.py and https://github.
com/fak/mapChEMBLPfam/blob/master/ecdf.R.
2.5.12 Small molecule binding at domain interfaces
To assess the degree of small molecule binding at domain interfaces, I compared the ligand
binding residues extracted from PDBe as described in Section 2.5.8 with the domain
boundary data obtained from Pfam as described in section 2.5.1. Residue coordinates
were translated between the Uniprot system ued by Pfam and PDBe as described in
section 2.5.10. For each domain i, the contribution to ligand binding ki was assessed as:
ki =
n(BSRPfami)
n(BSRall)
,
where n(BSRPfami) is the count of ligand-binding residues for a domain i and n(BSRall)
the total number of residues involved in ligand binding. For any domain i to be considered
as involved in ligand binding, ki was required to be greater or equal 0.3 and n(BSRall)
was required to be at least four. These thresholds were used to filter the results and
exclude cases where a domain contributes only marginally to ligand binding. The script
used to execute this analysis is available at https://github.com/fak/mapChEMBLPfam/
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blob/master/arch.py.
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Refined mapping of small molecule
binding to protein domains
3.1 Introduction
In the previous chapter, a simple heuristic was presented to associate small molecule
binding with Pfam-A protein domains. The mapping is a generic procedure that relies
on inferences made using domains with known small molecule interactions. It does
not require any additional information beyond the inferred catalogue of small molecule
binding domains. The mapping was applied to a great number of small molecule-
protein interactions with little need for computational or human resources. The heuristic
presented in the previous chapter delivered accurate mappings for about 88% of the
assessed interactions in the ChEMBL database. However, I also identified a number of
shortcomings inherent to the mapping procedure. One of them was the ineptidude to
process proteins containing more than one domain from the catalogue of small molecule
binding domains. Interactions of small molecules with such proteins would produce
conflicting mappings and were therefore left unprocessed. Secondly, the initial catalogue
of small molecule binding domains was constructed from known interactions of single
domain proteins. Thus, the catalogue is ‘blind’ to protein domains that have known
interactions with small molecules that do not occur in single domain proteins. Both
these issues are related to the more complex protein architectures. To address them, I
implemented a platform that facilitates the manual refinement of individual mappings
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and devised a workflow that allows for the integration of manual mappings with releases
of the ChEMBL database. This chapter provides a summary of the implementation of
the workflow and curation interface designed to resolve inconsistencies in the mapping of
proteins that have multiple binding sites for small molecules.
3.1.1 Proteins with multiple small molecule binding sites
A significant proportion of the multi-domain architectures in the ChEMBL database could
not be adequately processed using the mapping heuristic described in chapter 2 alone.
One formidable challenge was imposed by proteins with multiple binding sites for small
molecules. An analysis of proteins with conflicting methods (see section 3.2.4) revealed
three predominant configurations associated with multiple small molecule binding sites.
These are:
• phosphotyrosine signalling adapters
• multifunctional enzymes
• proteins with allosteric binding sites.
In the remainder of this section I introduce these configurations in more detail and provide
examples that are relevant to the mapping heuristic. Figure 3.1 illustrates exemplary
crystal structures for each type of configuration.
Phosphotyrosine signalling (PTS) is a ubiquitous process in metazoan cells that
mediates external and internal signals of cell proliferation, diﬀerentiation, immune
response and others. PTS relies on three components. The components are protein
tyrosine kinases (PTKs), protein tyrosine phosphatases (PTPs) and modular adapters that
recognise specific phosphorylated sites and recruit a downstream signalling component to
the phosphorylated element (Hunter, 2009). One of the most common adapters in PTS
is the SH2 domain that co-occurs with both, PTKs and PTPs (Pawson, 2004; Liu et al.,
2006). SH2 domains are a prevalent feature in the genome of multicellular organisms, but
absent from most unicellular eukaryotes. It is likely that the first phosphotyrosine-sensing
SH2 domain occurred at around the same time as the divide of lineages into unikonts
and bikonts (Liu et al., 2011a). The human genome encodes around 50 proteins with
both a PTK and SH2 domain. Diﬀerent members of this large family of SH2 domains
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Figure 3.1: Examples of proteins with multiple small molecule interactions sites. The left
hand side shows structures of whole protein complexes, the right-hand side shows individual
chains. Small molecule binding sites are shown in approximation as red circles overlaid with
ligands from the crystal structure. Panel A: 1opl - c-Abl tyrosine kinase. The protein contains
a Pkinase_Tyr domain (green, shown with bound inhibitor PD166326), and an SH2 domain
(blue, approximate binding site for substrates and inhibitors is indicated by red ellipse) Panel
B: 3qgt - Bifunctional DHFR-TS as a homo-dimeric complex. Each chain contains a DHFR_1
domain (yellow, with Pyrimethamine) and a Thymidylat_synt domain (blue, with Deoxyuridine
monophosphate). Panel C: 4jsx - full length homo-tetrameric complex of the AMPA-subtype
glutamate receptor. The orthosteric site is located in a cleft between the Lig_chan-Glu_bd
(blue) and Lig_chan (green) domains. Two additional sites are located in this region of
the receptor. The N-terminal domain of the AMPA-R harbours a binding site for lectins.
Philanthotoxins block the central pore of the receptor.
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recognise specific substrate proteins through a number of diverse binding modes across
the central β-sheet of the domain (Liu et al., 2006). The first known inhibitors of the SH2
domain were peptides (Domchek et al., 1992; Burke et al., 1994), but today a number of
small molecule inhibitors are known for this domain type (Machida and Mayer, 2005;
Kraskouskaya et al., 2013). PTKs on the other hand are well-established targets in drug
discovery and thus any approach to mapping small molecule binding to proteins of this
type must account for the possibility of small molecule binding to either domain. A
crystal structure of an exemplary protein in this category (tyrosine-protein kinase ABL1)
is illustrated in Figure 3.1A and approximate binding sites are indicated. Modular
adapters are also found in proteins that are not involved in PTS. For example, the
protein complex mTOR relies on a Rapamycin_bind domain as an adapter to recruit
substrates. This process can be inhibited by a complex of the macrolide rapamycin and
the endogenous protein FKBP12. The mTOR complex can also be targeted through
its PI3_PI4_kinase domain and multiple inhibitors of this domain have been described
(Thoreen et al., 2009; Liu et al., 2011b). A crystal structure and outlines of respective
binding sites are displayed in Appendix figure 1.
The second configuration that frequently exhibits multiple small molecule binding sites
are multifunctional enzymes. Multifunctional enzymes are in many instances the product
of gene fusion events (Bashton and Chothia, 2007). Early work suggested gene fusion
as a mechanism for the formation of bifunctional enzymes in the histidine biosynthesis
pathway of S. typhimurium (Yourno et al., 1970). Systematic analyses of fused protein
domains in E. coli found that domain fusion frequently occurs among functionally related
proteins (Marcotte, 1999; Enright et al., 1999) and in particular among enzymes in
shared metabolic pathways (Tsoka and Ouzounis, 2000). The bifunctional dihydrofolate
reductase-thymidylate synthase (DHFR-TS) in bikonts is a product of such a fusion
event. This multifunctional enzyme catalyses two subsequent steps in the biosynthesis of
thymidylate monophosphate (Ivanetich and Santi, 1990). Both TS and DHFR have been
studied as targets for small molecule cancer therapeutics (Touroutoglou and Pazdur,
1996; Takimoto, 1996) and DHFR-TS itself has been recognised as a viable target for
anti-parasitic treatments (Knighton et al., 1994; Yuvaniyama et al., 2003; Vanichtanankul
et al., 2011). DHFR-TS forms homo-dimers and each monomer consists of a DHFR_1 and
Thymidylate_synth domain, corresponding to the two fused enzymatic units. Mapping
of small molecule binding to domains of the DHFR-TS thus depends on the specificity
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of any given small molecule ligand. Figure 3.1B illustrates a crystal structure of the
DHFR-TS homo-dimer and indicates small molecule binding sites. Other proteins in this
category of multi-functional enzymes are for example the the fatty acid synthase (Maier
et al., 2008), the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (Hasemann et al.,
1996; Rider et al., 2004) or the orotidine-5’-monophosphate decarboxylase (Wittmann
et al., 2008).
A classical configuration in proteins with multiple sites for small molecule binding is
the presence of allosteric sites. The term ‘allosteric’ signifies that binding takes place
at an additional site that is spatially separate from, for example, the main binding
site of a receptor, or the active site of an enzyme1. Allosteric binding sites are known
for both endogenous as well as artificial ligands. Enzyme function is often modulated
through allosteric binding of metabolites from the metabolic pathway that a given enzyme
contributes to. For example, the activity of the phosphofructokinase is inhibited by
allosteric binding of phosphoenolpyruvate to an allosteric site on the enzyme (Whitby
et al., 2000). Allosteric modulation also occurs in diﬀerent types of membrane receptors,
including class C GPCRs, ionotropic glutamate receptors and other ligand-gated ion
channels. AMPA-subtype glutamate receptors (AMPA-Rs) for example have five2 distinct
binding sites which can be targeted with small molecules to modulate the receptor’s
activity (Traynelis et al., 2010; Sobolevsky et al., 2009). The orthosteric site of the
AMPA-R binds glutamate and is located in a cytosolic, agonist binding domain (ABD).
Two additional sites exist in the ABD, one at the dimer interface, binding aniracetam
and related small molecules, and another at the base of the ABD, binding small molecules
from the class of 2,3-benzodiazepines. The N-terminal domain (NTD) of the AMPA-R is
known to interact with lectins, a class of glycosylated proteins. A corresponding domain
in the structurally related NMDA-subtype glutamate receptor (NMDA-R) binds the
inhibitor ifenprodil and related small molecules. An additional site lies in the central
pore of the AMPA-R, which can be blocked by philanthotoxins, a class of small molecules
derived from insect venoms (Stromgaard et al., 2000). Small molecule binding to allosteric
sites is often desired in a drug discovery context (Christopoulos, 2002) and it is hence
expected that a significant portion of measurements in the ChEMBL database relate to
1Such sites are referred to as orthosteric sites when contrasted to allosteric sites.
2One of these sites corresponds to five partly overlapping sites at the base of the agonist binding
domain (Kumar and Mayer, 2012).
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allosteric inhibitors. A mapping of small molecule binding should therefore account for
allosteric mechanisms in cases where the ortho- and allosteric sites lie within diﬀerent
domains in a given protein.
3.1.2 Outline
Proteins with multiple domains make up more than half of the proteins in simple
prokaryotic organisms and about 80% of proteins in eukaryotic genomes (Apic et al.,
2001). In contrast, less than 50% of the 5,631 proteins in the ChEMBL target dictionary
had more than one Pfam-A domain. In one part, this is due to incomplete coverage with
Pfam-A models (Mistry et al., 2013) and in another to the preference in drug discovery
to select proteins with simple domain architectures as therapeutic targets (Hopkins and
Groom, 2002). The heuristic described in chapter 2 resulted in conflicting mappings when
applied to proteins with more than one binding site for small molecules. In addition,
the mapping was not applicable to proteins that do not contain any of the domains in
the catalogue of domains with known small molecule interactions, even if small molecule
interactions for such a protein were known from other sources. In this chapter, I present
a manual curation approach that addresses these issues. It involves both, adjustments of
the catalogue, as well as manually curated mappings for protein targets with conflicting
domain architectures.
3.2 Results
3.2.1 A workflow for manual refinement and integration with
the ChEMBL database
The integration of small molecule bioactivity data from the ChEMBL database with other
bioinformatics resources was a principal goal of my thesis project. The mapping of small
molecule binding to Pfam-A domains establishes a link between the CHEMBL database
and protein family annotations from the Pfam database. Both of these databases have
active and asynchronous release cycles: new releases of the ChEMBL database occur
every three to four months while Pfam releases are less frequent and follow a roughly
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biannual cycle.3
To achieve persistent integration of the mapping and its manual refinement presented
in this chapter with future releases of the ChEMBL database, I devised a workflow
consisting of a python script and a modified MySQL instance of the ChEMBL database.
The modification consisted of two tables, pfam_maps and valid_domains, that were
added to the default schema of the ChEMBL database.4 Figure 3.2 shows a schematic
representation of the workflow.
The table valid_domains contains a list of all Pfam-A domains with evidence for
small molecule binding. The initial version of this table consists of all domains identified
from the mapping described in the previous chapter. The pfam_maps table holds mappings
of all eligible bioactivity measurements to Pfam-A domains. Each entry of this mapping
carries a tag to mark if it has been manually curated. Both tables are created using the
loading routine (see Methods section 3.4.1). Given a list of validated domains, the script
projects these domains onto assay targets and maps associated bioactivity measurements
to the projected domains. The loader script also tags mappings that are in conflict with
other mappings. The projection encompasses all functional and binding assays that
can be mapped directly to a protein sequence. A full specification of the scope of the
mapping is provided in Methods section 3.4.2.
The ensuing step in this workflow is manual curation. For manual curation, I
implemented a user interface as descibed in section 3.2.2 and Methods section 3.4.6.
All measurements that were manually mapped to Pfam-A domains are tagged as such.
In response to release updates of the ChEMBL database, these manual mappings can
be exported into a text file (manual_maps). This text file, together with the exported
valid_domains table, constitutes the input for the loader script, which projects mappings
onto the next release of the ChEMBL database. In a second step, it replaces all conflicting
mappings that have been manually curated with the corresponding mappings from the
manual_maps file. Thus, I have created a workflow that allows for renewed application of
the mapping heuristic described in Chapter 2 to new releases of the ChEMBL database,
while retaining the manual modifications to older releases. The workflow thus has three
3archives of all releases of the ChEMBL and Pfam databases are available through ftp://
ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/ and ftp://ftp.sanger.ac.uk/pub/
databases/Pfam/releases/
4A visualisation of the schema of chembl_15 can be downloaded from ftp://ftp.ebi.ac.uk/pub/
databases/chembl/ChEMBLdb/releases/chembl_15/chembl_15_erd.png.
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MySQL instance of ChEMBL Manual conflict resolution 
(optional) 
pfam_maps & 
valid_domains 
manual_maps valid_domains pfam_maps 
loading routine export routine 
Figure 3.2: Flow chart for manual refinement and integration with ChEMBL release cycle.
The schematic outlines the workflow components and their relationships. Red scrolls symbolise
tables that are added to the ChEMBL schema. Beginning with the catalogue of domains
in valid_domains and a list of previously assigned manual mappings in manual_maps, the
loading routine scans targets in the ChEMBL target dictionary for the presence of validated
domains and assigns mappings accordingly. Measurements that result in conflicting mappings
are forwarded to the curation interface. At the end of a curation cycle, all manual mappings are
exported to a new version of the manual_maps table using the export routine. Domains with
known small molecule interactions can be added either directly by editing the valid_domains
table or through the curation interface (not implemented at time of writing).
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processing components, a loading routine, described in Methods section 3.4.1, an export
script, described in Methods section 3.4.3, and the curation interface, which is described
in section 3.2.2.
Together with Dr. Anna Gaulton, I also devised a routine to include mappings
from the heuristic as well as the refined manual mappings in the ChEMBL database.
Mappings for ChEMBL releases chembl_14 and earlier were generated using the mapping
heuristic described in chapter 2 only, while mappings for releases chembl_15 and later
were a combination of heuristic mappings and existing manual mappings. I prototyped
the loading and export routines while Anna Gaulton implemented the schema changes
necessary to accommodate the mapping. Beginning with the release chembl_15, the
database schema contains a set of tables that describe small molecule binding sites (the
corresponding schema sections in chembl_15 are shown in Appendix figure 12). Similar
to the loader script described earlier, a script is in place to project validated Pfam-A
domains and existing manual mappings onto activities in the database. These mappings
are represented in the aforementioned tables and can be accessed using SQL statements.
As an example, Pfam-A mappings for an assay of the bifunctional dihydrofolate reductase-
thymidylate synthase of Trypanosoma cruzi (CHEMBL1167426, from Schormann et al.,
2010) can be obtained with a SQL query of the form:
SELECT pdb.predbind_id, dom.domain_name
FROM assays ass
JOIN activities act
ON act.assay_id = ass.assay_id
JOIN predicted_binding_domains pdb
ON pdb.activity_id = act.activity_id
JOIN site_components sc
ON pdb.site_id = sc.site_id
JOIN domains dom
ON dom.domain_id = sc.domain_id
WHERE ass.chembl_id = ‘CHEMBL1167426’;
The mappings as represented in the ChEMBL database are static and cannot be
changed between releases. Conflicting mappings curated between releases can be inte-
grated into the next release of the ChEMBL database using the most recent export of
the manual_maps table.
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With this workflow in place, manual curation was applied as described in sections
3.2.3 and 3.2.4. The following section 3.2.2 describes my implementation of a platform
for manual curation.
3.2.2 Prototype of a manual curation platform
Manual curation of measurements associated with domain configuration that have mul-
tiple binding sites requires considerable time and organisation and diﬀerent domain
architectures may require diﬀerent strategies to resolve conflicting mappings and may
thus not be achieved through the application of a generic algorithm. To accommodate
these requirements I decided to implement a platform that would allow for convenient,
documented and reversible assignments based on manual curation decisions.
The platform was built using the Django web-development framework (version 1.3,
Django, 2011). This framework was used as a communication layer between an HTML-
based user interface (UI) and a modified MySQL instance of the ChEMBL database
with an additional table pfam_maps for the mapping information. This table is part of
the workflow described in section 3.2.1. The columns of this table are laid out in the
Methods section 3.4.4. The UI was composed of three sections, ‘Evidence’, ‘Conflicts’
and ‘Resolved’. A schematic representation of the sitemap is shown in Figure 3.3.
The section ‘Evidence’ was implemented to provide an overview of the catalogue of
Pfam-A domains with known small molecule interactions and to list for each Pfam-A
domain the evidence for which it was included in the catalogue. For most domains,
this evidence consisted of activity measurements obtained from a query against the
current state of the database backend. A strip-plot visualisation generated from these
measurements was intended to assist the interpretation of evidence for small molecule
binding. In some cases, on the basis of reports in the literature (see section 3.2.3). The
‘Evidence’ section of the UI was programmed to display evidence of small molecule
binding in the form of literature references in such cases. Screenshots of the ‘Evidence’
section and an index page are shown in Appendix figures 6 and 7. The graph displayed
on the ‘Evidence’ page shows some of the evidence for small molecule binding to the
COesterase domain.
The ‘Conflicts’ section provides an overview of the domain architectures that result
in conflicting mappings. The UI was programmed to display a list of assays performed
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index
|
|-- Evidence portal
| |
| +-- Evidence
|
+-- Conflict portal
| |
| +-- Conflict
| |
| +-- Conflict details
|
+-- Resolved portal
|
+-- Resolved
|
+-- Resolved details
Figure 3.3: Sitemap of the curation platform user interface. The index page provides links
to the three sections ‘Evidence’, ‘Conflicts’ and ‘Resolved’. The portal page of the ‘Evidence’
section provides a list of all Pfam-A domains in the catalogue of domains with known small
molecule interactions. Each entry in this list links to a page providing evidence for small
molecule binding to the individual domain. The portal page of the ‘Conflicts’ section provides a
list of all domain architectures resulting in conflicting mappings and each entry links to a set of
pages detailing the assays aﬀected by the conflicting mappings. The ‘Resolved’ section mirrors
the ‘Conflicts’ section, listing assays for which small molecule binding was resolved manually.
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on proteins of a given architecture. For each assay, the user is presented with a view of
the domain architecture, a short description of the assay as well as links to the ChEMBL
and Pubmed entries corresponding to an an assay and its source document. Manual
curation decisions, together with comments justifying a decision, are passed back to the
database and stored in the mapping table. Once resolved, an assay is moved from the
‘Conflicts’ section to the ‘Resolved’ section. Screenshots of the ‘Conflicts’ section and its
index page are shown in Appendix figures 8 and 9.
The‘Resolved’ section is a mirror of the conflicts section displaying resolved conflicts.
As in the ‘Conflicts’ section, the user is presented with a view of the architecture, a short
description of the assay and links to the source document. In addition, the UI displays
the name of the Pfam-A domain to which small molecule binding was mapped in the
manual curation process as well as the comment left by the curator. The UI can be used
to revoke the mapping for a given assay and thus pass this assay back to the conflicts
section. Screenshots of the ‘Resolved’ section and its index page are shown in Appendix
figures 10 and 11.
In summary, I created a platform that allows to manually determine the Pfam-A
domain at which small molecule binding takes place if more than one possible mapping
exists. The platform enables manual mappings and their revision using the ‘Conflicts’
and ‘Resolved’ sections. The catalogue of Pfam-A domains with known small molecule
interactions can be reviewed and adjusted using the ‘Evidence’ section. Changes made in
either of the sections are fed back to the database tables pfam_maps and valid_pfam. In
these tables, changes are logged and documented using timestamps and user comments.
3.2.3 Refinement of the catalogue of domains with evidence for
small molecule binding
Evidence for small molecule binding to Pfam-A domains was initially obtained from
measurements of small molecule binding to single domain proteins. As described in
section 2.2.3 and the Methods section 2.5.3, a measurement was included if the measured
potency was better than 50 µM and the assay target could be unambiguously mapped to
a single protein sequence. The initial catalogue was assembled using binding data from
the chembl_13 release and yielded a list of 274 Pfam-A domains.
Using the ‘Evidence’ section of the curation interface, I reviewed the evidence for
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each of these 274 domains and reassessed whether a domain should be included in the
catalogue of Pfam-A domains with known small molecule binding. This assessment
was carried out on the basis of binding data from the chembl_15 release. In principle,
a reassessment of evidence for small molecule binding should be unnecessary as the
evidence is not expected to change or disappear: an interaction once measured should
persist also in new releases of the ChEMBL database. However, assay annotations in the
ChEMBL database are subject to iterative improvements by biocurators, which can lead
to changes in assigned target sequences or annotation flags such as the assay_type and
relationship_type fields in the assays table of the ChEMBL database. In fact, my
work related to the initial implementation of the mapping triggered a revision round of
assay annotations (Yvonne Light, EBI, personal communication). I further decided to
adjust the potency threshold from 50 µM to 10 µM when reviewing evidence for individual
Pfam-A domains. Activities in that range often derived from highly specialised assay
setups that can not reliably be compared to more standardised formats (see also section
3.3.1). In some cases multiple measurements with potency just below that threshold were
observed and these were accepted as suﬃcient evidence for small molecule binding. In
total, 34 Pfam-A domains were removed from the list of validated Pfam-A domains. In
chembl_10, this would have reduced the total number of mapped activities by 4,580 from
a total of 190,557 (2.4%). The impact on the overall coverage of the mapping is thus only
minor. Of those 34 removed domains, 15 were removed because after revision of assay
annotations no activities were mapped to these domains. A further 12 were removed
because none of the associated measurements met the more stringent potency criteria of
this refinement round and 7 were removed because associated assay annotations were
incorrect. Table 3.1 lists all removed domains and provides justification for their removal.
In addition, the Pfam-A domains Telo_bind and Peptidase_M84 were removed and
replaced with the domains POT1 and Reprolysin_5 to reflect name changes in the latest
release of the Pfam database.
As a further manual modification of the catalogue of validated Pfam-A domains, I
added a number of domains that were not initially included because they do not occur
alone, but only in combination with other domains. Based on indications in the scientific
literature, I added five domains to the catalogue of Pfam-A domains with known small
molecule interactions. The names of these domains, together with exemplary literature
references are listed in table 3.2. Below I present a short justification for each domain
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Table 3.1: Pfam-A domains with insuﬃcient evidence for small molecule binding. Table
provides names of removed domains together with the number of tested ligands and the highest
measured potency.
domain name number of ligands most potent
ANF receptor None –
Aph-1 None –
BsuBI PstI RE 1 19 µM (IC50)
DNA pol A 3 51 µM (IC50)
dUTPase 9 18 µM (Ki)
Glyco hydro 14 6 65 µM (IC50)
Glyco hydro 20 4 20 µM (Ki)
Glyco hydro 47 None –
Glyco transf 29 None a –
HCV NS4a None b –
HIT 3 34 µM (Ki)
Hormone 2 None a –
ICMT None –
IL5 None a –
IL8 None a –
KH 1 None –
Lectin legB 6 19 µM (IC50)
Myb DNA-binding None –
NAGidase None –
NAPRTase 2 14 µM (IC50)
PALP 12 4.6 (pKd)
PEN-2 None –
Peptidase C48 None –
Presenilin None c –
Ras 5 12 µM (IC50)
RE HindIII 2 17 µM (IC50)
RHD None –
SHMT 1 17 µM (Kd)
TNF None –
Tubulin None –
Urotensin II None –
V-set None –
zf-CCCH None –
Lig chan None d –
Legend: a - assay maps to incorrect target; b - high Mw peptide ligands; c - cell-based assay;
d - assay maps to protein fragment
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Table 3.2: Overview of domains that were added manually. Five domain types that were
added manually to the catalogue of domains with known small molecule interactions are listed
together with references providing evidence for small molecule binding at these domains.
domain name references
7tm 3 Jensen and Bra¨uner-Osborne, 2007; Urwyler, 2011; Flor
and Acher, 2012
ANF receptor Kunishima et al., 2000; Malitschek et al., 1999; Pin and
Pre´zeau, 2007; Mun et al., 2004; Kew and Kemp, 2005;
Mony et al., 2009
Lig chan Armstrong and Gouaux, 2000; Unno et al., 2011
7tm 2 Pantaloni et al., 1996; Siu et al., 2013
SH2 Machida and Mayer, 2005; Taylor et al., 2008; Krask-
ouskaya et al., 2013
that was inserted into the catalogue in the manual refinement step. In many instances
the evidence for small molecule binding to a Pfam-A domain is ample. Here, I limit
myself to providing a few references to key publications or review articles.
3.2.3.1 Small molecule binding to the SH2 domain
The SH2 domain is well known as an ‘adapter’ that mediates protein-protein interactions
between cell-signalling proteins(Liu et al., 2006). While it is recognised as a potential
target for cancer therapeutics, for a long time the only known SH2 inhibitors were peptides
and peptidomimetics (Sawyer, 1998). Today, a range of small molecule inhibitors of
the SH2 domain exist, but have not yet reached the clinic (Machida and Mayer, 2005;
Taylor et al., 2008; Kraskouskaya et al., 2013). The inclusion of the SH2 domain into the
catalogue triggered a number of conflicting mappings with the Pkinase_Tyr domain.
3.2.3.2 Small molecule binding to the Lig_chan domain
The Lig_chan domain occurs in ionotropic glutamate and GABA receptors. These
receptors have a characteristic domain structure including a transmemebrane domain
(TM), an agonist binding domain (ABD) and N-terminal domain (NTD) (see section
3.1.1). The Pfam-A domains corresponding to these structural domains are the Lig_chan
domain, the Lig_chan-Glu_bd and the ANF_receptor domain. However, the boundaries
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of the Lig_chan Pfam-A domain extend well into the ABD in all crystal structures that
I examined. Two examples that are based on a crystal structure of AMPA binding to
GRIA2 (Armstrong and Gouaux, 2000) as well as Neodysiherbaine A binding to GRIK2
(Unno et al., 2011) are shown in figure 3.4. A large part of the ABD domain is made up of
residues belonging to the Lig_chan domain and most contacts with the respective ligands
in these structures are made through the Lig_chan domain. Within the ChEMBL target
dictionary, the Lig_chan-Glu_bd domain occurs exclusively as a unit with the Lig_chan
domain. This arrangement is comparable to the enzyme doublets discussed in section
2.3.3.2. Here, I used the Lig_chan domain as a proxy for the Lig_chan-Glu_bd and
Lig_chan doublet. The insertion of the Lig_chan domain created a number of conflicting
mappings with the ANF_receptor domain, that also occurs in ionotropic glutamate and
GABA receptors.
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Figure 3.4: Binding of two small molecules at the interface of the Lig_chan-Glu_bd and
Lig_chan domains. Residues within binding domains are shown in space-filling representation,
and other residues are shown in cartoon representation. Panel A and B depict the binding of
AMPA (AMQ) and Neodysiherbaine A (NDZ) at the interface of the Lig_chan-Glu_bd (green)
and Lig_chan (pink) domain of the AMPA and kainate glutamate receptors (pdb: 1ftm, 3qxm).
3.2.3.3 Small molecule binding to the ANF_receptor domain
The ANF_receptor domain occurs in proteins with diverse domain architectures. Among
the proteins containing the ANF_receptor domain are the class C GPCRs and ionotropic
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glutamate receptors (iGluRs). The family of type C GPCRs comprises metabotropic
glutamate receptors (mGluRs), calcium-sensing receptors (CaRs), GABAB-Rs and taste
receptors. Glutamate and γ-Aminobutyric acid, the natural ligands for the mGluR and
GABAB-R (as well as the artificial ligand baclofen and others) bind their respective
receptors at the dimer interface formed by two ANF_receptor domains (Kunishima et al.,
2000; Malitschek et al., 1999; Pin and Pre´zeau, 2007). Binding of L-amino acids to the
CaR is also mediated through the ANF_receptor domain (Mun et al., 2004). The group
of iGluRs includes the AMPA, NMDA and kainate receptors. Ifenprodil and a series of
analogous compounds are well known inihibitor of the NMDA receptor that acts through
the ANF_receptor domain (Kew and Kemp, 2005; Mony et al., 2009). The ANF_receptor
domain had been removed from the catalogue because in the chembl_15 release, there
was no evidence for small molecule binding to single domain proteins containing the
ANF_receptor domain. However, given the ample evidence in the literature for small
molecule binding to this domain, I reinserted the ANF_receptor domain back into the
catalogue of domains with known small molecule interactions.
3.2.3.4 Small molecule binding to the 7tm_3 domain
Proteins in the ChEMBL target dictionary that contain a 7tm_3 domain belong to the
class of type C GPCRs, which includes mGluRs, CaRs, and GABAB. In addition to a
7tm_3 domain, receptors of this type contain a copy of the ANF_receptor domain. Class
C GPCRs receptors form dimers in the cellular membrane. There are numerous synthetic
modulators that bind class C GPCRs through an allosteric site located in the 7tm_3
domain (Jensen and Bra¨uner-Osborne, 2007; Urwyler, 2011; Flor and Acher, 2012). Given
the large number of ligands available for class C GPCRs, I inserted the 7tm_3 domain
into the catalogue. This resulted in 3,893 mapping conflicts with the ANF_receptor
domain, which had to be resolved manually.
3.2.3.5 Small molecule binding to the 7tm_2 domain
The 7tm_2 domain occurs in class B GPCRs. Receptors in this class are hormone
receptors and their endogenous ligands are usually large peptides such as glucagon or
secretin. Class B GPCRs consist of a seven-transmembrane domain (7tm_2) and an
extracellular domain (HRM). Studies of splice variants (Pantaloni et al., 1996), mutation
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studies (see Siu et al., 2013 for a summary), and the crystal structure of the glucagon
receptor (Siu et al., 2013) have shown that ligand binding is mediated by both domains.
The 7tm_2 and HRM domain always occur together in the ChEMBL target dictionary,
thus forming a unit comparable to the enzyme doublets discussed in section 2.3.3.2. Here,
the 7tm_2 domain was included as a proxy for the HRM domain.
In summary, a manual revision of the catalogue of Pfam-A domains with evidence for
small molecule binding resulted in the removal of 34 Pfam-A domains with insuﬃcient
evidence for small molecule binding, and the addition of five domains that had previously
not been included because they occur only in multi-domain architectures, resulting in
a final total of 29 removed Pfam-A domains. Some of these added domains resulted in
additional conflicting mappings.
3.2.4 Manual curation of conflicting mappings
The total number of bioactivity measurements in the chembl_15 release that were
covered by the mapping procedure was 360,429. Of these, 12,322 measurements (3.4%)
were associated with conflicting mappings while another 14,442 measurements (4%)
were associated with architectures containing multiple instances of the same domain
type. Curation was not carried out on the latter configurations since the mappings
correctly associate small molecules with the correct domain type. I identified ten
configurations of Pfam-A domains that resulted in conflicting mappings. An overview of
these configurations is given in table 3.3.
Each of these configurations were subjected to manual curation and curation was
completed for the vast majority of conflicting measurements (see last column in table
3.3) . In an eﬀort to make curation decisions transparent, I recorded my comments that
justify each curation decision. In the following, I present domain configurations that
caused conflicting assignments when subjected to the mapping heuristic and discuss the
strategies I used to manually resolve these conflicts.
The largest number of conflicting assignments (n = 4,931) derived from domain
architectures containing both an SH2 domain as well as a Pkinase_Tyr domain. This
architecture is found mainly in non-receptor tyrosine kinases (NRTKs) (Hubbard and Till,
2000). Most NRTKs are involved in downstream integration of growth factor signalling and
thus are attractive targets for cancer therapeutics, such as the ABL1 inhibitor imatinib
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Table 3.3: Domain configurations in conflicting mappings. The co-occurring domains from the
catalogue of Pfam-A domains with known small molecule interactions are listed in the column
headed ‘configuration’. The numbers of associated measurements and assays are laid out in the
columns ‘n(measurements)’ and ‘n(assays)’.
configuration n(measurements) n(assays) resolved
7tm 3 vs. ANF receptor 3,893 327 59%
ANF receptor vs. Lig chan 1,988 234 31%
ANF receptor vs. Pkinase Tyr 10 1 complete
Carb anhydrase vs. Y phosphatase 3 1 complete
DHFR 1 vs. Thymidylat synt 1,163 60 complete
HCV capsid vs. RdRP 3 35 4 complete
OMPdecase vs. Pribosyltran 7 4 complete
Pkinase Tyr vs. SH2 4,931 491 complete
RVP vs. rve 8 1 complete
SH2 vs. Y phosphatase 284 15 complete
for the treatment of chronic myeloid leukaemia (Druker et al., 2001). Drug discovery
and medicinal chemistry projects have to the largest extent sought to inhibit NRTKs
through the kinase function and thus explored small molecules binding the Pkinase_Tyr
domain. More recently, inhibition of NRTKs has also been achieved using small molecules
binding the SH2 domain (Machida and Mayer, 2005; Taylor et al., 2008; Kraskouskaya
et al., 2013). However, the vast majority of assays in the medicinal chemistry literature
measure inhibition of the Pkinase_Tyr domain. While inspecting conflicting mappings
of this type in the curation interface I noticed that assay descriptions contain the string
‘SH2’ in cases where NRTK inhibition is mediated through the SH2 domain. Therefore,
conflicting mappings of this type could simply be resolved by matching a simple regular
expression over the associated assay descriptions.
Domain architectures containing both a 7tm_3 domain as well as an ANF_receptor
domain yielded 2,329 conflicting mappings. Proteins with architectures of this type belong
to the class C GPCRs (Pin et al., 2003). This class of GPCRs encompasses calcium
sensing receptors, GABAB receptors and metabotropic glutamate receptors. Unlike
other GPCRs, these receptors form dimers when activated. Class C GPCRs bind their
endogenous ligands through a so-called ‘venus flytrap’ module which corresponds to the
ANF_receptor domain. In the medicinal chemistry literature, this site is referred to as
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the orthosteric site. However, most of the artificial modulators that have been developed
for class C GPCRs exert their function through an allosteric site closer to the membrane.
This site falls mostly within the boundaries of the 7tm_3 domain. Manual curation of
binding site assignments was based on assay descriptions. During this process, I queried
assay descriptions for the terms ‘allosteric’ and ‘orthosteric’. Further I queried assay
descriptions for names of compounds frequently used in radio-ligand displacement assays
such as ‘MPEP’, ‘LY354740’ and ‘baclofen’. The occurrence of any of these names in an
assay description provides indirect information about the binding site that is assessed
by a given assay. The generic procedure I employed for manual curation is described in
section 3.4.7.
The third largest number of conflicting mappings was caused by proteins containing
both an ANF_receptor domain and a Lig_chan domain. In the ChEMBL target dictio-
nary, this domain combination occurred in ionotropic glutamate receptors. Ionotropic
glutamate receptors have up to five documented sites through which small molecules can
modulate the receptor function. Figure 3.1 gives an overview of these sites and their
location relative to the receptor’s domain architecture. Manual curation of this type
of mapping conflict proved diﬃcult, as the exact site of interaction was in many cases
undocumented in both the assay description and the original publication. Assays for this
type of receptor are often set up to measure displacement of a radioactive ligand. In
most cases, the displaced ligands are well-documented chemical probes (Kew and Kemp,
2005; Jensen and Bra¨uner-Osborne, 2007). One viable strategy of manually mapping
small molecule interaction sites is thus by inference from the ligand whose displacement
is measured in the assay. While this strategy could be applied with some success, there
still remained a number of assays for which the site of small molecule binding could
not be extracted from either the assay description or the original publication. These
mappings were left uncurated.
Conflicting mappings caused by proteins containing both a DHFR_1 and Thymidylat_synt
domain derived from the bifunctional dihydrofolate reductase-thymidylate synthase of
bikont organisms such as Trypanosoma cruzi and Plasmodium falciparum. The site of
small molecule binding was extracted using the standard procedure for manual curation
outlined in the Methods section 3.4.7.
The remaining architectures that resulted in conflicting mappings had only few
associated measurements and could eﬀortlessly be curated on a case-by-case basis using
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the standard procedure for manual curation.
3.2.5 Coverage of measurements in the ChEMBL database
The primary aim of adding domains manually to the catalogue (see section 3.2.3) was to
extend the coverage of the mapping and make it applicable to domain architectures that do
not contain any of the domains contained in the initial version of the catalogue. In a first
step, I evaluated the mapping coverage κmeas as a fraction of measurements with domain
mappings over all measurements in the ChEMBL database. Only measurements that
represented proven small molecule-protein interactions were included in this calculation.
The query to select these proven measurements was designed in analogy to the query used
to detect evidence for small molecule binding to a single-domain protein: measurements
were required to originate from binding assays with potency expressed as either of the
following IC50, EC50, AC50, Ki, Kd, and a potency value of at least 50 µM (see Methods
section 3.4.8). Using these criteria, I retrieved 308,548 measurements of small molecule
protein interactions from the ChEMBL database (release chembl_15). Of these, 270,893
were mapped to at least one protein domain, resulting in a coverage κmeas of 87.8%. I also
evaluated coverage on a per-protein basis κprot. The number of targets covered by the
mapping in chembl_15 was 2,181 of a total of 2,800 targets with proven small molecule
interactions, resulting in a coverage κprot of 78.0%.
For a more detailed view of the mapping coverage in multi-domain proteins, I
examined patterns of domain co-occurrence among proteins with measured small molecule
interactions. To represent these patterns, I created a network graph in which nodes
represent Pfam-A domains and vertices represent proteins that contain any two connected
domains in their sequence (see Figure 3.5 and Methods section 3.4.8). The entire network
consists of 884 nodes which partitioned into a giant component of 317 nodes connected by
864 edges and 183 smaller components comprising a total of 567 nodes connected by 1,005
edges. Some of the nodes in the giant component, such as the Pkinase, Pkinase_Tyr
and SH2 domains formed large numbers of connections with domains that were otherwise
isolated. Other nodes were embedded in intricate subnetworks, such as the ANF_receptor,
Lig_chan and 7tm_3 domains. Viral polyproteins were represented by large isolated
clusters of highly connected domains. The majority of network components consisted
of only a few domains. Many of these represent enzymatic doublets as discussed in
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section 2.3.3.2, for example the combination of GST_C and GST_N domain or Tubulin and
Tubulin_C domains. The network view also revealed that the coverage of all possible
domain architectures was incomplete. Only 65 domains from the catalogue were projected
in the mapping process. These co-occur with 291 additional domains, resulting in a
subnetwork of 356 domains connected by 373 edges. In contrast, a remaining 567 domains
do not co-occur with any of the domains from the catalogue. As shown earlier, these
remaining architectures account for only a minority of measured small molecule-protein
interactions in the ChEMBL database.
3.3 Discussion
3.3.1 Changes to the catalogue of domains with known small
molecule interactions
Manual curation of the catalogue of Pfam-A domains with known small molecule in-
teractions resulted in the removal of 34 Pfam-A domains and insertion of 5 Pfam-A
domains. Pfam-A domains were removed if evidence for small molecule binding was
deemed insuﬃcient. The initial catalogue was adapted from Kruger et al., 2012. The
catalogue presented in this publication was derived from an application of the mapping
heuristic presented in chapter 2 to the chembl_13 database release.
Subsequent releases of the database have seen improvements in the target annotation
for a number of assays. Thus, a number of Pfam-A domains that were mapped to assays
of small molecule binding in the chembl_13 release are no longer associated with these
assays in the chembl_15 release. Such disassociation can occur when assay targets that
were initially mapped to protein fragments containing only a single domain are mapped
to full length proteins with multiple domains. In other cases, assay meta-data stored
in database fields such as assay_type or relationship_type may have been corrected,
for example to reflect that the readout from an assay relies on whole-cell response rather
than a cell-free system. Consequently, Pfam-A domains with no associated measurements
from binding assays in the chembl_15 release were removed from the catalogue.
As described in section 3.2.3, I also applied a more stringent potency threshold of 10
µM to evaluate whether a measurement counts as evidence for small molecule binding.
I selected this threshold over the more lenient threshold of 50 µM because experience
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from the initial mapping had shown that measurements with potency less than 10 µM
were often associated with extraordinary assay formats such as fragment or natural
product screens and protein-protein interaction data. It can also be argued that potencies
in the higher µM range are often mediated by unspecific eﬀects, such as aggregation
or denaturation (McGovern et al., 2002; McGovern et al., 2003; Shoichet, 2006). The
threshold of 10 µM was not strictly enforced: for example, if more than a handful of
suﬃciently diverse compounds exhibited activities slightly above the 10 µM threshold I
retained the corresponding Pfam-A domains in the catalogue.
One of the objectives of the initial construction and later manual refinement of the
catalogue was to to obtain a list that can reliably be associated with small molecule
binding. The exclusion of a Pfam-A domain from the catalogue does not imply that
such domains cannot interact with small molecules. It rather signifies that no assays of
single domain proteins in the ChEMBL database exists for this domain type. By this
logic, it was inevitable that a number of Pfam-A domains that are genuinely known to
interact with small molecules would be missed from the catalogue, especially such domains
that do not occur in single domain proteins, as for example the Pkinase_Tyr domain.
Owing to its significance in drug discovery, the Pkinase_Tyr domain had already been
included in the initial mapping. To account for additional domains from this category, I
assembled a list of multi-domain architectures that are frequently found in the ChEMBL
target dictionary. I examined the 15 most frequent multi-domain architectures from the
ChEMBL target dictionary and assessed the corresponding Pfam-A domains for their
potential to bind small molecules. Table 3.4 lists the most frequent architectures and
indicates components that were already included in the mapping. This list was used
to prioritise Pfam-A domains for manual insertion into the catalogue of domains with
known small molecule interactions.
The manual insertion of Pfam-A domains supplements the catalogue with domains
that do not occur in single domain proteins. The insertion of only five domains is
somewhat inconsequential, because it is certain that other domains exist that are eligible
to be added to the catalogue in this way. However, this process is time-consuming and
insertion of individual domains would often not contribute more than a few mapped
activities per added domain. The curation interface has therefore been set up in a way
that allows for incremental improvements of the catalogue.
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Table 3.4: Top 15 multi-domain architectures in the ChEMBL database. Multiple occurrences
of a Pfam-A domain in an architecture are indicated by (x[n]) in parentheses in the architecture
column. The column ‘count’ provides the number of time an architecture occurred in ChEMBL
and the column ‘mapped’ indicates whether a mapping was made using homology transfer
from the catalogue of Pfam-A domains with known interactions. If no mapping was made, this
column indicates ‘False’.
architecture count mapped
Hormone recep, zf-C4 24 Hormone recep
Neur chan LBD, Neur chan memb 19 Neur chan LBD
Pkinase Tyr, SH2, SH3 1 18 False
Inhibitor I29, Peptidase C1 17 Peptidase C1
7tm 3, ANF receptor, NCD3G 12 ANF receptor
ANF receptor, Lig chan, Lig chan-Glu bd 12 ANF receptor
7tm 2, HRM 11 False
Pyr redox, Pyr redox 2, Pyr redox dim 10 False
C1 1, C1 1, C2, Pkinase, Pkinase C 10 Pkinase
Hemopexin (x4), PG binding 1, Peptidase M10 9 Peptidase M10
Pkinase (x2) Pkinase C 8 Pkinase
AChE tetra, COesterase 8 COesterase
ABC membrane (x2), ABC tran (x2) 7 False
DPPIV N, Peptidase S9 7 False
CARD, Peptidase C14 7 Peptidase C14
Neur chan LBD, Neur chan memb (x2) 6 Neur chan LBD
GAF (x2) PDEase I 6 PDEase I
Peptidase S9, Peptidase S9 N 6 False
Lipoxygenase, PLAT 6 False
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3.3.2 Conclusions
The mapping presented in chapter 2 provided a framework for the refined mapping
presented in this chapter. The purpose of the refinement was to provide a reliable resource
that relates small molecule binding to Pfam-A domains. I anticipate that this resource
will be useful for repurposing studies that seek to relate proteins from newly-sequenced
pathogen genomes to existing drug targets by protein sequence. It may further be
useful for applications in the field of proteochemometrics (PCM) that seeks to optimise
predictive models of small molecule bioactivity by incorporating protein descriptors.
Together with Anna Gaulton, I devised a process to make these mappings an integral
part of the ChEMBL database in releases of chembl_17 and upwards. Furthermore,
the refined mapping is accessible through a stand-alone web application that provides
a rich context of domain-related information on small molecule binding. This resource
is decoupled from the release cycle of the ChEMBL database to prevent bottlenecks in
the release preparation of either resource. The curation interface was constructed in a
way that I hope will encourage participation of the chemical biology community. While I
have carried out curation for the majority of conflicting mappings, the decisions I have
made can be reviewed and indeed revoked by registered users. Future releases of the
ChEMBL database will introduce a steady but manageable flow of additional mapping
conflicts that can equally be addressed by group-internal and community curators.
3.4 Methods
3.4.1 Loading routine
The loading routine projects Pfam-A domains from the catalogue of Pfam-A domains
with known small molecule interactions onto all proteins that are defined as assays targets
under the scope of the mapping (see section 3.4.2). The routine parses the catalogue
of Pfam-A domains with known small molecule interactions from the valid_domains
table. It also parses all manual mappings that were made in previous curation cycles
from the manual_maps table. The projection is applied to all assays that do not have
manual mappings assigned. Measurements that already have manual mappings assigned
from previous curation eﬀorts are annotated using the manual_maps table. The code for
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the loading routine is available at https://github.com/fak/pfam_map_loader/blob/
master/loader.py
3.4.2 Scope of the mapping
The scope of the mapping was defined in a SQL query in the loader script. This query
defines which measurements from the ChEMBL database are subject to the mapping.
Essentially, the mapping was applied to binding and functional assays in which the target
is unambiguously defined and with readouts of the types ‘Ki’, ‘Kd’, ‘IC50’, ‘EC50’, ‘AC50’
or logarithmic conversions thereof. A SQL query defining the scope is reproduced below:
SELECT DISTINCT act.activity_id
FROM activities act
JOIN assays ass
ON ass.assay_id = act.assay_id
JOIN target_dictionary td
ON ass.tid = td.tid
WHERE ass.assay_type IN(‘B’,‘F’)
AND td.target_type IN(‘PROTEIN COMPLEX’, ‘SINGLE PROTEIN’)
AND act.standard_relation =‘=’
AND ass.relationship_type = ‘D’
AND act.standard_type IN(
‘Ki’, ‘Kd’, ‘IC50’, ‘EC50’, ‘AC50’,
‘log Ki’, ‘log Kd’, ‘log IC50’, ‘Log EC50’, ‘Log AC50’
‘pKi’, ‘pKd’, ‘pIC50’, ‘pEC50’, ‘pAC50’
)
3.4.3 Export routine
The export routine was used to produce the two tables manual_maps and valid_domains
after each round of manual curation. It is a simple script that writes the results of a SQL
query for all manual mappings into a tab-separated text file. The code for this routine is
available at https://github.com/fak/pfam_map_loader/blob/master/exporter.py.
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3.4.4 Mapping tables
Mapping tables relate measurements of small molecule binding to Pfam-A domains. The
main mapping table is called pfam_maps and forms part of a modified schema of the
ChEMBL database. The manual_maps table is a subsection of the pfam_maps table that
comprises all measurements from assays that had been manually curated. This table is
produced after each curation round using the export routine.
The pfam_maps table contains mappings for all assays (and associated measurements)
under the scope of the mapping. Mappings are defined using a combination of the
activity_id, component_id and domain_id fields which are also found in other tables
of the ChEMBL database. In addition, the pfam_maps table contains the following
columns:
• domain_name - provides the domain name of the mapped domain
• category_flag - indicates the category of mapping
• status_flag - indicates the status of a mapping
• manual_flag - indicates whether a mapping has been manually curated
• comment - comment to justify curation decision
• timestamp - indicates the time a mapping was last changed.
The category of mapping was set to 0 if a given binding event was not mapped to
more than one domain, or, in other words, if there were no conflicts with other domains.
The category of mapping was set to 1 in cases where small molecule binding was mapped
to multiple domains of the same type. If small molecule binding was mapped to diﬀerent
domain types the category of a mapping was set to 2. The status_flag was used as a
‘switch’ that indicates whether a mapping is valid or not. This flag was set to 1 for all
conflicting mappings and to 0 for all mappings that did not conflict with other mappings
or where conflicts had been manually resolved. The manual_flag was set to 0 by default,
but changed to 1 for all mappings associated with an assay that had been manually
curated. The manual_maps table is simply a subsection of the pfam_maps table including
all rows where manual_flag is equal to 1.
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3.4.5 Catalogue of Pfam-A domains with known small molecule
interactions
The catalogue of Pfam-A domains with known small molecule interactions was stored
in the valid_domains table. This table contains the names of all Pfam-A domains for
which evidence for small molecule binding was found either from measurements of single
domain proteins in the ChEMBL database or from the literature. Pfam-A domains that
were removed from the catalogue through manual curation as described in section 3.2.3
were retained in this table, but labelled as invalid. The table consists of four columns:
• domain_name - provides the domain name of the mapped domain
• removed_flag - indicates whether a domain has been removed from the catalogue
manually
• comment - comment provides pointer to literature evidence for small molecule
binding for a given domain
• timestamp - indicates the time a mapping was last changed.
3.4.6 Prototype of a curation platform
The curation platform was implemented using the Django web application framework.
The application consists of four parts:
• a data model that describes the schema of the database backend
• a number of views that contain functions to retrieve and arrange content from the
database
• a URL management system that relates input URLs to views
• a number of HTML templates to display content generated by the views functions.
Details of the architecture for Django web applications are documented elsewhere
(e.g. http://djangobook.com) and here, I describe only aspects that are specific to the
implementation of the curation platform. The data model was created from a MySQL
database instance hosting the chembl_15 release of the ChEMBL database using the
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django-admin.py syncdb command. The data model can be applied to future releases
of the ChEMBL databases even though future schema changes might require slight
adjustments. The data model is available at https://github.com/fak/pfam_maps/
blob/master/chembl_15/models.py.
Views were programmed to generate dynamic content in response to requests generated
at the UI. In most cases, user requests trigger the execution of a database query and
subsequent processing of the query results. The processed results are forwarded to
be rendered in the corresponding HTML template. The python functions for these
views can be accessed at https://github.com/fak/pfam_maps/blob/master/chembl_
15/views.py and some supporting functions at https://github.com/fak/pfam_maps/
blob/master/chembl_15/helper.py.
The URL management system directs requests generated at the UI to functions
defined in the Views section. All content generated by these functions is then routed to
HTML templates via the URL management system. The code for this system is available
at https://github.com/fak/pfam_maps/blob/master/chembl_15/urls.py.
The html templates are written in HTML and the Django template language. The
formatting and CSS styles of the html documents are based on the EBI main website.
User input is fed back to the functions defiend in the views section using the POST
protocol. All templates can be accessed at https://github.com/fak/pfam_maps/tree/
master/chembl_15/templates/chembl_15.
Evidence for small molecule binding in the evidence pages is presented dynamically
using the plotting library d3.js (Bostock et al., 2011). The javascript code used to generate
these plots is available at https://github.com/fak/pfam_maps/blob/master/chembl_
15/static/chembl_15/js/scatterplot.js.
Protein domain structures in the conflict_details section are visualised using
a dedicated library domain_graphics.js provided by the Pfam webserver at http:
//pfam.sanger.ac.uk/static/javascripts/domain_graphics.js.
3.4.7 Standard procedure of manual curation
The standard procedure of manual curation consisted of up to four steps. These steps
were carried out iteratively and the process was stopped as soon as a step yielded suﬃcient
information to reach a curation decision. The items were inspected in the following
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order: (1) assay description, (2) publication title, (3) publication abstract, (4) publication
full-text. I searched any of these four items for keywords the ‘allosteric’, ‘orthosteric’,
‘competitive’ and ‘non-competitive’. Frequently, the site of binding could also be derived
indirectly from the lead structure or comparisons of the evaluated compounds with
existing, well-documented chemical probes. In cases where none of the above items
contained suﬃcient information to reach a curation decision, no decision was made and
the assay was retained for a future curation round.
3.4.8 Coverage and network view
The coverage κmeas of all relevant measurements in the ChEMBL database was determined
as the fraction :
κmeas =
nmeas(mapped)
nmeas(total)
(3.1)
In this fraction, nmeas(total) corresponds to the total number of measurements from
the ChEMBL database that represent small molecule-protein interactions. Of those,
nmeas(mapped) indicates the number of measurements that were mapped to one or more
protein domains.
Another measure of the coverage, κprot, was determined as:
κprot =
nprot(mapped)
nprot(total)
(3.2)
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Here, nprot(mapped) corresponds to the number of proteins containing one or more
domain from the catalogue of domains with known small molecule interactions and
nprot(total) represents the total number of proteins for which small molecule binding was
measured. Measurements that represent small molecule binding events were obtained
using the following SQL statement below. This statements selects from all activities in
ChEMBL those that have a relevant activity type and suﬃcient potency in binding or
functional assays.
SELECT DISTINCT dc.tid, COUNT(DISTINCT activity_id)
FROM assays ass
JOIN(
SELECT td.tid, td.target_type, COUNT(cd.domain_id) as dc
FROM target_dictionary td
JOIN target_components tc
ON tc.tid = td.tid
JOIN component_sequences cs
ON cs.component_id = tc.component_id
JOIN component_domains cd
ON cd.component_id = cs.component_id
WHERE td.target_type IN(‘SINGLE PROTEIN’, ‘PROTEIN COMPLEX’)
GROUP BY td.tid
) as dc
ON dc.tid = ass.tid
JOIN activities act
ON act.assay_id = ass.assay_id
WHERE act.standard_type IN(‘Ki’,‘Kd’,‘IC50’,‘EC50’, ‘AC50’)
AND ass.relationship_type = ‘D’
AND assay_type IN(‘B’, ‘F’)
AND act.standard_relation IN(‘=’)
AND standard_units = ‘nM’
AND standard_value <= 50000
GROUP BY dc.tid ORDER BY COUNT(activity_id)
Using the target identifiers obtained in this query, a network of domain co-occurrences
was constructed by the enumeration of all pair-wise domain combinations. This list
of domain pairings was imported and visualised using the Cytoscape software (version
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2.8, Shannon et al., 2003). Features of the Cytoscape software were also used to
assemble the network statistics presented in section 3.3.1. The script that was used
to query and process the measured small molecule-protein interactions is available at
https://github.com/fak/mapChEMBLPfam/blob/master/analysis.py.
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Chapter 4
Integration of small molecule
potency measurements with the
phylogeny of their protein targets
4.1 Introduction
The introduction to this Chapter is split in two parts. Section 4.1.1 lays out the
principles of phylogenetic relationships and the protein homology concept and highlights
its relevance in a drug discovery context. Section 4.1.2 describes the rat as a model
organism in drug discovery and discusses the evolutionary relationship to humans. It
also presents a brief overview of physiological and molecular similarities and diﬀerences
between the two species. Section 4.1.3 provides an outline of the integration work and
analysis I have carried out in this context for the completion of my Ph.D. thesis.
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4.1.1 Phylogenetic relationship between drug targets
Pharmacological intervention relies on the interaction of a chemical with molecular
components of the body. To our current understanding of pharmacology, most of
these molecular components are proteins, with some exceptions involving nuclear DNA,
extracellular sugar-polymers and lipids. When examining a specific protein as a target of
pharmacological intervention, it is useful to view the protein in its evolutionary context.
In section 1.4.1, I introduced the concept of homology, which applies to genes and proteins
sharing a common ancestor. Proteins that are related through gene duplication are
called paralogs, while proteins that are related through a speciation event are called
orthologs. Figure 1.2 provides an overview of these relationships. It was deduced from
first principles that gene duplication enables fast functional divergence on the grounds
that one paralog can retain the function of the ancestor. Orthologs on the other hand
should have conserved function, as a loss of the function of the ancestor would likely have
a detrimental eﬀect on fitness. This is also known as the ‘ortholog conjecture’ (Conant
and Wolfe, 2008; Studer and Robinson-Rechavi, 2009).
Many aspects of modern drug development rely on the principles laid out by the
ortholog conjecture. The use of animal models is an extrapolation from the model species
to man and in most cases implicitly assumes that the protein target of a pharmacological
intervention serves a similar function in both species and is indeed susceptible to similar
chemical perturbations. A number of studies show that phenotypic responses to small
molecule perturbation can drastically diﬀer between species. For example, reduced
growth of yeast colonies and abnormal angiogenesis in mice would be corresponding
‘phenologous’ responses to Lovastatin administration (McGary et al., 2010; Cha et al.,
2012). Both the traditional approach of direct extrapolation between species as well as
this less established approach of extrapolation through modules of ‘phenologs’, rely on
functional conservation of underlying molecular components. Given its importance in
the drug discovery process, there is a surprising lack of systematic studies to support
the ortholog conjecture in the context of small molecule perturbation. Following the
molecular biology revolution that enabled cloning and over-expression of drug targets
in cellular systems in the 1990s, a number of studies have been published that compare
small molecule binding between orthologous proteins. These studies are of relatively
small scale and focus on diﬀerences between species (mainly human and rat or mouse)
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observed for individual orthologous pairs and relatively small numbers of ligands (for
example Lovenberg et al., 2000; Barker et al., 1994; Erion et al., 2005).
Another hallmark of modern drug discovery is the concept of selective perturbation,
which seeks to reduce unwanted side eﬀects through the development of ligands that
interact exclusively with a desired receptor. Ligand selectivity for a given protein is most
often probed against proteins that are linked through a common ancestor and thus form
a family of paralogous proteins. Knowledge of the within-family selectivity is of vital
importance for mode-of-action studies; the discovery of the vanilloid-receptor-like protein
3, for example, provided an improved model of thermal hyper-sensitivity at a time where
drugs were under development for its paralog, the vanilloid receptor (Xu et al., 2002).
The notion that drug action in many cases is mediated through interaction with multiple
rather than one specific protein target has lead to the rise of the polypharmacology
concept (Roth et al., 2004; Paolini et al., 2006; Yildirim et al., 2007). It states that
an ‘unselective’ pharmacological profile may be an advantageous property for a drug
candidate. Targeted polypharmacology is diﬃcult to attain in a practical sense (Morphy
and Rankovic, 2005; Hopkins et al., 2006; Morphy and Rankovic, 2007); so far, it has
been applied to ‘design’ inhibitors with multiple activities against (paralogous) members
of the kinase family (Knight et al., 2010). Both the traditional approach of selective
perturbation as well as the polypharmacology approach, rely on the notion that selectivity
between paralogous proteins can be attained in a targeted manner. Large and medium
scale studies have been conducted that compare small molecule potency between paralogs
across the kinome (Metz et al., 2011) or, using literature data from ChEMBL, the family
of G-protein coupled receptors (Lin et al., 2013).
The recent availability of public small molecule bioactivity data means it is possible to
compare small molecule binding to orthologs and paralogs systematically and on a large
scale. In this chapter of my thesis I explore an approach by which I examine directly the
interaction of phylogenetic relation and small molecule potency.
4.1.2 Rats as model organisms in drug discovery
Rats are among the most popular organisms to study human disease. Rats, together
with mice, guinea pigs, and others, form the large mammalian order of Rodentia. The
characteristics shared by many species in this order are considered advantageous for
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Figure 4.1: Tree of evolu-
tionary distances. Figure is
adapted from Cooper et al., 2003.
Branch lengths approximately
scale with the frequency of sub-
stitution averaged over four sites
in the CFTR and BRCA1 genes
and highlight the acceleration of
non-synonymous substitution in
the two rodent species rat and
mouse. Mouse
Rat
Human
Baboon
Cat
Dog
Cow
Pig
model organisms and include unproblematic husbandry, short generation times and a
relatively low cost of maintenance. Rats have long been preferred over mice in biomedical
research because they are less aggressive and physiological parameters, such as heart
rate and renal clearance, are generally closer to those in humans (Gill et al., 1989). Of
particular relevance to pharmaceutical research, a higher blood volume facilitates dosage
and administration of trial substances. Mice have traditionally been the model of choice
for geneticists, owing to the relative ease of genetic manipulation and the possibility of
cloning animals from embryonic stem cells (Wakayama et al., 1999; Zambrowicz and
Sands, 2003). Genetic manipulation has proven more diﬃcult in rats, where cloning is
reliant on the somatic nuclear transfer methodology (Zhou et al., 2003) or lentiviral
transduction (Hamra et al., 2002; Ryu et al., 2007); both methodologies lack the precision
and eﬃciency of cloning from embryonic stem cells. The sequencing of the rat genome
in 2004 (Gibbs et al., 2004), induction of embryonic stem cells and targeted embryonic
knock-outs in 2009 (Li et al., 2009; Geurts et al., 2009) are likely to further the use of
rats as model organisms in biomedical research.
Humans and rats share their mammalian origin and the most recent common ancestor
dates back to about 91m years (Hedges et al., 2006). Since their divergence, the non-
synonymous substitution rate in mice and rats has increased, while that of humans has
decreased, leaving the respective rates at a roughly three-to-one ratio (Cooper et al.,
2003). A phylogenetic tree representing the relationships between rats and a number of
other mammalian species is shown in Figure 4.1. The number of one-to-one orthologs (of
protein-coding genes) between the human and rat genome is estimated around 10,000
with an average sequence identity of 88.3% (Gibbs et al., 2004). A study that compared
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the G-protein coupled receptor repertoires of the human and mouse genome found
that humans and mice have 343 receptors of endogenous ligands in common. This
corresponds to almost the entire complement of this type of receptor in the human and
mouse genomes, where total numbers of these receptors are 367 and 392, respectively
(Vassilatis et al., 2003). A study comparing the repertoire of kinases in human and
mice identified 501 kinases with one-to-one orthologous realtionships (Caenepeel et al.,
2004). Taken together, these findings suggest that, at least with regard to some major
classes of drug targets, orthologous relationships between the human and rat genome are
relatively straightforward. Naturally, the extrapolation from pharmacological studies in
rats to treatment outcomes in humans requires comparison on multiple levels that go well
beyond the conservation of orthologous relationships. Gene expression in response to drug
administration was found to be at least partly conserved for acetaminophen at liver-toxic
doses (Kienhuis et al., 2009). A more recent study of transcriptional modules responding
to multiple stimuli found only 15% of transcriptional modules were conserved between
humans and rats (Iskar et al., 2013) - even though studies in unperturbed organisms
had found higher conservation (Su et al., 2002; Liao and Zhang, 2006; Brawand et al.,
2011). Besides well-documented diﬀerences in cytochrome P450-mediated metabolism
(Guengerich et al., 1986; Kobayashi et al., 2003) and pharmacokinetic parameters such
as renal clearance and the volume of distribution (Ward and Smith, 2004a; Ward and
Smith, 2004b), there are also concerns that the rearing of rats in laboratory conditions
may alter their natural metabolic state (Martin et al., 2010). Thus, with increasing
complexity of the level of comparison it appears that extrapolation between rats and
humans becomes more problematic. In my thesis work, I evaluated extrapolation from
rats to humans at the lower intermediate level of in vitro drug response. The work has
important implications for the use of rats in pharmaceutical research as it helps pinpoint
where, on the scale of increasingly complex inter-species comparisons, we should start
factoring in diﬀerences between humans and rats.
4.1.3 Outline
This chapter describes an approach of integrating small molecule bioactivity data from
the ChEMBL database and homology information from the EnsemblCompara Genetrees
pipeline. The approach was used to examine the link between phylogenetic relationship
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and the conservation of compound potencies between pairs of proteins retrieved from
the ChEMBL target dictionary. The scope of the study was not limited to a particular
family of proteins, but rather ranged across all protein families. The relationships
that were examined in this study are orthology between human and rat proteins and
paralogy between human proteins. I chose to examine orthologs between proteins from
humans and rats because of the importance of rats as model organisms in drug discovery.
The ChEMBL database is rich in potency data measured against proteins from rats,
reflecting their prominent role in preclinical development and ADMET1 testing. While
in theory the approach presented here could be extended, the availability of potency
data for other species is limited and would not allow to draw conclusions with the same
confidence. Table 4.1 summarises activity counts for the top six organisms. Potency data
for human proteins is abundant in the ChEMBL database, as would be expected from
a database that extracts its core content from the medicinal chemistry literature. The
comparison of small molecule potencies across paralogous proteins is important in drug
discovery because its pharmacological profile across related proteins gives insights into
the selectivity of a compound and potential oﬀ-target eﬀects.
Table 4.1: Summarized above are unique activities per species. Only activities of type ‘B’
that could be mapped unambiguously to a Uniprot accession were counted.
Organism binding activities
H. sapiens 157,145
R. norvegicus 23,278
M. musculus 6,567
HIV 1 6,361
B. taurus 2,750
C. porcellus 2,190
C. elegans 1,772
S. scrofa 1,535
HCV 1,017
O. cuniculus 968
1ADMET is an acronym for absorption, distribution, metabolism, excretion and toxicity.
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4.2 Results and Discussion
4.2.1 Controlling for assay variability in the ChEMBL data set
ChEMBL is a collection of bioactivity measurements extracted from the relevant literature
published during the last 20 years. Hence, I started this project with the expectation
that diﬀerences in experimental set-up as well as measurement and reporting errors
would result in considerable noise of potencies recorded in ChEMBL. It was therefore
desirable to obtain a means to control for this noise when analysing potency diﬀerences
between human-rat orthologs and human paralogs. As an estimate of the inter-assay
variability, I extracted potency measurements from the ChEMBL database that had
been reported for the same compound and target, but in diﬀerent assays. I retrieved
measurements for both human and rat proteins. As described in the Methods sections
4.4.1 and 4.4.2, the query was limited to activities of the type IC50, EC50, Ki and the
respective logarithmic conversions of these activity types. In the original implementation
of this project (Kruger and Overington, 2012), values obtained from all measurement
types were compared directly, without additional conversion between IC50 and Ki. This
was a simplification, as the relationship of IC50 and Ki depends on assay parameters.
Frequently, it can be evaluated as
Ki =
IC50
1 + [S]Km
, (4.1)
where Km is the enzyme specific Michaelis-Menten constant (Michaelis and Menten,
1913; Michaelis et al., 2011) and [S] the substrate concentration. However, for potency
measurements in ChEMBL, the assay parameters Km and [S] are rarely available and thus
no attempt was made to convert between the two activity types. Recently, Kalliokoski
and colleagues published a study that suggests a conversion factor of 2.3 applied to Ki
measurements (corresponding to a subtraction of 0.355 log units) when mixing data of the
types Ki and IC50 (Kalliokoski et al., 2013). I followed this guideline for the preparation
of my thesis by adjusting all Ki by the oﬀset of 0.355 log units. After processing, I
constructed a distribution of inter-assay diﬀerences from pairwise comparisons. To
prevent comparison of measurements that were duplicates in the database, I excluded all
paired measurements that were exactly equal.
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First, I examined the resulting distributions for each species separately, as shown in
Figure 4.2A. This comparison showed that the fraction of highly similar measurements
was higher for rat proteins compared to human proteins. One factor that contributes
to this apparent diﬀerence is the composition of the data in terms of target classes. As
shown in Figure 4.2C, diﬀerent target classes exhibit diﬀerent degrees of between-assay
variability. One possible explanation for this observation lies in the specific assay formats
used for targets in diﬀerent classes, some of which have higher fidelity than others. Thus,
the composition in terms of target class influences the overall shape of the distribution
for each species. For example, the proportion of transporter data, which is in general
more similar between measurements, is higher for rat compared to human. However,
some diﬀerences persisted even after target classes had been taken into account. To
compensate for the observed diﬀerences when estimating the noise between assays, 1,500
paired measurements were picked at random from each species. Thus, the number of data
points in the ortholog analysis was approximately matched (see section 4.2.2). Samples
were picked only once, but to make sure the sample was representative, 1,000 additional
samples were taken as described in the Methods section 4.4.2 and 50 of them visualised
in Figure 4.15. This procedure allowed to determine standard errors of distribution
parameters. As representative parameters, I examined quantiles that would correspond
to the intervals covered by one and two standard deviations in a normal distribution
(68.4% and 95.5% of all data). They are reported in Table 4.2. The low amplitude of
associated standard errors shows that, at a sample size of 3,000 paired measurements,
resulting distributions are representative of the underlying data.
A graphical summary of the distribution that was sampled for the remaining analysis
Table 4.2: Quantile estimates of 1,000 sampled distributions of inter-assay diﬀerences. The
column ‘quantile’ indicates the distribution quantile, the column ‘mean value’ the quantile
value averaged over 1,000 sampled distributions and the column ‘std. error’ the standard error
of the parameter value across 1,000 sampled distributions.
quantile mean value std. error
2.3% −2.28 0.057
15.9% −0.84 0.023
median (50%) −0.01 0.007
84.1% 0.84 0.025
97.7% 2.14 0.054
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is provided in Figure 4.3. The distribution of diﬀerences between measurements is
symmetric around the origin. Notably, the shape of the distribution peak suggests that
the distribution can be described using the model of a Laplace distribution. A good fit
of a Laplace distribution was obtained with the parameters µ = 0.0 and b = 0.75 for
location and scale, respectively (see also section 4.2.4 and Figure 4.7). The selection and
filtering of potency measurements was designed to be consistent with human-rat orthologs.
Indeed, the distribution of observed potency diﬀerences between orthologs can also be
modelled using a Laplace distribution (see section 4.2.7). This is unexpected as under
the central limit theorem, the mean of a large number of independently distributed error
variables should tend towards a normal distribution, under the provision that the variance
of the error is finite. However, a normal distribution might underestimate the variance
in cases of unexpected error (Shlyakhter, 1994) and in such cases a double-exponential
(Laplace) distribution is a better model. In the given data, unexpected errors might be
due to the influence of unit transcription errors2 and in cases where comparisons of IC50
and Ki data are particularly unfavourable. Unit transcription errors are visible in the
provided probability density distribution as small peaks where the diﬀerence equals ±3
pIC50 units. These errors have a strong eﬀect on the variance of the distribution because
they frequently change the observed value by three or more orders of magnitude.
Importantly, the non-normal distribution of the data required the use of non-
parametric methods in subsequent analysis steps. As a numeric measure of the correlation
between potencies measured for combinations of identical compounds and targets in
diﬀerent assays, the Spearman rank correlation coeﬃcient was determined as ρ = 0.74.
More informative than Spearman’s correlation is a diﬀerence plot as shown in Figure
4.3B, following specifications by Bland and Altman (Bland and Altman, 1986). The
quantile intervals that would correspond to the intervals covered by one and two standard
deviations in a normal distribution (68.4% and 95.5% of all data) were determined by
bootstrapping with one thousand iterations and reported together with the standard error
as −0.88±0.03/0.81±0.03 pIC50 units and −2.20±0.8/2.13±0.08 pIC50 units, respec-
tively. These values are global averages that may not reflect accurately the measurement
error for individual pairs of values. However, they demonstrate that deviations between
2Unit transcription errors occur when, at any point in the process of transferring measured potencies
into the database, a measurement unit is incorrectly reported, for example µM instead of nM. These
errors often lead to characteristic oﬀsets between measured and reported values in three orders of
magnitude.
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Figure 4.2: Overview of inter-assay variability for human and rat proteins. Panel A shows the
combined data for potency measurements against human (light-blue) and rat targets (dark-blue).
Panel B summarises the number of paired measurements obtained for each species in diﬀerent
target categories. Panel C summarises inter-assay variability for individual classes of drug
targets. Distributions for human proteins are outlined in light-blue and for rat proteins in
dark-blue. Diﬀerences between target classes may be caused by diﬀerent assay formats (e.g.
transcription factors versus transporters). Distributions for some classes are also skewed by
small sample numbers, e.g. secreted proteins.
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reported measurements in the ChEMBL database can be considerable, and in about a
third of the cases assessed in this study exceed one order of magnitude.
0.0
0.2
0.4
0.6
í í 0 2 4
delta(IC50)
pr
ob
ai
lit
y  
de
ns
ity
í
í
í
0
2
4
6
2 4 6 8 10 12
mean  IC50
de
lta
(IC
50
)
2
4
6
8
10
12
2 4 6 8 10 12
pIC50(measurement  1)
pI
C
50
(m
ea
su
re
m
en
t  2
)
A B C
Figure 4.3: Overview of inter-assay variability in ChEMBL. Panel A is a scatter plot of the
aﬃnities observed when comparing results from diﬀerent assays of the same compound and
target (1,500 human targets and 1,500 rat targets) and the probability density distribution
of diﬀerences between potencies observed in diﬀerent assays assessing identical compounds
and proteins. Panel B shows the same data transformed in a Bland-Altman plot. The x-axis
represents the mean of two measurements, the y-axis the diﬀerence between corresponding
measurements. Panel C shows the probability density distribution of diﬀerences between
potencies measured against human and rat proteins. Contributions from individual compounds
are represented as red tick marks at the bottom of the panel.
4.2.2 Conservation of potency between human-rat orthologs
With a baseline established for experimental and procedural noise, I wanted to assess
potency diﬀerences between human-rat orthologs. To this end, pairs of human-rat
orthologs were determined using annotation from the EnsemblCompara Genetrees pipeline
(Vilella et al., 2009), version 62. The Uniprot identifiers for these pairs were then used to
query the ChEMBL database for potency measurements for compounds with reported
activities against both a human protein and its ortholog in rat (see Methods section
4.4.1 and 4.4.3). In total, 2,782 pairs of measured potencies were retrieved from the
ChEMBL database. To be consistent with the processing of diﬀerences between assays,
all potencies that were exactly equal were excluded from the analysis, leaving 2,669
paired potencies. These broke down into combinations of 2,359 compounds and 151
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pairs of human-rat orthologs. The mapping between orthologs in this data set generally
followed a one-to-one pattern, meaning that for each human protein there was only one
rat protein in the data set and vice versa. Most of the proteins in this set are membrane
receptors or kinases, but a spectrum of other target classes is also present. A summary of
target classes represented in this set is presented in Table 4.3. With the number of drug
targets estimated at 324 (Overington et al., 2006), this study does not cover the complete
set of drug targets, but a significant subset with a relatively unbiased distribution across
target classes. In analogy to the data for inter-assay variability, a scatterplot of the raw
data, a diﬀerence plot and a probability density distribution of the observed diﬀerences
are shown in Figure 4.4. The observed bioactivities expressed as log transformed potency
values pIC50 range from 4 to 10 (i.e. across a broad range from single digit µM to
high pM ). The scatter of paired potencies roughly follows a straight line through the
origin with a unit slope. This finding was in line with expectations that potencies in the
two species should be correlated directly without any scaling eﬀects. The distribution
of diﬀerences is roughly symmetric and centred around zero. The probability density
distribution displays a slight increase at a potency diﬀerence of about 0.5 pIC50 units
between human and rat proteins. This increase reflects mainly potency measurements
for about 200 compounds against orthologs of the Histamine H3 receptor (HRH3). This
aspect is discussed in more detail in section 4.2.7. The median of the observed diﬀerences
was determined by bootstrapping with one thousand resampling iterations as 0.08±0.02
(std. error). The subtle shift towards higher potencies for human targets may be caused
by random fluctuations, but more likely reflects the human-centric nature of the drug
discovery process. This is discussed further in section 4.2.7. In either case, the species bias
within the data set is small if compared to the underlying noise. The quantile intervals
that would correspond to one and two standard deviations in a normal distribution are
−0.65±0.02/0.88±0.02 pIC50 units and -2.30±0.11/1.96±0.09 pIC50 units, respectively.
In absolute terms, the diﬀerences observed between these two species are thus substantial
and in about a third of all cases exceed one order of magnitude. However, as described in
section 4.2.1, diﬀerences between assays are in a similar range and diﬀerences between the
two species should be set in relation to this. Section 4.2.5 provides a detailed comparison
of the distributions of potency diﬀerences between assays, orthologs and paralogs.
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Table 4.3: Target classes represented in the ortholog data set.
Target class count compounds
Membrane receptor 76 1,504
Enzyme 48 501
Ion Channel 12 250
Transporter 7 366
Transcription factor 4 34
Undefined 3 8
Membrane other 1 5
Cytosolic other 1 1
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Figure 4.4: Overview of variability between human and rat orthologs in ChEMBL. Panel
A shows a scatter plot of the aﬃnities observed when comparing results from measurements
against human proteins (x-axis) against rat proteins (y-axis). Panel B shows the same data
transformed in a Bland-Altman plot. The x-axis represents the mean of two measurements,
the y-axis the diﬀerence between corresponding measurements. Panel C shows the probability
density distribution of diﬀerences between potencies measured against human and rat proteins.
Contributions from individual compounds are represented as red tick marks at the bottom of
the panel.
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4.2.3 Conservation of potency between human paralogs
As for human-rat orthologs, I wanted to assess potency diﬀerences between proteins
whose lineage traces back to a duplication event and which are thus related through
paralogy. To this end, I aimed to selected pairs of measured potencies and carry out the
analysis according to the same criteria as done for human-rat orthologs.
As discussed in section 4.1.3, the number of measurements available for rat proteins is
only a fraction of the number of measurements available for human targets. The analysis
of human-rat orthologous pairs was viable because the rarer measurements of rat proteins
were combined with abundant measurements against human proteins. Due to concerns
about availability of data for the rat, this part of the analysis focuses on proteins related
through paralogy within the human genome.
To proceed with the analysis of paralogs in analogy to the analysis of human-rat
orthologs, I obtained paralogous relationship assignments from the EnsemblCompara
Genetrees pipeline (version 62, 2011). In absence of an intrinsic rule to determine which
of two paralogous proteins to use as a reference and which as its paralog, proteins from
each pair were randomly assigned to either of the two arbitrarily named groups ‘reference’
or ‘paralog’. Potency diﬀerences were then calculated as for orthologs. Through this
procedure, the arithmetic signs of potency diﬀerences were preserved for all activities
measured against a specific paralogous pair. Using the query and filtering procedures
described in the Methods section 4.4.1 and 4.4.3, I retrieved 41,733 pairs of measurements
from ChEMBL. After filtering out potencies that are exactly equal or diﬀer by more than
20 pIC50 units, 41,454 paired measurements remained for analysis. Thus, data available
for human paralogs was much more abundant compared human-rat orthologs. The data
separated into combinations of 648 pairs of human paralogs with 20,219 compounds.
These 648 paralogous pairs were made up of combinations of 516 unique proteins.
I obtained a much larger number of paired measurements for human paralogs than for
human-to-rat orthologs. This was due both to the human-centric nature of the ChEMBL
database, as well as a combinatorial eﬀect: Protein coding genes often map to multiple
paralogs (one-to-many relationship) while orthologs typically only map to one or very
few orthologs in the rat genome. This could increase drastically the number of possible
permutations between paralogs. The theoretical upper limit θmax of one-to-many relations
in a hypothetical data set where all proteins are paralogs depends on the number of
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unique genes nu,
θmax =
nu!
2(nu − 2)! , (4.2)
while the lower limit θmin, which would be observed in a data set with only one-to-one
relationships, is simply half the number of all unique genes θmin =
nu
2 . In the set of
human-rat orthologs with shared small molecule potency measurements, the observed
number of combinations was found to be exactly equal to the lower limit and thus all
relationships in this set are one-to-one mappings. For human paralogs, the number of
observed combinations was 648 and thus greater than the lower limit of 258 for a set of
516 unique genes, but only a small fraction of the theoretical upper limit of 132,870.
To probe in more detail the homology constraints imposed by EnsemblCompara as
well as the contributions of one-to-one and one-to-many relationships in the paralog
set, I constructed a network of these relations. The graph of homologous relations
between proteins in the paralog set was visualised using the Cytoscape software (Shannon
et al., 2003) and is shown in Figure 4.5. Of the 166 connected components in this
network, 78 represent one-to-one relationships and 39 represent triplets. The 50 remaining
components represent one-to-many relations of between four and eight paralogous proteins.
Thus, the graph is characterised by small isolated clusters. In comparison, classic
polypharmacology networks (Paolini et al., 2006; Chen et al., 2009), where vertices are
assigned for shared compounds without the additional homology constraint, graphs are
typically dominated by a densely connected giant component. This is an indication that
the EnsemblCompara GeneTrees pipeline works with a conservative definition of paralogy
and assigns relationships only between close members of a gene family. The implication
for results presented in this section is that the potency diﬀerences presented here are
limited to closely related paralogs and do not include diﬀerences between more widely
related proteins.
The distribution of observed potency diﬀerences is summarised in Figure 4.6. As
for orthologs and the between-assay comparison, the distribution of diﬀerences is ap-
proximately symmetric and centred around zero. The exact median was calculated
as −0.07 ±0.006(std. error). The deviation in symmetry between the ‘reference’ and
‘paralog’ groups was likely the result of random fluctuation. The quantile intervals that
would correspond to one and two standard deviations in a normal distribution were
1.26±0.01/−1.48±0.01 pIC50 units and 2.82±0.02/−3.01±0.02 pIC50 units, respectively.
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Figure 4.5: Graph of relationships within the paralog data set. Nodes represent proteins
that are connected by edges if they are related through paralogy and have measured potencies
for at least one compound in common. (1) denotes a group of muscarinergic ACh receptors
and histamine H receptors. The most highly connected node represents the the HRH1. (2)
denotes a group of tyrosine kinases and the central node represent tyrosine-protein kinase BTK.
(3) denotes a group of heterogeneous aminergic GPCRs, including adrenoceptors, dopamine
receptors and serotonin receptors. (4) is a group of eicosanoid receptors. Table 2 in the appendix
section lists individual components for each highlighted group.
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Figure 4.6: Overview of potency diﬀerences between human paralogs. Panel A shows a
scatterplot where each dot represents potency measured against a ‘reference’ protein on the
x-axis and potency measured against respective paralogs are on the y-axis. Panel B shows
the same data transformed in a Bland-Altman plot. The x-axis represents the mean of two
measurements, the y-axis the diﬀerence between corresponding measurements. Panel C shows
the probability density distribution of diﬀerences between potencies measured against pairs of
human paralogs. Contributions from individual compounds are represented as red tick marks
at the bottom of the panel.
The deviation from symmetry of these intervals around zero could be approximately
corrected for by centring the intervals around the calculated mean of −0.07. Thus,
compared to human-rat orthologs, the proportion of compounds with equal potencies
against both proteins in a homologous pair is smaller for human paralogs. The observed
diﬀerences in measured potencies are on average greater for paralogs. The following two
sections provide a more detailed analysis of this finding.
4.2.4 Data model
The previous sections describe distributions of potency diﬀerences that were observed for
identical small molecules between assays of the same target, assays of orthologous targets
and finally assays of proteins that are paralogs. In this section I explore possibilities to
model the observed data. As seen in previous sections, the distribution shapes suggested
that the data were better approximated by models following a double-exponential distri-
bution rather than the default model of a normal distribution.
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Table 4.4: Fitted parameters for a model derived from the Laplace (L) and normal distribution
(N).
set L, location L, scale N, location N, scale
between assays −0.01 0.75 0.00 1.01
orthologs 0.08 0.77 0.14 0.86
paralogs −0.01 1.30 −0.02 1.43
I used q-q plots3 to compare the observed distributions of potency diﬀerences with
theoretical models based on either a double-exponential or normal distribution. As
shown in Figure 4.7 the double exponential was an appropriate fit for data in the
ortholog and between-assay categories. For data in the paralog category, the double-
exponential distribution fit well to the distribution peak, but distribution tails were
better approximated by a normal distribution. A fit of double exponential and normal
models to histograms of the distribution data is shown in Figure 4.7. Parameters for the
Laplace model as well as the rejected normal model were fitted as described in section
4.4.7 and are summarized in Table 4.4.
As briefly mentioned in section 4.2.1, the non-normal distribution of observed diﬀer-
ences may have been caused by non-experimental errors such as unit transcription errors
and mis-annotation of protein targets. A further contributing factor was likely residual
contamination with dependent values. For example, in the unfiltered data of in-between
assay measurements, I had observed a disproportionate amount of paired potencies that
were exactly equal (data not shown). For the majority of these pairs it could be assumed
that one of the measured potencies was reported in reference to a previously published
measurement. To eliminate this source of dependent measurements, I excluded pairs
of potency measurements that report exactly the same value for a given combination
of ligand and protein target. Unavoidably, this would have removed some pairs that
were genuinely equal. Therefore, to keep processing consistent, paired potencies that
were exactly equal were also removed from the data sets for orthologs and paralogs. It
is however possible that this step alone was not suﬃcient to eliminate all dependent
measurements from the data. Kramer et al (Kramer et al., 2012) proposed that previously
published values might be reported in subsequent publications as rounded values and/or
3In q-q plots or quantile plots, observed quantiles are plotted against the quantiles of a theoretical
distribution proposed to model the observed data.
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Figure 4.7: Fit of
theoretical distributions
to the observed data.
Histograms of the data
with fitted theoretical
models of a normal (blue)
and Laplace distribu-
tion (red) are shown
for measurement diﬀer-
ences between assays
(A), between human-rat
orthologs (C) and between
human paralogs (E).
Panels B, D and F show
q-q plots for measurement
diﬀerences between assays
(B), between human-rat
orthologs (D) and between
human paralogs (F). The
theoretical quantiles for
plots titled ‘qq-Normal’
were derived from a
normal distribution,
quantiles for plots ti-
tled ‘qq-Laplace’ were
derived from a Laplace
distribution.
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lead to a confirmation bias according to which experimentalists would ‘tweak’ their assays
to obtain measurements that are in agreement with previously published values. This
would result in paired potencies that are not exactly equal, but still more similar than
entirely independent measurements. With regard to the results presented here it would
be surprising if rounding and confirmation bias also applied on a large scale to potency
measurements for orthologous or indeed paralogous proteins, yet both populations are
not accurately described by a normal distribution.
On the whole it seemed more practicable to keep the filtering and processing of data
consistent across all sets and accept that the data are not normally distributed, possibly
owing to unexpected error and residual contamination with dependent measurements.
Instead, the data were modelled using a Laplace distribution. The scale of a Laplace
distribution is estimated by the average absolute deviation (AAD), which is more robust
to fluctuations in the distribution tails compared to the variance, the measure of scale
for a normal distribution. The mean absolute deviation is determined as
AAD =
1
N
N￿
i=1
|Yi − Y |. (4.3)
The implication of accepting the Laplace distribution as a model of the data was that
statistical methods reliant on estimations of the variance or standard deviation would not
be suitable and instead more robust metrics were required. Therefore, I used Spearman’s
rank correlation method to determine correlation coeﬃcients and the non-parametric
Mann-Whitney U-test instead of Student’s t-test. The Laplace distribution has previously
been applied to model error in gene expression data (Purdom and Holmes, 2005).
4.2.5 Evolutionary relationship and conservation of potency
In this section I describe an analysis of links between evolutionary relationship and
measured diﬀerences in small molecule potencies. The ortholog conjecture states that
orthologs, which share a common ancestor, but are separated through speciation have
conserved function while paralogs arise from gene duplication events within a genome
and, owing to the redundancy thus acquired, can evolve to develop divergent functions
(Fitch, 1970; Chervitz et al., 1998; Tatusov et al., 1997). The purpose of the analysis
was to examine if the contrast of functional conservation in orthologs versus functional
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diversification in paralogs is also reflected in the response properties towards small
molecule perturbation.
As a basis for the comparison I examined the distributions of potency diﬀerences for
each category, orthologs, paralogs and between assays. In line with the expectation that
there should not be a systematic bias between human and rat orthologs or the random
groupings assigned when comparing potencies between assays or between human paralogs,
the distributions for all categories had their mean and median around zero. With
regard to conservation of response to small molecule perturbation, the most informative
measure is distribution spread. The distribution spread decreases with the proportion
of small molecules perturbing two homologs with the same or very similar potency. On
the contrary, the spread increases with the proportion of small molecules that have
substantially diﬀerent potencies for two homologous proteins. For the distribution of
potency diﬀerences between assays, the conservation of small molecule response properties
is complete as proteins are identical. This distribution was used as a proxy to describe
noise in the data. A comparison of the between-assay distribution with those for
orthologs and paralogs then allowed me to infer the degree to which small molecule
response properties are conserved relative to data noise on one hand and paralogs or
orthologs on the other hand. Three measures of dispersion were calculated for each
distribution to quantify robustly the spread for each distribution. As described in the
previous sections (see 4.2.1, 4.2.2, and 4.2.3), the quantile intervals that would correspond
to the interval covered by plus or minus one standard deviation and plus or minus two
standard-deviations. In addition, distributions were assessed visually as shown in Figure
4.8.
The results indicate that there are only small diﬀerences between the baseline and
human-rat orthologs, potency diﬀerences between paralogs are more disperse. The lack of
distinction between the baseline and human-rat orthologs led me to conclude that from
this global perspective, diﬀerences in susceptibility to small molecule perturbation are no
greater between human and rat than between assays against identical proteins from the
same species. These results are in line with expectation that protein function is largely
conserved between two species that are, in evolutionary terms, closely related. On the
contrary, this was not the case for human paralogs, for which potency diﬀerences were
more disperse than both the baseline of diﬀerences between assays as well as diﬀerences
between human-rat orthologs.
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Figure 4.8: An over-
lay of the distributions
of potency diﬀerences
between assays (grey),
between human-rat or-
thologs (red) and hu-
man paralogs (blue) is
shown in this Figure.
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Figure 4.9: Probability density distribu-
tions of sequence identities for paralogs
across the human genome (dark blue) and
within the data set retrieved from ChEMBL
(light blue). A density distribution of se-
quence identities is also shown for human-
rat-orthologs across the entire genome of
the two species (dark red) as well as those
pairs that were part of the analysis (light
red).
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4.2.6 Sequence identity, ligand molecular weight and potency
diﬀerences in paralogous pairs
The last common ancestor of humans and rats dates back approximately 92.3 Million
years (number adopted from http://www.timetree.org, (Hedges et al., 2006)). All
pairs of human-rat orthologs arose at this one point in time. In comparison, pairs of
human paralogs have arisen at many diﬀerent points spanning a vast time interval that
extends to the present day. Most human paralogs are more ancient than the speciation
event that separates humans and rats (Gibbs et al., 2004). Sequence identity is often
viewed as a proxy of the point in time at which two genes diverged. Figure 4.9 shows
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sequence identities between all pairs of human-rat orthologs and human paralogs that
were retrieved from the EnsemblCompara Genetree Pipeline. Most human-rat orthologs
have highly conserved sequences in the range of 90% to 100% identity, while most paralogs
had much lower sequence identity, frequently around 30%. Given the pronounced contrast
between orthologs and paralogs, I examined diﬀerences in susceptibility to small molecule
perturbation as a function of sequence identity. To this end, sequence identity was
determined on three levels, i) the full protein sequence, ii) the sequence of the Pfam
domain that presumedly mediates small molecule binding and, where possible, iii) the
site of small molecule binding. Definitions of small molecule binding sites were based on
an evaluation by Surgand et al. (Surgand et al., 2006) for GPCRs and the ‘canonical’
site definition from Kinase Sarfari for kinases. In the Methods sections 4.4.4, 4.4.5, 4.4.6,
I give a detailed account of how sequence identity was determined on the three levels.
From this, I calculated the Spearman’s correlation coeﬃcient ρ of the absolute diﬀerence
in small molecule binding and the sequence identity on the full protein level, both for
orthologs and paralogs. For orthologs, there was no detectable correlation of sequence
identity and the absolute diﬀerence in small molecule binding. In this case, ρ was −0.020
and the associated p-value 0.30. For paralogs on the other hand, ρ was −0.080 with a
p-value of 1.2× 10−59. Hence, there was a statistically significant negative correlation
that implied that human paralogs with more divergent sequences are also more likely
to show diﬀerences in their susceptibility to small molecule perturbation. However, due
to its small amplitude, it was diﬃcult to decide if it reflected a meaningful trend or
merely a small deviation from the exact null hypothesis that there is no relationship at
all between sequence identity and susceptibility to small molecule perturbation. Further,
on the level of Pfam domains and binding residues, the observed coeﬃcients ρ were
−0.084 and −0.202 respectively, and associated p-values 1.7× 10−63 and 5.8× 10−201. A
graphical summary of all examined relationships is provided in Figure 4.10. As stated,
ρ was consistently negative for pairs of human paralogs and increased with the level
of resolution of the sequence comparison. Taken together, these findings corroborate a
meaningful relationship of sequence divergence and diﬀerences in small molecule binding.
The increase of ρ with the level of resolution observed here further suggests that the
impact of residue substitutions is generally much larger for positions in close proximity
to the site of ligand binding. This suggests that mutations in or near a binding site have
the greatest eﬀect on diﬀerences in susceptibility to small molecule perturbation.
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Figure 4.10: Absolute potency diﬀerences for each pair and compound are plotted against
sequence identity for the full Uniprot sequence (left), the sequence of the Pfam domain predicted
to mediate small molecule binding (centre) and binding site residues of GPCRs and kinases
(right).
I also examined the relationship of the molecular weight of the ligand and diﬀerences in
small molecule binding between paralogous pairs. Ligands that undergo interactions with
larger numbers of residues should have a higher likelihood of exhibiting diﬀerent potencies
towards paralogous proteins as they are more likely to ‘sense’ residue substitutions, given
there are any in or near the binding site. The number of interactions that a small
molecule undergoes with any given protein depends to some extent on a property termed
molecular complexity (Hann et al., 2001). This property cannot be accurately quantified
without knowing the binding mode of a small molecule as it depends on the number and
quality of protein-ligand interactions. Here, I used molecular weight of the ligand as a
proxy for molecular complexity. My analysis showed a very weak positive correlation
of molecular weight and potency diﬀerences (Spearman’s correlation coeﬃcient: 0.062,
p-value: 3.1 × 10-36). By traditional standards, the very low p-value should indicate
significance but the high number of data points in this analysis (41,334) might warrant a
more stringent threshold. Figure 4.11A shows a density representation of the data. The
possibility that only a subset of the paralogous pairs in the analysis has substitutions
near the binding site that are ‘sensed’ by some, but not all ligands was identified as one
factor that could contribute to a very low eﬀect size. To investigate this, I examined the
correlation of molecular weight and potency diﬀerences for individual pairs of homologous
targets. This reduced the numbers of data points examined at one time, bringing it closer
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to traditional experimental setups. A summary of this analysis is shown in Figure 4.11B.
I found that the number of pairs that have a positive correlation is higher compared to
pairs with a negative correlation and that this diﬀerence becomes more pronounced with
increasingly stringent p-values. Table 4.5 summarises this observation for five p-value
thresholds. Table 4.6 lists paralogous pairs left in the analysis under the most stringent
p-value thresholds. Note that eighteen of those have a positive correlation of absolute
potency diﬀerences with molecular weight, while only three have a negative correlation.
Taken together, I interpreted the above observations as an indication that mutations in
or near the binding site have important implications in the functional diversification of
paralogs.
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Figure 4.11: Ligand molecular weight and absolute potency diﬀerences. Panel A shows
absolute potency diﬀerences plotted against molecular weight. To avoid overplotting, a density
function was used to represent the distribution of 41,334 data points. Panel B shows a plot of
correlations calculated for individual pairs of paralogs. Each dot represents a pair of paralogs.
The position on the x-axis represents the Spearman correlation coeﬃcient, and the position on
the x-Axis the negative logarithm of the associated p-value.
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Table 4.5: Correlation of molecular weight and absolute potency diﬀerences for individual
pairs of paralogs. Counts of pairs with positive (+) and negative (−) correlations are shown at
diﬀerent p-value thresholds. The ratio of pairs with positive correlation over the total number
of pairs consistently increases with more stringent thresholds.
p-value (+) (−) % (+)
total 294 245 0.55
< 0.01 55 29 0.65
< 0.001 33 15 0.68
< 0.0001 22 8 0.73
< 0.00001 18 3 0.86
Table 4.6: Individual pairs of paralogs in the molecular weight analysis. Listed below are
pairs of paralogs where p-values associated with the correlation of ligand molecular weight
and absolute potency diﬀerences are p <0.00001. The columns ‘reference’ and ‘paralog’ define
each pair, ‘-log(p-value)’ the negative base 10 logarithm of the p-value and ρ the Spearman
correlation coeﬃcient. The bottom three pairs show a negative correlation.
reference paralog -log(p-value) ρ
Muscarinic ACh-R M5 Muscarinic ACh-R M3 10.7 0.78
Muscarinic ACh-R M4 Muscarinic ACh-R M5 7.0 0.68
Nitric-oxide synthase, brain Nitric oxide synthase, inducible 14.6 0.58
Muscarinic ACh-R M3 Muscarinic ACh-R M4 5.7 0.58
β-secretase 1 β-secretase 2 7.1 0.48
S1P-R Edg-1 S1P-R Edg-3 11.7 0.46
Cathepsin S Cathepsin K 20.6 0.45
Matrix metalloproteinase 2 Matrix metalloproteinase 13 8.1 0.44
Thyroid hormone-R α Thyroid hormone-R β-1 5.4 0.42
Cathepsin S Cathepsin L 11.8 0.42
Melanocortin-R 5 Melanocortin-R 4 15.3 0.41
Dopamine D3-R Dopamine D2-R 24.5 0.40
Caspase-7 Caspase-3 6.6 0.38
A1b adrenergic-R A1a adrenergic-R 6.5 0.36
Adenosine A3-R Adenosine A2b-R 12.8 0.34
Cannabinoid CB1-R Cannabinoid CB2-R 16.3 0.25
Butyrylcholinesterase Acetylcholinesterase 6.0 0.24
Melanocortin-R 4 Melanocortin-R 3 5.2 0.20
Serotonin 2c-R Serotonin 2a-R 5.5 -0.20
Vasopressin V2-R Vasopressin V1a-R 7.0 -0.41
Somatostatin-R 3 Somatostatin-R 5 6.5 -0.45
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4.2.7 Assessment of individual homologous pairs
The previous parts of this analysis are based on a global approach that looks at averages
over a wide range of compounds and proteins. In this part, I present an analysis of
individual targets. To this end I implemented a testing procedure that compared the
distribution of diﬀerences for individual orthologous pairs to the distribution of diﬀerences
observed between assays for human and rat proteins (as described in section 4.2.1). In an
analogous procedure, I also examined distributions for individual pairs of paralogs and
how they compared to the distribution of diﬀerences observed between assays against
human proteins. Non-parametric Mann-Whitney U tests were carried out to assess if
the measured diﬀerences for each pair of orthologs or paralogs were consistent with
the distribution of diﬀerences between assays. The resulting p-values should not be
considered indicative of significance, but rather as a ranking criterion that evaluates
both the eﬀect size and the number of tested compounds. This procedure conceptually
follows the selection of diﬀerentially expressed genes (Chen et al., 2007). Here, the aim
of p-values is not to attach significance, but to prioritise diﬀerentially expressed genes for
further analysis, e.g. manual inspection or experimental validation. Similarly, p-values
calculated in this analysis are intended as a criterion for prioritisation and not a hard
threshold of sgnificance. For this reason, I did not adjust p-values for multiple comparison.
Volcano plots for both orthologs and paralogs are shown in Figure 4.12A, B. The median
absolute eﬀect size was 0.57 pIC50 units for paralogs and 0.43 pIC50 units for orthologs.
P-values were generally greater for orthologs, a consequence of both smaller eﬀect size as
well as fewer tested compounds. As shown in Figures 4.12C and D, I found there is a
larger fraction of human proteins that are on average more susceptible to small molecule
perturbation than would be expected under a random model, such as the one for paralogs.
As discussed previously, this may point towards a bias caused by the human-centric
nature of the data in ChEMBL.
The ten paralogous pairs with the greatest systematic deviation from the control dis-
tribution are summarised in Table 4.7. A prominent diﬀerence emerged between the
nociceptin receptor and other members of the opioid receptor family. The nociceptin
receptor is known to have a substantially diﬀerent profile of ligands compared to its
relatives, the opioid receptors (Thompson et al., 2012).
A table of the ten top-ranking orthologous pairs is provided in Table 4.8, summarising
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Figure 4.12: Volcano plots for orthologs and paralogs summarise the systematic deviations
from the control distribution for individual homologous pairs. Each point represents a reference
protein and its paralog (A) or a human protein and its rat ortholog (B) and its position on
the x-axis the potency diﬀerence between the two, averaged over all tested compounds. The
position on the y-axis indicates the negative logarithm of the associated p-value. Points are
coloured according to the sequence identity between two proteins in a pair. The count of pairs
on either side of the ordinate is summarised in barplots for orthologs (C) and paralogs (D).
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Table 4.7: Human paralogs with greatest overall potency diﬀerences. The columns ‘reference’
and ‘paralog’ provide names of paralogous pairs, ‘￿’ the observed average potency diﬀerence
between measurements of the protein indicated in the ‘reference’ column and its paralog. The
column ‘n’ indicates the number of measurements that were compared for each pair of paralogs.
reference paralog p-value ￿ n
Nociceptin receptor Delta opioid receptor 3.2× 10−124 2.55 232
Nociceptin receptor Mu opioid receptor 1.9× 10−114 1.24 520
Nociceptin receptor Kappa opioid receptor 1.8× 10−98 1.54 280
Delta opioid receptor Mu opioid receptor 5.7× 10−97 −0.89 921
Carbonic anhydrase I Carbonic anhydrase II 4.2× 10−91 −0.74 993
Dipeptidyl peptidase VIII Dipeptidyl peptidase IV 9.6× 10−83 −2.18 252
Melanocortin receptor 3 Melanocortin receptor 4 1.7× 10−79 −0.93 506
α-adrenoceptor 1b α-adrenoceptor 1a 1.0× 10−53 −1.31 186
Delta opioid receptor Kappa opioid receptor 1.9× 10−48 −0.63 901
Dipeptidyl peptidase IX Dipeptidyl peptidase IV 3.5× 10−47 −2.11 165
eﬀect sizes and p-values. These values must be interpreted with caution, especially in
cases where the number of associated publications is small. In such cases, the observed
diﬀerence may be founded in systematic bias between two assay-setups and not be
biologically relevant. This was definitely the case for the neuronal acetylcholine receptor
subunit α-7, where, due to mis-annotation in the database, measurements from a cell-
based assay were compared with measurements from a biochemical assay. Orthologs
of the HRH3 were identified as the highest ranking pair using my method. Given the
large number of ligands tested, the estimated bias of 0.54 log-units on average for the
human receptor seemed robust and indeed, the species-specific pharmacology of the
HRH3 had been noted in some of the articles the underlying data was derived from
(Black et al., 2007; Nersesian et al., 2008; Zhao et al., 2009) and had also been described
in independent research articles (Lovenberg et al., 2000; Ligneau et al., 2000). I also found
evidence in the literature that the serotonin transporter (SERT), ranked second using
my method, exhibits species-specific pharmacology for a number of chemotypes (Barker
et al., 1994). In my analysis, 309 compounds had on average a bias of 0.47 log-units for
the rat SERT. Across fifty compounds, the estimate of the average bias for the human
Fructose-1,6-Bisphosphatase (1,6FBP) over its rat ortholog was 0.77 log-units, a bias that
had also been reported in the literature (Erion et al., 2005). The last column in Table
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4.8 lists publications reporting species-specific pharmacology for some of the remaining
proteins in this analysis. It is important to underline that the observed diﬀerences
are reported as averages across multiple diﬀerent compounds and that true diﬀerences
might apply only to a subset of these compounds. This was for example observed with
the HRH3 (see section 4.2.8) and explains the somewhat paradoxical finding that a
considerable number of proteins appear to have species-specific pharmacology while from
a global perspective the potency patterns appear conserved across human-rat orthologs.
In addition I noticed that, when potencies of all compounds measured against a pair
were averaged, the fraction of pairs where the human ortholog was more susceptible to
small molecule perturbation was disproportionately higher. The explanation for this
might lie in the human-centric nature of drug discovery. The goal of drug discovery is
ultimately to obtain compounds that are potent against human proteins - and potency
optimisation of lead structures would typically be carried out against human proteins. It
is thus likely that there is a bias for compounds with higher potencies against human
proteins in the underlying data set.
Table 4.8: Human to rat orthologs with greatest overall potency diﬀerences. The column ‘￿’
provides the observed average potency diﬀerence between measurements of the human protein
and its rat ortholog. The column ‘n’ indicates the number of measurements that were compared
for each orthologous pair. The column ‘citation’ provides references to publications that report
significant diﬀerences in small molecule response between the human and rat ortholog.
name p-value ￿ n citation
Histamine H3 receptor 2.01× 10−35 0.56 325 Lovenberg et al., 2000
Serotonin transporter 3.29× 10−26 −0.45 309 Barker et al., 1994
Neur ACh-R α-7 subunit 2.86× 10−24 −2.36 49 None
Fructose-1,6-bisphosphatase 1.37× 10−13 0.80 50 Erion et al., 2005
NaV type X α-subunit 9.69× 10−10 0.74 45 None
Adenosine A1 receptor 4.87× 10−8 −0.55 78 Maemoto et al., 1997
GnRH receptor 5.69× 10−8 0.50 118 Arora et al., 1999
D-amino-acid oxidase 1.10× 10−7 1.65 14 None
Neurokinin 1 receptor 1.43× 10−7 1.72 20 Fong et al., 1992
Adenosine A2a receptor 4.07× 10−6 0.38 112 None
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4.2.8 Small molecules as probes of the binding site
The perturbation of protein function by small molecules is ultimately mediated by
interactions between specific residues and the small molecule acting as a ligand. Medicinal
chemistry experience shows that small changes in the chemistry of the ligand can have a
great impact on the interaction. For example, it has been reported that the addition of a
single methyl group to the structure of a lead compound can change binding aﬃnity by
one order of magnitude (Shamovsky et al., 2008; Davis and Teague, 1999; Zhi et al., 1999;
Hopkins et al., 2004; Hann et al., 2001). In the context of evolutionary relationships, I
wanted to investigate if the same concept applies to amino acid substitutions between
related protein targets.
As I described in chapter 4.2.6, I observed a meaningful inverse correlation between
sequence identity and diﬀerences in small molecule binding between pairs of human
paralogs. From this protein-centric perspective, it seems plausible that amino acid
substitutions in or near the site of ligand interaction have more profound eﬀects than
substitutions elsewhere. The integration of multiple experiments also permitted to
examine this question from a ligand-centric perspective. By using the ensemble of tested
compounds for a pair of related proteins, the impact of changes in the binding site could
be measured indirectly. In the simplest case, potency diﬀerences between two proteins
would be observed consistently for all tested compounds. Such cases would be indicative
of an amino acid substitution at a position that is involved in interactions with all tested
ligands. A more subtle scenario would involve only a subgroup of small molecules showing
consistent diﬀerences in potency across two homologous proteins. Such pairs could be
viewed as having an amino acid substitution in a position that mediates interactions
with some, but not all tested small molecules. Clearly, this indirect eﬀect depends not
only on substitutions between the proteins, but also the set of tested molecules. From
a practical point of view, it is impossible to identify all active compounds let alone
their potencies against a homologous pair. I wanted to investigate if, given the limited
number of known potencies, any inferences could be made about substitutions promoting
selectivity between homologous targets.
Orthologs of the HRH3 had emerged as the orthologous pair with the most distinct
diﬀerences in susceptibility to small molecule perturbation between the two species
human and rat. Of 325 tested ligands, 201 had at least 0.5 pIC50 units higher potency
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against the human protein over the rat protein. I carried out a simple clustering of the
325 ligands to assess if any chemical features of the ligands were associated with higher
aﬃnity for the human ortholog of the HRH3. The clustering was based on the simple
LINGO fingerprint descriptors (see Methods section 4.4.8) and yielded one large cluster
of 189 compounds and 17 additional clusters with mostly between 5 and 18 compounds as
well as 15 singletons. Figure 4.13 illustrates potencies observed for compounds assigned
to the diﬀerent clusters. From manual inspection of the clusters, I concluded that
the largest cluster contained mainly compounds characterized by a pyrrolidine moiety
and a smaller group of compounds with a biphenyl scaﬀold. Compounds in cluster
5, which predominantly had higher potencies for the human receptor, are all based
on a steroid scaﬀold. All compouds in cluster 32 contained a diazepine moiety; these
compounds also had higher potencies at the human receptor. Compounds in cluster 10
contained a terminal imidazole moiety. Compounds in this cluster had higher potency at
the rat receptor. Cluster 17 contained exclusively compounds with an indole scaﬀolds.
Compounds in this cluster mostly had equal potencies at the human and rat receptor.
The fingerprints and clustering method used here are basic methods that are not very
sensitive. However, as I confirmed by manual inspection of the clusters, these methods
were suitable to separate compounds from diﬀerent chemical series evaluated against the
HRH3 receptor.
A sequence alignment showed that there were only few substituted positions in the
two receptors. The overall sequence identity was 94.2%, an aligment is shown in the
Methods section 4.16. Small molecule binding in Type I GPCRs is normally coupled to
the cavity in the transmembrane region of the receptor. To tighten this estimate further,
I constructed homology models for the human and rat HRH3, based on all structures
of Type I GPCRs available at this time, including a crystal structure of the human
histamine H1 receptor (HRH1) (Shimamura et al., 2011). The ligand doxepin of 3rze was
used as a surrogate ligand for modelling the binding site of the human and rat ortholog
of the HRH3. The models were constructed using the Modeller software (see Methods
section 4.4.7.3) and aligned using functionality of the QtMG package. Figure 4.14 shows
an overlay of the two models. Datasets containing the PDB and alignment files describing
the model were made available as described in table 4.12 in Methods section 4.4.7.3.
The peptide backbones of the transmembrane helices of the two receptor models
aligned well. The overall root mean square deviation of the two models was 0.21 A˚
138
Chapter 4. Integration of small molecule potency measurements with the phylogeny of
their protein targets
	













   
	


	













  
  


 
 

 
 

 
 

 
 

 
 

 
 

! !   
!   ! !  
















 










" " "
"
"
" 
"
 

Figure 4.13: Clustering of ligands of the HRH3 receptor. Panel A summarises measured
potencies. Dots represent potencies measured against the human receptor (x-axis) and rat
receptor (y-axis). Dots are coloured according to the cluster they were assigned to. The diagonal
line represents exactly equal measurements and is drawn as a standard of comparison. Panel
B summarises probability density functions of the potency diﬀerences observed between the
human and rat HRH3 for each cluster separately. Contributions from individual compounds are
represented as red tick marks at the bottom of each plotting facet. Panel C shows exemplary
structures from each cluster. Highlighted in red are shared features among compounds in the
same cluster. Cluster 24 contains multiple series.
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Figure 4.14: Homology models of the HRH3 receptor. In this overlay, model coordinates are
represented as cartoon-structures, the human HRH3 in green, and the rat HRH3 in yellow.
Panel A shows a lateral view of the aligned receptors, panel B an approximately 90° rotated view
onto the top of the receptor. Parts of the extracellular loop region have been clipped from this
view. The substituted residue T119A between human and rat is shown in stick representation.
A hypothesised hydrogen bond between the hydroxyl group of T119 and doxepin is shown as a
dashed line. The ligand Doxepin is adopted from the published crystal of the HRH1, 3rze.
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over 1,253 aligned backbone atoms. One of the few substituted positions in the aligned
receptors was in close proximity to the modelled ligand doxepin. The substitution in
question is from threonine in human to alanine in rat at position 119 in the Uniprot
sequence. The distance between the oxygen in the hydroxy-group of threonine and the
oxygen-atom in the oxazepine moiety of the ligand is 2.7 A˚. In their analysis of the
structure, Shimamura and colleagues note that the hydroxy-group of T119 undergoes
hydrogen-bonding with the oxygen of the E-, but not the Z-isomer of doxepin. They
further note that it does not contribute significantly to binding aﬃnity in predicted
complexes of the HRH1 with olopatadine, cetirizine and fexofenadine. It is therefore
plausible that the substitution Thr119Ala is the cause of the observed potency oﬀset
between the human and rat HRH3 for a subset of compounds. This pair of HRH3
receptor orthologs is a striking example of how subtle diﬀerences in the local context of
ligand binding can modulate susceptibility to small molecule binding and override overall
sequence similarity.
4.3 Conclusion
In this part of my thesis work I integrated small molecule potency measurements and
homology information. I created an assembly of pairwise comparisons for human-rat
orthologs and human paralogs. My analysis of these comparisons showed that, across
measurements of human-rat orthologs, potency diﬀerences were no greater than the
variability that was observed between assays of identical targets. These findings indicate
that susceptibility to small molecule perturbation is largely conserved between humans
and rats on a molecular level. From the perspective of small molecule-protein interactions
represented in the ChEMBL data base, my work thus confirms the use of rats as
model organisms in pharmaceutical research. However, on the level of more complex
interactions, such as transcription networks and metabolism, species diﬀerences may limit
the predictive power of extrapolations, even between closely related species (Odom et al.,
2007; Kutter et al., 2012; Martin et al., 2010). In cases where the underlying functional
modules are conserved, phenotypic outputs can be related and used to predict the eﬀect
of a specific perturbation in one species from the phenotype observed in another species
(McGary et al., 2010). A systematic search for relationships between phenotypic responses
in diﬀerent species allows for more precise interpretations of phenotypic observations and
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can thus facilitate the use of phenotypic screens in drug discovery (Kapitzky et al., 2010;
Hoehndorf et al., 2013).
In this chapter, I also highlighted a number of proteins that may have altered
susceptibility to small molecule perturbation across the two species, most prominently
the HRH3. I further observed that for a majority of paired measurements, potency was
greater at the human receptor, albeit insignificantly. This observation is likely an artefact
of the human-centric nature of drug discovery that favours compounds with potency
in men, not rats. In contrast, potency diﬀerences between human paralogs exceeded
assay variability. This finding is in line with the ortholog conjecture that states that
gene duplication within a genome enables neo- and sub-functionalisation. My thesis
work thus adds a new perspective to a recent debate around this hypothesis (Nehrt
et al., 2011; Altenhoﬀ et al., 2012; Chen and Zhang, 2012) using the indirect measure of
susceptibility to perturbation by small molecules. This is also interesting from the point
of view that most of the small molecules in this analysis are artificial ligands that can not
have shaped the evolution of their receptor, but rather have been ‘retrofitted’ to emulate
natural ligands. The use of potency data as a functional output in phylogenetic studies
opens venues that have traditionally been reserved for sequence- and annotation-based
approaches. For example, findings from a recent study that examines mutation rates of
drug targets in a number of mammalian species as a function of subcellular localisation
(Wang et al., 2013) might be tested using small molecule potency data.
Perhaps surprising was that the observed correlation of sequence divergence and
measured potency diﬀerences was so weak, even when taking into account the vast amount
of noise inherent to the potency data. Changes in overall protein structure correlate
with sequence identity for homologous pairs (Chothia and Lesk, 1986). Apparently,
structural diﬀerences between homologous pairs do not translate directly to diﬀerences
in susceptibility to small molecule perturbation. Reconciliation of these outwardly
contradictory findings can be found in the hypothesis that functional sites in proteins
are subject to purifying selection (Lichtarge et al., 1996; Ma et al., 2003) and are thus
more conserved than other residues on the protein surface. By increasing the focus on
residues involved in small molecule binding, I was able to obtain a clearer signal for the
correlation of sequence divergence and diﬀerences in small molecule binding and could
thus demonstrate that the conservation of ligand binding depends to a large degree on
few, but crucial mutations in the binding site more than overall sequence identity.
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4.4 Methods
4.4.1 Retrieval and processing of measured potencies
The Python library MySQLdb was used to interface with a MySQL instance of ChEMBL
(version 10). A SQL statement was written to obtain the potency values and associated
parameters for further analysis. The requirements within the query were set to obtain
only potencies from binding assays against protein targets that are neither multimers
nor complexes ( assay type = ‘B’, target type = ‘PROTEIN’, multi = 0, complex
= 0). A further requirement in the query was for the sequence of the assay target to
match its Uniprot identifier directly, rather than through homology (relationship type
= ‘D’). Potencies of the types ‘IC50’, ‘EC50’, ‘Ki’, ‘pA2’, ‘pKi’ were obtained
for rat and human proteins and stored in Python objects. Potencies expressed as
IC50, EC50, Ki were converted to the corresponding logarithmic scale. Following
guidelines published by Kalliokoski et al. (Kalliokoski et al., 2013), an oﬀset of 0.35
was subtracted from all pKi measurements to avoid loss of data quality when mixing
IC50 and Ki data. The queries that were used to obtain the measurement data from the
ChEMBL database can be inspected at https://github.com/fak/globalAnalysis/
blob/master/queries.py. The script that was used to filter and process the data is
deposited at https://github.com/fak/globalAnalysis/blob/master/mkDict.py.
4.4.2 Data assembly for inter-assay comparison
The Python objects described in 4.4.1 were queried for compounds tested against identical
targets in diﬀerent assay systems. Potencies were retrieved and processed as described in
Methods 4.4.1. If multiple measurements were found for a combination of a compound
and protein target, two measured potencies were selected at random and kept for
comparison. For each of the two species H. sapiens and R. norvegicus all pairs obtained
in the inter-assay comparison were written to a tab-separated text file. For comparison
against the data obtained for human-rat orthologs, a comparable number of inter-
assay comparisons were selected at random, one half from the table generated for H.
sapiens, one half from the table generated for R. norvegicus. The functions that I
used to sample pairs of measurements are interAssaySampled, orthologSampled, and
paralogSampled and can be inspected at https://github.com/fak/globalAnalysis/
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blob/master/writePairs.py.
Diﬀerences between measurements were calculated and those exactly equal to zero or
with an an absolute value greater than twenty were discarded. This step was performed
to exclude the most implausible values and to filter out values that are duplicated in the
database or reported as references to previous papers. The sample of 3,000 measurement
pairs was taken only once and at random and written to a tab-separated file. The
analysis is documented at https://github.com/fak/globalAnalysis/wiki/summary.
Figure 4.15 shows the probability density function that was calculated from the first
sample, and for comparison, one hundred additional probability density functions that
were sampled in the same manner. This part of the analysis is also documented at
https://github.com/fak/globalAnalysis/wiki/sampling.
4.4.3 Data assembly for homologous pairs
The assembly of both pairs of human-rat orthologs as well as pairs of human-rat orthologs,
was based on mappings provided by the EnsemblCompara GeneTrees pipeline (Vilella
et al., 2009), accessed through the BioMart website (Ensembl version 62, http://
apr2011.archive.ensembl.org/biomart/martview/). Queries against this website
return tables listing all combinations of homologous genes identified within a genome
(human paralogs) or between the genomes of two species (human-rat orthologs). The
homologous pairs from these tables were used to query the python objects described
in Methods 4.4.1) for compounds with measured potencies against both components,
matching on Uniprot accessions. For instances where a compound had more than one
potency measured against an identical target, the median of all values was obtained.
Pairs of homologous proteins together with the paired potency measurements were
written to two tab-separated files, one for human-rat orthologs, one for human paralogs.
For downstream analysis, diﬀerences between measurements were calculated, and those
exactly equal to zero or with an an absolute value greater than twenty were discarded.
This was to ensure that both diﬀerences between assays and diﬀerences between human-
rat orthologs had been processed in the same way. The function that was used to match
homologous proteins is deposited at https://github.com/fak/globalAnalysis/blob/
master/mkHomologTable.py .
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Figure 4.15: Panel A shows an overlay of 100 distributions sampled from human and rat data.
Shown in light blue in panel B is the probability density function that was fitted to the data
sampled from observed inter-assay diﬀerences. The grey curves represent probability density
functions fitted to one hundred additional random samples.
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4.4.4 Sequence identity for full-length proteins
Sequence identities between pairs of homologous proteins were obtained from alignments
generated by the EnsemblCompara GeneTrees pipeline. It is based on a combination of
multiple alignment algorithms, consensified by M-Coﬀee (Wallace et al., 2006). Ensem-
blCompara provides both the sequence identity of a query protein against its homolog,
as well as vice versa the sequence identity of the homolog versus the query protein. From
these two, the higher value was selected to focus the alignment on a region common to
both proteins and most likely involved in small molecule binding.
4.4.5 Sequence identity on a Pfam domain level
Sequence identity was also determined on a protein domain level. Here, the aim was to
compare sequences of the protein domains that mediate small molecule binding. To this
end, a heuristic mapping described in Methods 4.4.9 were used as an estimate of the
true Pfam domain mediating small molecule binding. For each protein in a homologous
pair, the Pfam domain identifier as well as its start and end positions within the protein
sequence were obtained from database tables generated as described in sections 2.5.1
and 2.5.3. Start and end positions were then used to slice full length sequences obtained
from the protein sequence field in target dictionary to yield the Pfam domain
sequence only. The EMBOSS implementation of the Needleman-Wunsch algorithm
needle (EMBOSS version 6.4.0, Needleman and Wunsch, 1970; Rice et al., 2000) was used
to produce pair-wise global sequence alignments for each pair of Pfam domains. Following
recommendations for closely related protein sequences, needle was executed using a gap-
open penalty of 10, gap-extend penalty of 0.5 and the EBLOSUM62 substitution matrix.
Output was generated in the ‘pair’ format and parsed from stdout using the python
regular expression module re. The function that was used to carry out the alignment is
pfam_a from https://github.com/fak/globalAnalysis/blob/master/align.py.
4.4.6 Sequence identity on a binding site level
Sequence identity between homologous pairs was also determined on a binding site
level, where possible. Thirty critical binding site residues for members of the fam-
ily of G-protein coupled receptors were specified in a publication by Surgand et
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al. (Surgand et al., 2006). I applied the residue positions specified to a family-wide
multiple sequence alignment obtained from GPCR Sarfari https://www.ebi.ac.uk/
chembl/sarfari/gpcrsarfari. The positions corresponding to the residues highlighted
by Surgand et al are listed in Table 4.9. Similarly, known binding site residues are listed
for kinases in the chemogenomics resource Kinase Sarfari. Kinase Sarfari operates with
five distinct binding site definitions, ‘Canonical’, ‘Gleevec’, ‘PKA’, ‘MEK2’, and ‘P38’.
In this analysis, I applied the ‘Canonical’ binding site definition to all kinases. Site
definitions adopted from Kinase Sarfari are outlined in Table 4.10.
For both kinases and GPCRs, the residues corresponding to the binding site definitions
were obtained from the family-wide multiple sequence alignments provided by GPCR
Sarfari and Kinase Sarfari. For each homologous pair, sequence identities were calculated
using the EMBOSS implementation of the Needleman-Wunsch algorithm needle (EM-
BOSS version 6.4.0, Needleman and Wunsch, 1970; Rice et al., 2000). Residue positions
in this comparison are fixed and hence the alignment should be gap-free. To minimise the
chances of introducing gaps into the alignment by chance, a gap-open penalty of 100 was
used. Output was generated in the ‘pair’ format and parsed from stdout using the python
regular expression module re. The function that was used to carry out the alignment is
bSite from https://github.com/fak/globalAnalysis/blob/master/align.py.
Table 4.9: Critical binding site residue positions in the GPCR family alignment.
Helix Ballesteros - Weinstein alignment residue
TM1 1.35, 1.39, 1.42, 1.46 65, 69, 72, 76
TM2 2.57, 2.58, 2.61, 2.65 132, 133, 136, 140
TM3 3.28, 3.29, 3.32, 3.33, 3.36, 3.40 164, 165, 168, 169, 172, 176
TM4 4.56, 4.60 239, 243
TM5 5.38, 5.39, 5.42, 5.43, 5.46 350, 351, 354, 355,358
TM6 6.44, 6.48, 6.51, 6.52, 6.55 485, 489, 492, 493, 496
TM7 7.35, 7.39, 7.43, 7.45 532, 536, 540, 542
4.4.6.1 Assessment of potency diﬀerences between homologous proteins
For each combination of a compound and pair of homologous proteins, measured pairwise
potencies were plotted in scatterplots detailing the observed potency against a protein on
the x-axis and the observed potency against its homolog on the y-axis. The Spearman
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Table 4.10: Critical binding site residue positions for the ‘Canonical’ site definition for kinases.
Kinase binding model residue positions
‘Canonical’ site definition 73, 77, 78, 87,
... 159,161,
... 227, 231, 254, 256,
... 318, 319, 320, 321, 322, 323,
... 354, 355, 356, 359,
... 494, 495, 497,
... 536,537
rank correlation coeﬃcient ρ was calculated using the R function cor.test. For each
combination, potency diﬀerences were calculated and plotted as probability density
distributions. Probability density functions were calculated using the kernel density
estimation function density with a gaussian kernel and the bandwidth selector nrd0.
Bland-Altman plots were constructed following specifications from Bland and Altman,
1986. Interval-lines indicate the 2.3% - 15.9% quantiles 84.1% - 97.7% quantiles, respec-
tively. If the data were normally distributed, these quantiles would coincide with ±one or
±two standard deviations. Quantiles and the distribution median with associated error
estimates were determined from one thousand iterations of a case resampling bootstrap.
The bootstrap was implemented using the R library boot.
4.4.6.2 Data models
Using the observed potency diﬀerences as an input, probability densities for a Laplace
distribution were simulated using the function dlaplace() from the R package VGAM.
The general probability density function of the Laplace distribution is
P (x) =
1
2b
e(−
|x−µ|
b ), (4.4)
where µ is a location parameter and b a scale parameter. For fitting to the sampled
diﬀerences between assays as well as human-rat orthologs and human paralogs, the
parameters µ and b were estimated with the analogic method, i.e. by applying the same
function that determines parameters in the theoretical distribution to the actual data.
The Laplace distribution relies on the median as an estimate of location and the mean
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absolute deviation as an estimate of variance. Hence, I calculated these values for each
data set and used them as parameters for the Laplacian model. The alternative model - a
normal distribution - was constructed using the probability density distribution function
P (x) =
1
σ
√
2π
e−(x−µ)
2/2σ2 , (4.5)
where σ, the standard deviation, is the parameter of scale and µ the location parameter.
As for the Laplacian distribution, I estimated the parameters using the analogic method.
Hence, I determined µ as the mean of the observed distribution and σ as the standard
deviation. To compare the observed distributions with the theoretical models, I generated
q-q plots of the observed quantiles against quantiles that would be observed if the data
were drawn from the theoretical distribution. Theoretical quantiles were calculated
using the R functions rnorm and rlaplace. This part of the analysis is documented at
https://github.com/fak/globalAnalysis/wiki/data_model.
4.4.6.3 Assessment of individual homologous pairs
The testing of individual homologous pairs was based on a two-sided Mann-Whitney
U test. This non-parametric test was used to compare the distribution of observed
potency diﬀerences for individual pairs with a control distribution sampled from inter-
assay comparisons for identical targets. When analysing pairs of paralogs, the control
distribution was sampled from inter-assay comparisons of human targets, and when
analysing human-rat orthologs, the control distribution was sampled from a mixture
of human and rat inter-assay comparisons. The distributions of potency diﬀerences
for individual pairs were subjected to Mann-Whitney U tests (using the R function
wilcox.test). The estimate for the diﬀerence of means between control and query
distribution, as well as the associated p-value, were recorded for each homologous pair.
Because p-values were used as a ranking criterion rather than as a means to attach
significance, p-values were not corrected for multiple testing. The diﬀerence of means
was plotted as eﬀect size against the negative logarithm of the corresponding p-value in
a volcano plot using the R package ggplot2. This part of the analysis is documented
here https://github.com/fak/globalAnalysis/wiki/individual_homologs.
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4.4.6.4 Potency diﬀerences and sequence identity
The relationship of sequence identity between homologous pairs and the potency diﬀer-
ences observed between them for identical compounds was analysed on three levels: (i)
Full sequence (ii) predicted Pfam domain mediating the interaction and (iii) binding
site residues. Sequence identity measures were obtained as described in sections 4.4.4,
4.4.5, 4.4.6, respectively. The dependence between sequence identity and the absolute
diﬀerence in compound binding was evaluated using Spearman’s rank correlation co-
eﬃcient ρ calculated with the R function cor.test. To visualise the relationship of
sequence identity and the absolute diﬀerence in small molecule binding, density plots
were generated detailing the sequence identity between pairs of human paralogs on the
x-axis and the absolute diﬀerence in small molecule binding on the y-axis. This analysis
is documented here https://github.com/fak/globalAnalysis/wiki/sequence.
4.4.7 Homology model of the HRH3 receptor
4.4.7.1 Preparation of model templates
A number of GPCR structures were accessible through PDBe at the time the study
was conducted. Table 4.11 lists the highest resolution structure for each protein. From
the available structures, we selected all GPCRs with aminergic ligands as described by
Gloriam et al (Gloriam et al., 2009): The human β-adrenoceptor 2 (2rh1, 3nya, 3ny8,
3d4s), the turkey β-adrenoceptor 1 (2vt4), the human dopamine D3 receptor 3pbl and
the human HRH1 (3rze). Even though additional structures were available for the β-
adrenoceptor 2, these were not included as templates because they represent the receptor
in an interaction with agonistic rather than antagonistic ligands.
4.4.7.2 Sequence alignment
Sequences for the model templates were obtained from PDBe. Some of the structures con-
tain a part of the bacteriophage T4 lysozyme to stabilise the structure for crystallisation.
Prior to the alignment, these residues were removed from the template sequences by hand.
The initial alignment of model templates was extracted from a JOY alignment encompass-
ing the entire range of known GPCR crystal structures. The sequences of the human and
rat HRH3 were added and the alignment was refined manually. The refined alignment
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Table 4.11: Crystall structures of G-protein coupled receptors available in PDBe at the time
the study was conducted.
Id Name Ligand Species Resolution (A˚)
1u19 Rhodopsin RET B. taurus 2.2
2z73 Rhodopsin RET T. pacificus 2.5
2rh1 β-adrenoceptor 2 CAU H.sapiens 2.4
3nya β-adrenoceptor 2 JTZ H.sapiens 3.16
3ny8 β-adrenoceptor 2 JRZ H.sapiens 2.8
3d4s β-adrenoceptor 2 TIM H.sapiens 2.8
2vt4 β-adrenoceptor 1 P32 M. gallopavo 2.7
3eml adenosine A2a receptor ZMA H.sapiens 2.6
3odu CXCR4 chemokine receptor ITD H.sapiens 2.5
3pbl dopamine D3 receptor ETQ H.sapiens 2.9
3rze histamine H1 receptor 5EH/D7V H.sapiens 3.1
used to build the homology model is shown in Figure 4.16. The JOY alignment was
generated by John Overington and Kazuyoshi Ikeda, an online version is available at http:
//chembl.blogspot.co.uk/2012/12/gpcr-structure-human-par1-receptor.html.
4.4.7.3 Model building and visualization
The models of the human and rat HRH3 were build using the MODELLER program
(version mod9v8) (Sali and Blundell, 1993). The pdb files of all template structures
were curated to remove coordinates for any residue that was not part of the alignment
described in section 4.4.7.2. The parameters for the MODELLER program were set
to include doxepin, the ligand from the HRH1 receptor template structure, using the
automodel module. For both the human and rat HRH3, five models were generated and
the model with the lowest molpdf score selected for visualisation and analysis. Models
were aligned in two steps using functionality of the CCP4 molecular graphics program
(Potterton et al., 2002). First, a rough alignment was obtained based on a secondary
structure matching algorithm (Krissinel and Henrick, 2004) and in second step this
alignment was refined using the ‘match close residues’ routine of the CCP4 molecular
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Figure 4.16: Protein sequence alignment for the template structures used to build a homology
model of HRH3. Sequences of the four template structures are shown together with protein
sequences for the human and rat HRH3 obtained from Uniprot. The coloring indicates ClustalX
similarity scores. Backslashes indicate chain breaks in the crystal structure, usually a result of
missing electron density or chimeric constructs. The substitution from Thr in human to Ala in
rat is located in the centre of the second row in the alignment.
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graphics program. The root mean square diﬀerence between two models is defined as
RMSD =
￿￿￿￿ 1
n
n￿
i=1
￿
(pix − qix)2 + (piy − qiy)2 + (piz − qiz)2
￿
, (4.6)
where pi and qi are vectors describing the position of the i-th backbone atom in three
dimensions (x, y, z) and was determined using inbuilt functionality of the program.
Distances between the modelled ligand doxepin and the mutated residue Ala119Thr
were calculated using the geometry toolbox that is part of the program. The generated
models and alignment files were made available through figshare (www.figshare.com)
and assigned individual digital object identifiers (DOI) as summarised in table 4.12.
Table 4.12: Overview of deposited model and alignment files.
doi description
10.6084/m9.figshare.915370 Homology model of human HRH3.
10.6084/m9.figshare.915371 Homology model of rat HRH3.
10.6084/m9.figshare.915368 Alignment of template sequences and human HRH3.
10.6084/m9.figshare.915369 Alignment of template sequences and rat HRH3.
4.4.8 Cluster analysis of HRH3 ligands
The clustering of HRH3 ligands was based on LINGO fingerprints. LINGO fingerprints
have been described as a simple and eﬃcient method to capture and represent molecular
properties directly from a SMILES string representation (Vidal et al., 2005; Grant et al.,
2006). I used the Open Eye toolkit OEChem TK (OEChem, 2006) to calculate LINGO
fingerprints. The term I used to evaluate pairwise distances between compounds is the
Tanimoto coeﬃcient, defined as
Tc =
fi∧j
fi + fj + fi∧j
, (4.7)
where fi∧j is the number of features two compounds i, j have in common, while fi and
fj represent the number of features found exclusively in one or the other compound (Jac-
card, 1901, see also http://www.daylight.com/dayhtml/doc/theory/theory.finger.
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html). This term was calculated for all pairwise combinations using the OEChem TK
function OETanimoto. An implementation of the single linkage algorithm from the
Python module hcluster (Eads, 2008) was used to calculate a dendrogram from the
input distance matrix. To assign compounds to clusters, a Tc similarity threshold of 0.5
was set. This value was chosen arbitrarily upon inspection of the dendrogram, with the
aim of obtaining between five and ten major clusters.
4.4.9 Mapping small molecule binding to Pfam domains
To determine the Pfam domain most likely to mediate small molecule binding, I used an
adaptation of the mapping described in Chapter 2. In contrast to the heuristic presented
there, if a protein was found to contain more than one domain from the dictionary of
validated domains, the binding site was mapped to the domain with the highest count of
occurrence among single-domain targets.
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Conclusions
During my Ph.D. project at the European Bioinformatics Institute, I have developed
approaches to integrate an important source of small molecule bioactivity data, the
ChEMBL database, with sources of protein evolutionary relationship data. To achieve
this, I have used computational methodologies that would typically be attributed to
the disciplines of data mining and statistical analysis. Where required, specialised
bioinformatics methods and programs were used to process biological and chemical
information. In the following, I summarise and discuss the findings of my studies and
provide an outlook onto future avenues of research.
5.1 Integration of small molecule bioactivity data
and protein domain annotation
Chapters 2 and 3 describe the implementation of a heuristic mapping of small molecule
binding to protein domains. In an evaluation against crystallographic data extracted
from PDBe, the heuristic accurately predicted the correct domain of ligand binding in
97% of cases for single domain proteins and 89% of cases for multi-domain proteins. I
was able to demonstrate that most measured small molecule interactions are limited
to a small number of domains that are associated with the great target classes in drug
discovery: GPCRs, kinases, ion channels and a number of enzymes. The analysis also
provided statistics for small molecule binding at domain interfaces and delivered detailed
insights into the patterns of co-occurrence of domains in potential drug targets. The
refined mapping of small molecule binding to protein domains is now an integral part of
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the ChEMBL database, where it provides the community an improved index for sequence-
and protein family-based queries.
The mapping heuristic and its manual refinement presented in chapter 2 and chapter
3 constitute an approach of annotation transfer between related protein sequences.
Annotation transfer was proposed as a method to annotate genes in newly sequenced
genomes (Shah and Hunter, 1997; Bork et al., 1998). In these approaches, annotation
that is present for one gene is transferred onto a newly sequenced gene if the two genes
are deemed to be suﬃciently related. In the case of my proposed mapping heuristic, the
information being transferred is the presence or absence of a small molecule binding site
and its relationship established through Pfam-A domains. Like other implementations
of annotation transfer, this approach is subject to a number of limitations. Functional
divergence between related protein sequences can lead to the loss or reconfiguration of a
specific function. It has been shown that variation in the configuration of small molecule
binding sites increments with sequence divergence (Devos and Valencia, 2000) and it
is well appreciated that protein structure, in this mapping approximated by Pfam-A
domains, is more conserved than protein function (Hegyi and Gerstein, 1999). Given that
the annotation transferred in this instance is simply the presence or absence of a binding
site, the mapping heuristic is expected to be relatively robust to functional divergence,
which is typically more subtle. Another limitation to annotation transfer approaches
is the complexity introduced by multi-domain architectures (Hegyi and Gerstein, 2001;
Rost, 2002). This was clearly reflected in the diﬀerence in performance between single-
and multi-domain proteins in the case of the mapping heuristic presented here. A third
limitation is of a more speculative nature: the dictionary of small molecule binding
domains is constructed based on measured interactions with synthetic small molecules. If
it turned out that potent small molecule ligands could be found for all domains that are
presently not part of the dictionary of validated domains, this would make the mapping
pointless as each multi-domain protein would be put forward for curation. Experience
from drug discovery suggests that this is not a likely scenario (Hopkins and Groom,
2002; Russ and Lampel, 2005). However, the progress that has been made towards the
development of ligands for the SH2 domain (Kraskouskaya et al., 2013) is a cautionary
call to monitor future developments.
Most other approaches of mapping small molecule binding to protein domains rely
on protein structural information and do not infer binding sites by annotation transfer
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(Snyder et al., 2006; Bashton and Thornton, 2010; Wang et al., 2012b; Moya-Garc´ıa
and Ranea, 2013). The advantage here is that mappings do not rely on inference and
can be expected to be more accurate. However, the annotation transfer-based approach
provides the benefit that the mapping can be applied to any given protein, including
those for which no crystal structure exists to date. One approach of mapping small
molecule binding sites that uses annotation transfer was published by Davies in 2011
(Davis, 2011). This approach assigns potential small molecule binding sites to sequence
regions that match precalculated profiles of existing small molecule binding sites. This
method is more sophisticated than the method I propose because it takes into account
the local context of each binding site. However, the precalculated profiles of binding sites
require at least one crystal structure describing this site. The only requirement of the
mapping heuristic presented in this thesis is that an interaction between a small molecule
and a protein domain has been measured at least once and that protein domains are
detectable using Pfam-A domain models. It is thus well suited to map small molecule
binding to the heterogeneous set of protein targets with measured interactions in the
ChEMBL database.
In its findings of frequently targeted domain types, the mapping heuristic agrees to
the largest extent with previously published studies (Hopkins and Groom, 2002; Paolini
et al., 2006; Overington et al., 2006). However, owing to its wide scope, it also maps small
molecule binding to domain types that were not considered in previous studies of this
type. Such domains contribute only a tiny fraction of measured interactions individually,
but in the sum they actually form a significant portion of measured interactions. This
long tail of domains can help generate hypotheses for novel drug targets.
5.2 Integration of small molecule bioactivity data
and protein homology information
In chapter 4, I have presented an approach that integrates small molecule bioactivity
data from the ChEMBL database with protein homology information obtained from
EnsemblCompara Genetrees. The findings of this approach were that ChEMBL contains
a wealth of small molecule potency data measured against human proteins that could be
compared with potency data measured against orthologous proteins in other species. I
found that the overlap of small molecules tested against both human and rat proteins
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was suﬃcient to carry out a large scale analysis of the conservation of small molecule
binding between the two species. In general, susceptibility to small molecule binding
between the two species is conserved, as the overall diﬀerences are no greater than what
would be expected from measurements of the experimental error. I also identified pairs
of proteins for which small molecule binding diﬀered between the two species, most
prominently the HRH3. For this receptor, I proposed a probable mutation explaining the
observed diﬀerence between the two species. In analogy to the analysis of orthologs, I used
annotations from EnsemblCompara Genetrees to identify pairs of closely related paralogs
and found that overall diﬀerences in susceptibility were greater than the experimental
error noise and greater than diﬀerences observed between orthologs. I observed a weak
relationship between sequence identity and diﬀerences in susceptibility to small molecule
binding. The strength of this relationship increased with the level of resolution of the
comparison, but in general terms remained weak, even on a binding site level.
Broadly speaking, this study follows a long tradition of molecular level evaluations of
functional conservation between species. In 1983, Max Perutz laid the foundation for
this type of work with a study on hemoglobin, which compared functional properties
of this protein between mammalian, amphibian and fish species and identified the
structural correlates of these diﬀerences (Perutz, 1983). The analysis presented here
diﬀers from Perutz’s work and its successors in its scale, as diﬀerences were studied on
about 150 orthologous pairs and 650 paralogous pairs. An added contrast is the nature
of the measured entity in this study. It is not a physiological function, but rather the
susceptibility of a protein to perturbation by artificial small molecules that played no role
in the evolution of a protein. This somewhat limits the authority of my analysis to answer
evolutionary questions, but also gives rise to some speculative questions concerning
the nature of (artificial) small molecule-protein interactions. Do they mostly emulate
interactions with natural binding partners, and, if so, what is the probability of impacting
protein function through a mechanism that is not part of the evolved repertoire of
mechanistic responses of a protein? The analysis presented here cannot answer these
questions, but they are within the wider remit of pharmacophylogenetic approaches
(Searls, 2003b).
A recent debate quite close to the subject matter of this study concerns the validity
of the ortholog conjecture. The ortholog conjecture states that paralogs, which arise from
gene duplication, are free to evolve divergent functions, while the function of orthologs
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diverges at a much slower rate and is largely conserved between closely related species.
The conjecture was derived from first principles stated by Fitch in 1970 (Fitch, 1970). A
study seeking to trace functional divergence in duplicated genes found that functional
divergence is a rare event and that silencing of a duplicated gene is a much more frequent
outcome (Lynch, 2000). In 2009, Studer and colleagues pointed out that there was
little systematic evidence to support the ortholog conjecture, despite its compelling
theory (Studer and Robinson-Rechavi, 2009). A study by Nehrt and colleagues challenged
the ortholog conjecture, with its finding that paralogs share more gene ontology (GO)
annotation terms than orthologs, on average. In contrast, the findings from my analysis
showed greater conservation between orthologs in terms of susceptibility to small molecule
perturbations. In their study, Nehrt and colleagues had corrected for diﬀerent levels of
sequence identity before comparing overlap of GO terms. For lack of orthologous pairs
with low levels of sequence identity, this was not possible in my analysis. That, and
the artificial nature of the interactions that were the subject of my analysis, made it
impossible to compare our findings directly. Later in 2012, Altenhoﬀ and colleagues
published a study that identified authorship bias as a confounding factor in the analysis
of Nehrt and colleagues and concluded that functional conservation, measured as overlap
of GO terms, is slightly greater in orthologs. To say I contributed to this debate would
overstate my role, but from enjoyable and insightful conversations with the authors of both
studies it appears that integration of small molecule bioactivity data can be applied to
examine fundamental evolutionary processes. The finding from this study, that response
to small molecule perturbation is more conserved in orthologs, is also in agreement with
an experimental study that evaluated diﬀerences in response to small molecule binding to
odorant receptors (Adipietro et al., 2012). Having stated that diﬀerences between human
paralogs were greater than the overall assay-noise, it is nevertheless remarkable that
comparable potencies were observed for many combinations of ligands and paralogous
pairs. This observation might indicate a pronounced degree of functional promiscuity
between paralogous proteins, which has previously been described as an essential feature
of biological systems (Nobeli et al., 2009).
Global analyses of large-scale chemical and biological experiments were proposed as
early as 2002 (Root et al., 2002). The authors of this proposal identified the capacity to
detect subtle, non-obvious relationships in such data as one of the strengths of such anal-
yses. To some extent this applies to my study, which is not an analysis of one large-scale
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experiment, but rather a large-scale aggregation of multiple, heterogeneous experiments
collected from the scientific literature and aggregated in the ChEMBL database. To ac-
count for the background noise created by this heterogeneity, I constructed a distribution
of inter-assay diﬀerences. In a similar approach, Kramer and colleagues published a study
that examined the variation in heterogeneous measurements of inhibition constants Ki
(Kramer et al., 2012). Kramer and I had been corresponding prior to the publication of
this study and we agreed that it would be important to exclude duplicate measurements
from such evaluations as they would artificially reduce variability. In my study, I excluded
all values that are exactly equal, as it is very unlikely that these would be independent
measurements. Kramer and colleagues took this filtering process further and excluded
also values that are only slightly diﬀerent and are likely rounded duplicates of other
measurements. To fully rule out dependence of measurements, Kramer further excluded
measurements from publications with overlapping authors. Thus, Kramer’s analysis
provides a true estimate of inter-assay noise, while my analysis provides a useful standard
of comparison for diﬀerences observed between orthologs and paralogs.
Assay noise in itself is a clear limitation to the analytic capabilities of this study and it
is likely that the correlation between sequence identity and conservation of susceptibility
to small molecule perturbation would have been stronger in a dataset with less inherent
noise. In the initial implementation of the analysis, this was further aggravated by the
uncorrected comparison of IC50 and Ki-values (see section 4.2.1), but in the analysis
presented here, Ki-values have been adjusted using a correction factor for ChEMBL
bioactivity data published by Kalliokoski in 2013 (Kalliokoski et al., 2013).
This study constitutes a comparison of small molecule response in two species that
are highly relevant to drug discovery. The finding that small molecule response is largely
conserved between these two species on a molecular level does not come as a surprise, but
had not been demonstrated systematically before. It should however not be interpreted to
signify pharmacological equivalence between the two species. Comparisons on a cellular
and organismal level are far more complex. For example, a comparison of human and
mouse tissues demonstrated that transcriptional regulation is species-specific for the
majority of transcribed modules (Odom et al., 2007) and there are serious concerns about
the use of laboratory rodents as controls for disease models (Martin et al., 2010).
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5.3 Summary, conclusion and outlook
In my thesis project, I have applied a data integration approach to bridge the gap between
bioactivity data stored in the ChEMBL database and protein evolutionary information
from two resources, Pfam and EnsemblCompara GeneTrees. I have demonstrated that
this approach can improve indexing and organisation of bioactivity data and facilitate
analyses at the interface of chemical biology, drug discovery and protein evolution.
Future studies can build on this approach to further integration, for example with
genomic resources such as the 1,000 Genomes Project (Abecasis et al., 2010) or the
clinical trials resource ClinicalTrials.gov to extend the bioactivity data obtained mainly
from early stage drug discovery projects into the clinical stage.
Now that it is accessible through the ChEMBL schema, the mapping of small
molecule binding to protein domains warrants further analysis, for example of the
distribution of measured interactions per domain type. Eventually, the development of
these distributions over time can reveal trends in the development of candidate drug
targets. Ligand sets associated through the mapping with individual domain types can
be analysed for their chemical properties and utilised to train models for target prediction
as previously demonstrated (Bender et al., 2009). The manual curation interface will be
made accessible through a public webserver which hopefully can engage the scientific
community to participate in the curation eﬀort and ensure a legacy for this mapping.
These eﬀorts can take inspiration from the wikipedia integration of the Pfam database
and others (Mons et al., 2008; Huss et al., 2008; Punta et al., 2012).
Having shown that integration of small molecule bioactivity data can answer questions
concerned with protein evolution it would be desirable to obtain the data needed to
extend this study to proteins from other species. This would allow to trace diﬀerences in
susceptibility to small molecule along a phylogenetic tree and could provide a trajectory
of mutations that influence small molecule binding. This in turn could instruct both
target validation eﬀorts as well as eﬀorts to optimise drug discovery lead structures.
A study making use of patient record data to predict oﬀ-target eﬀects of small
molecule drugs shows that data integration approaches can solve questions relevant to
clinical practice (Tatonetti et al., 2012). To bridge the gap between the fundamental
science of small molecule-protein interactions and clinical applications is maybe the most
challenging, but also most alluring step forward.
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Figure 1: Multiple binding sites of the mTOR complex. Left hand side shows structures
of whole protein complexes, right-hand side shows individual chains. Small molecule binding
sites are shown in approximation as red circles overlaid with ligands from the crystal structure.
PDB 3kg2 - complex of truncated human mTOR (light-gray) and mammalian lethal with
SEC13 protein 8 (gray). mTOR contains a Rapamycin_bind domain (green, binding site for
rapamycin/FKBP12 represented by red ellipse), a PI3_PI4_kinase (yellow, with torin-2) and
a FAT (blue) and FATC domain (pink).
Complete catalogue of Pfam-A domains obtained from initial mapping:
1. 2OG-FeII Oxy 3
2. 3Beta HSD
3. 7tm 1
4. AA permease 2
5. Abhydrolase 1
6. Abhydrolase 6
7. Abi
8. Acetyltransf 1
9. Acetyltransf 2
10. ACPS
11. Actin
12. A deaminase
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13. Adhes-Ig like
14. adh short
15. adh short C2
16. Aldedh
17. Aldo ket red
18. Alk phosphatase
19. Alpha-amylase
20. Alpha L fucos
21. Amidase
22. Amidinotransf
23. Amino oxidase
24. Aminotran 1 2
25. Aminotran 3
26. Aminotran 4
27. Aminotran 5
28. AMP-binding
29. AMPKBI
30. ANF receptor
31. An peroxidase
32. Aph-1
33. Arginase
34. ASC
35. Asp
36. Asp Glu race
37. ATP-synt C
38. Bcl-2
39. Bcl-2 BAD
40. Beta-lactamase
41. Beta-lactamase2
42. BNR 2
43. BsuBI PstI RE
44. Calc CGRP IAPP
45. Carb anhydrase
46. CBAH
47. CD36
48. Choline kinase
49. Clat adaptor s
50. CM 2
51. COesterase
52. COX1
53. CTP transf 2
54. Cupin 8
55. DAGK cat
56. DAHP synth 1
57. DAO
58. dCMP cyt deam 1
59. DHFR 1
60. DHO dh
61. DHquinase II
62. DMRL synthase
63. DNA methylase
64. DNA pol A
65. DNA pol lambd f
66. dNK
67. DSPc
68. dUTPase
69. dUTPase 2
70. EBP
71. ELO
72. EPSP synthase
73. ERG2 Sigma1R
74. ERO1
75. Esterase
76. Exo endo phos
77. FabA
78. FAD binding 3
79. FA desaturase
166
Appendix
80. FBPase
81. FKBP C
82. Flavodoxin 2
83. Flu M2
84. Folate carrier
85. Folate rec
86. G-alpha
87. GDA1 CD39
88. GDE C
89. Glucan synthase
90. Glyco hydro 1
91. Glyco hydro 14
92. Glyco hydro 15
93. Glyco hydro 18
94. Glyco hydro 20
95. Glyco hydro 30
96. Glyco hydro 35
97. Glyco hydro 47
98. Glyco hydro 79n
99. Glyco hydro 85
100. Glycolytic
101. Glyco transf 21
102. Glyco transf 29
103. Glyco transf 6
104. Glyoxalase
105. HCV capsid
106. HCV NS4a
107. Hemagglutinin
108. Heme oxygenase
109. Herpes TK
110. His Phos 2
111. Hist deacetyl
112. Histidinol dh
113. HIT
114. HN
115. Hormone 2
116. Hormone recep
117. H PPase
118. HSP20
119. HSP70
120. HTH 18
121. Hydrolase 4
122. ICL
123. ICMT
124. IDO
125. IF4E
126. IGPD
127. IL5
128. IL8
129. IMPDH
130. Ion trans
131. IU nuc hydro
132. KH 1
133. Lactamase B
134. Laminin G 1
135. Lectin legB
136. Lipase 3
137. Lipocalin
138. LMWPc
139. LpxC
140. LuxS
141. MAPEG
142. MBOAT
143. MCD
144. Melibiase
145. Metallophos
146. Metallothio
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147. Methyltransf 3
148. Methyltransf 31
149. MetJ
150. MFS 1
151. MIF
152. Multi Drug Res
153. Myb DNA-binding
154. NAD kinase
155. NAD synthase
156. NAGidase
157. Na H Exchanger
158. NAPRTase
159. Neur
160. Neur chan LBD
161. NMO
162. NNMT PNMT TEMT
163. Nramp
164. Nucleoside tran
165. OMPdecase
166. P2X receptor
167. p450
168. PAF-AH p II
169. PALP
170. Pantoate ligase
171. PAP2
172. PDEase I
173. PDGF
174. PEN-2
175. PEPCK
176. Pep deformylase
177. Peptidase C1
178. Peptidase C12
179. Peptidase C13
180. Peptidase C14
181. Peptidase C30
182. Peptidase C48
183. Peptidase M10
184. Peptidase M2
185. Peptidase M24
186. Peptidase M28
187. Peptidase M48
188. Peptidase M84
189. Peptidase S10
190. Peptidase S13
191. Peptidase S28
192. Peptidase S8
193. Peripla BP 4
194. PFK
195. PfkB
196. PGI
197. Phospholip A2 1
198. Phospholip A2 2
199. Phosphorylase
200. PIG-L
201. PKD channel
202. Pkinase
203. Pkinase Tyr
204. PMI typeI
205. PMM
206. PNP UDP 1
207. polyprenyl synt
208. Poxvirus
209. Prenyltransf
210. Presenilin
211. Pribosyltran
212. Pro CA
213. Pro isomerase
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214. Pterin bind
215. PTR2
216. Put Phosphatase
217. Pyridoxal deC
218. Ras
219. RdRP 3
220. RE HindIII
221. RE ScaI
222. RHD
223. Rib hydrolayse
224. RmlD sub bind
225. RnaseA
226. RRM 1
227. RrnaAD
228. rve
229. RVP
230. SAM decarbox
231. SBF
232. Scytalone dh
233. SDF
234. SE
235. Serpin
236. SHMT
237. SIR2
238. SKI
239. S-methyl trans
240. SNF
241. Sortase
242. Spermine synth
243. SQS PSY
244. SSF
245. Steroid dh
246. Sugar tr
247. Sulfatase
248. Sulfotransfer 1
249. Telo bind
250. Tetraspannin
251. TetR N
252. TGT
253. Thy1
254. Thymidylate kin
255. Thymidylat synt
256. TIM
257. TK
258. TNF
259. Transpeptidase
260. Transthyretin
261. tRNA-synt 1e
262. Trp dioxygenase
263. Trypsin
264. TspO MBR
265. Tubulin
266. Tyr-DNA phospho
267. Tyrosinase
268. UDG
269. UDPGT
270. Urotensin II
271. V ATPase I
272. Vitellogenin N
273. V-set
274. Y phosphatase
275. zf-CCCH
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Figure 2: Evidence for small molecule binding to the Hydrolase_4 domain. Measured
interactions are shown for ten molecules. Molecules are identified as in the molregno database
field and measured potencies expressed as pIC50 values. Evidence for small molecule binding
to this domain comes from 13 publications recorded in the ChEMBL database. In total,
there were 124 compounds with 168 measured interactions for this domain. The protein
target for these compounds is the Monoglyceride lipase from M. musculus and R. norvegicus.
Interestingly, the human ortholog of this protein is assigned with the Hydrolase_6 Pfam-A
domain, rather than the Hydrolase_4 domain. The Hydrolase_4 Pfam-A model represents
a putative lysophospholipase domain and is found in bacteria and eukaryotes. It shares the
α-βhydrolase fold with a great number of other domains in the AB_hydrolase clan, members of
which are thought to derive from a common ancestor.
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Figure 3: Evidence for small molecule binding to the HSP70 domain. Measured interactions
are shown for ten molecules. Molecules are identified as in the molregno database field and
measured potencies expressed as pIC50 values. Evidence for small molecule binding to this
domain comes from two publications recorded in the ChEMBL database. In total, there were
79 compounds with 117 measured interactions for this domain. The protein target for these
compounds are various isoforms of the Heat shock 70 kDa protein H. sapiens, G. max (soy
bean) and E.coli.
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Figure 4: Evidence for small molecule binding to the PEPCK domain. Measured interactions
are shown for ten molecules. Molecules are identified as in the molregno database field and
measured potencies expressed as pIC50 values. Evidence for small molecule binding to this
domain comes from one publications recorded in the ChEMBL database. In total, there
were 21 compounds with 30 measured interactions for this domain. The protein target for
these compounds is the cytosolic phosphoenolpyruvate carboxykinase from H. sapiens and R.
norvegicus.
172
Appendix



	



   










Figure 5: Evidence for small molecule binding to the RrnaAD domain. Measured interactions
are shown for ten molecules. Molecules are identified as in the molregno database field and
measured potencies expressed as pIC50 values. Evidence for small molecule binding to this
domain comes from a single publication recorded in the ChEMBL database. In total, there
were 16 compounds with 23 measured interactions for this domain. The protein target for these
compounds is the rRNA adenine N-6-methyltransferase from S. pneumoniae and B.subtilis.
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Figure 6: Screenshot of the curation interface. Section: ‘Evidence’.
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Figure 7: Screenshot of the curation interface. Index page for ‘Evidence’ section.
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Figure 8: Screenshot of the curation interface. Section: ‘Conflicts’
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Figure 9: Screenshot of the curation interface. Index page for ‘Conflicts’ section.
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Figure 10: Screenshot of the curation interface. Section: ‘Resolved’
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Figure 11: Screenshot of the curation interface. Index page for ‘Resolved’ section.
179
Appendix
Table 1: Pfam-A domain types projected onto multi-domain proteins. The table summarises
all Pfam-A domain types from the catalogue of Pfam-A domains with known small molecule
interactions that were projected onto multi-domain proteins. The column headed ‘n(proteins)’
provides the number of multi-domain proteins a given Pfam-A domain was projected onto, the
column headed ‘n(activities)’ the number of corresponding measured acitivities.
domain id proteins activities
Pkinase Tyr 90 9,877
Pkinase 75 4,027
ANF receptor 48 2,358
Ion trans 46 3,889
Hormone recep 45 7,386
Neur chan LBD 33 1,163
Peptidase C1 30 4,069
Trypsin 26 3,808
Peptidase M10 21 4,053
PDEase I 17 724
7tm 1 13 1,184
Asp 10 1,603
COesterase 10 4,240
Peptidase S8 10 208
Peptidase C14 9 374
An peroxidase 7 630
Y phosphatase 7 207
Hist deacetyl 6 594
Tubulin 5 54
Transpeptidase 4 7
Glyco hydro 18 4 41
SNF 4 4,486
DSPc 3 92
Abhydrolase 1 3 183
Bcl-2 3 163
Metallophos 3 87
Continued on next page
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Table 1 – Continued from previous page
domain id proteins activities
adh short 2 47
Alpha-amylase 2 10
DNA methylase 2 68
FA desaturase 2 2
Glyoxalase 2 11
Hormone 2 2 8
Peptidase M84 2 443
PKD channel 2 47
adh short C2 2 193
FKBP C 2 5
IMPDH 2 269
MFS 1 2 56
Peptidase C30 2 113
Peptidase M28 2 105
Amino oxidase 1 14
Carb anhydrase 1 41
Glucan synthase 1 10
Glyco hydro 15 1 2
ICL 1 10
Methyltransf 31 1 16
Pro CA 1 99
RRM 1 1 112
SIR2 1 2
2OG-FeII Oxy 3 1 88
Aminotran 1 2 1 10
AMP-binding 1 48
DNA pol A 1 47
Exo endo phos 1 6
Glyco hydro 1 1 9
p450 1 52
Continued on next page
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Table 1 – Continued from previous page
domain id proteins activities
polyprenyl synt 1 21
RHD 1 5
rve 1 761
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Figure 12: Schema sections representing the mapping of small molecule binding to Pfam-A
domains in chembl_15 and upwards. Measured activities are linked to binding sites through
the activity_id and site_id fields in the predicted_binding_domains table. Binding site
can then further be linked to domain identifiers using the site_id and domain_id fields in the
site_components table. Sites can also be mapped to protein targets using the site_id and
tid fields in the binding_sites table.
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Table 2: Paralogous groups. This table provides a summary of the groups of paralogs
highlighted in Figure 4.5. The column groups are assigned according to the figure labels.
group Uniprot ID Name
1 Q9Y5N1 Histamine H3 receptor
1 P08173 Muscarinic acetylcholine receptor M4
1 P08172 Muscarinic acetylcholine receptor M2
1 P11229 Muscarinic acetylcholine receptor M1
1 P08912 Muscarinic acetylcholine receptor M5
1 Q9H3N8 Histamine H4 receptor
1 P35367 Histamine H1 receptor
1 P20309 Muscarinic acetylcholine receptor M3
2 P42681 Tyrosine-protein kinase TXK
2 P51813 Cytoplasmic tyrosine-protein kinase BMX
2 Q06187 Tyrosine-protein kinase BTK
2 P42680 Tyrosine-protein kinase Tec
2 Q13882 Protein-tyrosine kinase 6
2 Q08881 Tyrosine-protein kinase ITK/TSK
3 P25100 Alpha-1D adrenergic receptor
3 P35368 Alpha-1B adrenergic receptor
3 P21918 D(1B) dopamine receptor
3 P50406 5-hydroxytryptamine receptor 6
3 P35348 Alpha-1A adrenergic receptor
3 P08588 Beta-1 adrenergic receptor
3 P21728 D(1A) dopamine receptor
3 P07550 Beta-2 adrenergic receptor
4 P43088 Prostaglandin F2-alpha receptor
4 P34995 Prostaglandin E2 receptor EP1 subtype
4 P35408 Prostaglandin E2 receptor EP4 subtype
4 P43115 Prostaglandin E2 receptor EP3 subtype
4 P21731 Thromboxane A2 receptor
4 P43116 Prostaglandin E2 receptor EP2 subtype
4 Q13258 Prostaglandin D2 receptor
4 P43119 Prostacyclin receptor
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